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Abstract 
 
Brian Leinwand:  The Cost-Effectiveness of Treatments for Pediatric ADHD: The Effects of 
Gender and Comorbidity 
(Under the direction of Richard Hansen) 
 
 
Attention-deficit/hyperactivity disorder (ADHD) is the most prevalent psychiatric 
disorder among children. The condition can last well into adulthood, generating significant 
healthcare and societal costs. Treatments can include medications, cognitive-behavioral 
therapy or a combination of the two. The goal of treatment is to reduce symptoms that 
cause academic, social and emotional impairment. Comorbid psychiatric conditions can 
complicate treatment and generate additional costs.  Most research focuses on boys, 
although the disorder occurs frequently in girls.  Research suggests boys are more impaired 
in some symptom domains, while girls appear more impaired in others. A limited literature 
exists on the cost-effectiveness of different treatments for ADHD, and each study uses a 
short time horizon. The objective of this paper is to use discrete event simulation to model 
the long-term cost-effectiveness of two ADHD treatment modalities, accounting for gender 
and comorbidities. 
Data from the Multimodal Treatment Study of Children with ADHD and cost 
estimates from the literature were used to model the costs and outcomes of medication 
and combination therapy.  Treatment response was estimated via mixed-effects logistic 
regression as a function of gender, comorbidity status, ADHD severity, and treatment 
compliance.  Costs of clinician visits, medications, special education, juvenile justice, 
iii 
 
hospitalizations, and parental work productivity losses were estimated from the data and 
literature.  A discrete-event simulation modeled patients moving through the healthcare 
system over eight years to determine the long-term cost-effectiveness of the treatment 
modalities. 
The treatments performed similarly; both treatment arms produced successful 
responses between 3.8 – 4.4 years of the time horizon.  However, the 8-year treatment 
costs among patients on combination therapy were significantly higher than patients on 
medications alone ($39,000 vs. $22,000).  Additionally, the 8-year non-treatment costs 
among patients on combination therapy were significantly higher than patients on 
medications alone ($17,000 vs. $14,000). Costs and response rates did not differ by gender 
and comorbidity; however, data on gender-comorbidity subgroups were constrained by 
small sample sizes. The incremental cost-effectiveness ratios indicated that medication 
management was more cost-effective than combination therapy for boys and girls over an 
8-year time horizon.  Ultimately, limited resources can be used more efficiently when 
children are treated with medications alone.        
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Chapter 1: Introduction  
           
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed 
psychiatric disorder among children and affects approximately 3 percent to 5 percent of 
children (Newcorn et al. 1994). The cause of ADHD is still unknown, and multiple pathways 
may lead to the disorder (Brown et al. 2001). ADHD results in inattention, hyperactivity, 
and/or impulsivity, all of which can yield significant academic, social, and emotional 
problems at home or school (Barkley 1998). In school settings, children with ADHD often 
struggle with academic tasks, underachieve, and sometimes fail. Socially, children with 
ADHD have dysfunctional relationships with peers, teachers, and parents. Emotionally, 
these children may exhibit poor self-esteem and have a significantly higher risk for 
depression, anxiety, and/or behavioral problems (Barkley 1998; Biederman et al. 1991). The 
prevalence of comorbid conditions in children with ADHD is relatively high; ADHD 
commonly occurs in association with oppositional defiant disorder (ODD), conduct disorder 
(CD), learning/developmental disabilities, anxiety disorders, and depression among others 
(Klassen, Miller et al. 2004; Biederman et al. 1991).  
The presence of comorbidities with ADHD can drastically change how symptoms 
present themselves. For instance, Pliszka (1998) argues that ADHD alone and ADHD with 
conduct disorder are distinct subtypes with different etiologies. While the short-term 
response to medications is the same in these two groups, children with ADHD and conduct 
disorder have higher rates of antisocial personality. In addition, Pliszka (1998) argues 
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coexisting anxiety attenuates impulsivity in ADHD, and response to some medications is 
poorer in ADHD children with comorbid anxiety. In sum, comorbidities can affect the 
symptomology of ADHD as well as reduce treatment effectiveness.    
As with other pediatric mental disorders, the goal of treatment is to reduce ADHD 
symptoms, improve day-to-day functioning, and increase the well-being of the children and 
their close contacts (Klassen, Miller et al. 2004). Pharmacological treatment, most often 
stimulant medications, is used most in practice; however, behavioral therapy, parent 
training, and other treatments are important to good clinical care (Goldman et al. 1998). 
Medications such as methylphenidate reduce core symptoms of hyperactivity, impulsivity, 
and/or inattention in multiple populations (Goldman et al. 1998). Psychosocial therapies 
may include behavioral therapy, parent management training, classroom environmental 
manipulations, and daily report cards from teachers, among others (Goldman et al. 1998). 
Many parents and physicians believe that stimulants alone are sufficient for ADHD without 
comorbidity, but additional treatments (e.g., behavioral therapy) are necessary to control 
complex cases (Goldman et al. 1998).   
ADHD is costly to the health care system. Birnbaum et al. (2005) estimated both the 
ADHD-related treatment costs and overall health care costs for the U.S. population with 
ADHD against matched controls. Females with ADHD had $130 million more in treatment 
costs than female controls, while males with ADHD had $400 million more than male 
controls. Overall health care costs for females were $4.79 billion higher if they had ADHD, 
and overall health care costs for males were $8.51 billion higher if they had ADHD.   
3 
 
Clearly, ADHD is costly to society; however few studies focus on the cost-
effectiveness of treatments for ADHD, and even fewer examine cost-effectiveness 
accounting for comorbidities. Further, though ADHD is a chronic condition, cost-
effectiveness models generally use a one-year time horizon in their analyses due to the 
paucity of long-term data. King et al. (2006) extends the time horizon to age 18, however, 
the researchers modeled only medication treatment. While Jensen et al. (2005) compared 
medication and combination (medication + behavioral) therapies, the study used only a 14-
month time horizon. Such a short time horizon does not consider long-term implications of 
treatment for ADHD. As a consequence, the comparative cost-effectiveness of treatments 
over a time horizon longer than one year is unknown.     
Despite ADHD being one of the most extensively studied childhood mental 
disorders, the literature on ADHD is almost exclusively based on boys. No study has 
addressed the role gender plays in determining which treatment is most efficient. Although 
more prevalent in boys, the disorder causes substantial psychiatric disability in girls. The 
disorder occurs quite often in girls, though the exact prevalence in females is unclear. Prior 
estimates predict that at least 1 million girls in the U.S. may be affected by ADHD (Arnold 
1996). In epidemiologic studies, the role of gender has shown mixed results. Some clinicians 
argue that when a disorder is more common among one sex, those of the other sex who 
meet the threshold for a diagnosis are generally more seriously affected (Eme 1992). Others 
found that compared to girls, boys generally have higher levels of both ADHD symptoms 
and associated behavior problems (Thorell and Rydell 2008). Because researchers cannot 
agree on how ADHD affects girls, and the data suggesting ADHD treatment effectiveness are 
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conditioned upon the presence of comorbid symptoms (Jensen et al. 2005), a cost-
effectiveness analysis of different treatment options by gender and comorbidity status is 
warranted.   
 
1.1 Research Questions 
  The overarching goal of this project is to examine gender and ADHD from an 
economic point of view, specifically the differences in costs and outcomes between girls and 
boys. To study these gender differences, I used cost-effectiveness analysis to provide 
valuable information for payers and policymakers seeking to provide the most cost-effective 
treatment for ADHD, especially in this era of limited resources and ever-increasing health 
care costs. My primary research question involved the gender differential in the cost-
effectiveness for alternative ADHD treatments, and my study answers the following 
questions:  
1. What are the economic costs and patient consequences of various 
treatments for ADHD for girls compared to boys? 
2. How does the interaction of gender and comorbidity affect the cost-
effectiveness of treatments? 
3. What are the answers to these questions if one uses a long-term time 
horizon appropriate for a chronic condition? 
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1.2 Specific Aims         
Despite an increase of research on girls with ADHD in the past decade, most ADHD 
research focuses on boys. Because ADHD is understudied in girls, despite considerable 
impairments in multiple domains, research of ADHD in girls has become a priority. My 
project extends the literature of ADHD by using a discrete-event simulation approach to 
model the eight-year cost-effectiveness of two treatment options for ADHD used in Jensen 
et al. (2005) – medication therapy and medication/behavioral combination therapy. 
Discrete-event simulation modeling can address dynamic (or time-dependent) 
characteristics of a disease, contrary to the decision-tree framework of the Jensen et al. 
(2005) analysis. My project also extends the time horizon of prior cost-effectiveness 
analyses to capture the long-term costs and outcomes associated with the treatment of 
ADHD. Using a long-term perspective to model ADHD as a chronic condition, my model 
includes children ages 7 to 15, capturing the costs and outcomes experienced from 
childhood through mid-adolescence, which cannot be efficiently addressed using prior 
decision-tree designs. To address the literature’s unanswered questions about ADHD and 
gender/comorbidity, as well as the prior cost-effectiveness studies’ limitations, my project 
has two specific aims: 
 
1) I developed a discrete-event simulation model for the treatment of ADHD.  The model 
links the treatment decision to key outcomes for children and draws on data from a 
landmark randomized controlled trial (RCT) and relevant literature to develop estimates 
of the parameters of the model. The simulation model has two key features. First, it 
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incorporates a general structure that links treatment, ADHD severity, compliance to 
therapy, comorbidity, and gender.  Second, the relationships implied by the structure 
can be characterized by parameters, such as the rates of transition between levels of 
ADHD severity. 
Specifically, I first developed an ADHD natural disease-history conceptual model, 
which was validated by clinicians with expertise in ADHD and was focused on ADHD 
severity, normalization (response rates), treatment compliance, and societal/health care 
resource consumption. I populated the model parameters using data from the landmark 
ADHD RCT to determine the probabilities and standard errors of the model parameters. For 
those parameters not in the RCT, I drew on relevant literature to determine point estimates 
and distributions of parameters, which allowed the model to incorporate the uncertainty 
around these estimates.    
 
2) I provided evidence of the costs and outcomes of ADHD treatment, using simulation to 
model the cost-effectiveness of alternative treatments for childhood ADHD.  To 
determine the costs, outcomes, and cost-effectiveness of treatments for ADHD, I 
performed a discrete-event simulation to estimate the incremental cost-effectiveness 
ratios for each of the eight gender and comorbidity combinations listed below. 
Internalizing comorbidities refer to depression, bipolar disorder, obsessive-compulsive 
disorder, anxiety, and other conditions that describe one’s emotional state. 
Externalizing disorders refer to oppositional-defiant disorder, conduct disorder, 
disruptive behavior disorder, and other conditions that can be described as disruptive.   
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i) Male with no comorbidities 
ii) Male with internalizing comorbidities 
iii) Male with externalizing comorbidities 
iv) Male with both internalizing and externalizing comorbidities 
v) Female with no comorbidities 
vi) Female with internalizing comorbidities 
vii) Female with externalizing comorbidities 
viii) Female with both internalizing and externalizing comorbidities 
   
         My analyses provide valuable information to both health care payers and 
policymakers. Specifically, the analyses inform stakeholders about the cost-effectiveness of 
different ADHD treatment modalities over an eight-year time horizon, and if the most cost-
effective treatment differs by gender and comorbidity subgroups. If my results, and others’ 
results in different disease categories, can be implemented through cost-conscious clinical 
guidelines, the potential exists for reducing practice variation possibly stemming from 
inappropriate care. Through discrete-event simulation modeling, treatment for ADHD can 
achieve efficiency.
  
Chapter 2: General Background 
 
 Natural history models for disease chart the progression of disorders, but when the 
disease is complex, the task of creating these models can be difficult. Models are intended 
to simplify the situation; they cannot capture every dynamic of a disease and the system 
that treats it but must depict the key features in order to effectively represent the system. 
Several key features of the disorder must be kept in mind when modeling the outcomes and 
costs of ADHD – any good model must reflect the traits specific to ADHD. This literature 
review cannot hope to evaluate the enormous literature on ADHD. Rather, it offers a 
focused examination of elements that are particularly salient to building a model of the 
disorder and treatment.   
 
2.1 ADHD is a common disorder affecting patients in multiple domains of life.                                                                                            
 
ADHD is the most common childhood mental disorder typically characterized by 
inattention, hyperactivity, and/or impulsivity (Klassen, Miller et al. 2004). Generally, these 
characteristics appear early in a child’s life and develop over the course of years. According 
to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), children with ADHD 
may exhibit signs of being consistently inattentive, may show a pattern of hyperactivity or 
impulsive behavior uncharacteristic of others their age, or may show each type of behavior 
(American Psychiatric Association 1994). Therefore, health professionals identify three 
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subtypes of ADHD: predominantly hyperactive/impulsive, predominantly inattentive, and 
combined (Kube, Petersen et al. 2002).        
Hyperactive children are constantly in motion, talking unremittingly or playing with 
whatever is in sight. Sitting still for extended periods (e.g., dinner, school story time or 
testing sessions, religious services, etc.) can be extremely difficult (Francis 2007). Impulsive 
children may be unable to wait their turn in an activity or may abuse a classmate or teacher 
when angry. Inattentive children struggle to keep their minds on task and may become 
quickly bored with a task (Francis, 2007). If the child enjoys the task, he or she will probably 
remain attentive; even so, the child may struggle to complete the task. The severity of these 
of hyperactive, impulsive, and inattentive symptoms can rise and fall in response to a 
myriad of events transpiring over the patient’s lifetime (DuPaul and Barkley 1992). With a 
strong relationship between symptom severity, costs, and outcomes, effectively modeling 
ADHD severity is vital. 
The estimated prevalence for ADHD in school-age children varies widely and 
depends on a number of variables, including the methods of ascertainment, the informants, 
the population sampled, the diagnostic criteria applied and the gender of the individual 
affected. A developmental perspective reveals that while ADHD is generally perceived as a 
childhood disorder, many children continue to show symptoms well into adolescence. 
Despite limited prevalence data, estimates show that 30 percent to 70 percent of children 
with ADHD continue to present symptoms through adolescence (Silver 2000; Wender, Wolf, 
et al. 2001). ADHD presents a broad range of poor outcomes in children and adolescents, 
including criminality, poor performance in school, social skills deficits, and comorbid mental 
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health disorders (Mannuzza and Klein 2000; Murphy and Barkley 1996). Therefore, models 
of ADHD treatment and outcomes should span through childhood and adolescence to 
accurately depict the nature of ADHD. 
 
2.2 Diagnosing ADHD 
The standard for diagnosing ADHD is to apply diagnostic criteria provided by the 
DSM-IV (American Psychiatric Association 1994). These criteria were created using the most 
empirically sound methods ever used to formulate criteria for a psychiatric disorder 
(Johnston and Scoular 2008). Five criteria must be met for a DSM-IV clinical diagnosis of 
ADHD (Wolraich 2006). The first requirement is that six or more of the nine inattention 
symptoms and/or hyperactivity-impulsivity symptoms must have been present for at least 
six months, to a point that they are disruptive and inappropriate for the child’s 
developmental level (Wolraich 2006). The next criterion states that some of these 
symptoms causing impairment must have been present before the age of seven. Third, 
some impairment from the symptoms must be present in two or more settings (e.g., school 
and home) (Wolraich 2006). Fourth, there must be clear evidence of significant impairment 
in social, school, or work functioning. Finally, the symptoms must not happen only during 
the course of autism, schizophrenia, or other psychotic disorders (Goldman et al. 1998). 
Fundamentally, the symptoms must not be better accounted for by another mental 
disorder (e.g., mood disorder, anxiety disorder, dissociative disorder, or a personality 
disorder).         
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 The diagnosis of ADHD depends on reports of characteristic behaviors by people 
who observe the children. The clinician must obtain information from multiple sources, 
generally the parent(s) and teacher(s).  Information is best garnered via both direct 
interviews with parents/teachers and DSM-IV-based rating scales (Wolraich et al. 2003). The 
rating scales (Table 1) can indicate the presence of ADHD (or be used for screening 
comorbid conditions); however, they are not sufficient in and of themselves to make a 
definitive diagnosis. Symptoms evaluated during the diagnostic process are as follows 
(Goldman et al. 1998):  
Inattention  
1. Often does not give close attention to details or makes careless mistakes in 
schoolwork, work, or other activities.  
2. Often has trouble keeping attention on tasks or play activities.  
3. Often does not seem to listen when spoken to directly.  
4. Often does not follow instructions and fails to finish schoolwork, chores, or duties in 
the workplace (not due to oppositional behavior or failure to understand 
instructions).  
5. Often has trouble organizing activities.  
6. Often avoids, dislikes, or doesn't want to do things that take a lot of mental effort 
for a long period of time (such as schoolwork or homework).  
7. Often loses things needed for tasks and activities (e.g., toys, school assignments, 
pencils, books, or tools).  
8. Is often easily distracted.  
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9. Is often forgetful in daily activities.  
 
Hyperactivity 
1. Often fidgets with hands or feet or squirms in seat.  
2. Often gets up from seat when remaining in seat is expected.  
3. Often runs about or climbs when and where it is not appropriate (adolescents or 
adults may feel very restless).  
4. Often has trouble playing or enjoying leisure activities quietly.  
5. Is often "on the go" or often acts as if "driven by a motor".  
6. Often talks excessively.  
 
Impulsivity 
1. Often blurts out answers before questions have been finished.  
2. Often has trouble waiting one's turn.  
3. Often interrupts or intrudes on others (e.g., butts into conversations or games).  
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Table 1: Typical ADHD Symptom Rating Scales Used for Outcome Assessment 
Rating Scale 
 
Ages Rater Total Items 
ADHD Rating Scale-IV 
(ADHD-RS) 
 
5 – 18 Parent & Teacher 18 
Swanson, Nolan, and 
Pelham-IV (SNAP-IV) 
 
5 – 11 Parent & Teacher 90 
Swanson, Kotkin, Agler, 
M-Flynn, and Pelham 
(SKAMP) 
 
7 – 12 Clinician         
(Classroom Setting) 
10 
Connors Rating Scales 
(Long or Short Version) 
 
3 – 17;                        
Self-Report  12 - 17  
Parent, Teacher, Self 
Report 
27 – 87 
Vanderbilt ADHD Rating 
Scales 
 
6 – 12 Parent & Teacher 55 Parent; 43 Teacher 
Strengths and 
Weaknesses of ADHD 
Symptoms and Normal 
Behavior Scale (SWAN) 
 
5 – 11 Parent 30 
Inattention/Overactivity 
with Aggression 
Connors Teacher Rating 
Scale (IOWA) 
 
6 – 12 Teacher 10 
Brown Attention-Deficit 
Disorder Scales (BADDS) 
3 – 7 Parent & 
Teacher;      8 – 12 
Parent, Teacher, & 
Self;  12 – 18 Self-
Report 
Parent, Teacher, Self-
Report 
44 Parent; 50 Teacher; 
40 Self Report 
 
 
 
2.3 ADHD is a chronic condition that drives service utilization and costs.  
 
 Undiagnosed or untreated ADHD can have many deleterious effects in virtually 
every aspect of life. ADHD has a profound impact on the way individuals participate in 
activities of daily living and can be a burden on public systems and society as a whole. 
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Because ADHD is a chronic condition, these impacts can be significant. These impacts are 
direct drivers of service utilization (hence costs) and are vitally important to address when 
modeling ADHD.       
 
     2.3.1 ADHD impacts health care utilization and costs. 
Cost of illness studies attempt to measure the economic impact of a given disease 
across a defined population, and are prevalent in the ADHD literature (Burd et al. 2003). 
The results of all direct medical cost studies found that children with ADHD had higher 
annual costs than either matched or unmatched controls. The higher costs were a function 
of increased hospitalizations, primary and specialty care visits, and pharmaceutical 
expenses. Additionally, the incremental increase in treatment costs associated with ADHD 
plus comorbid conditions compared to ADHD in isolation are considerable (Burd et al. 
2003). Comorbid depression increased costs by $358 per patient per year, while ODD 
increased costs by $258, bipolar disorder by $541, CD by $488, and anxiety by $499 (Burd 
et al. 2003).   
 
2.3.2 ADHD impacts utilization of non-health care public services. 
 
           The impact of ADHD on society is significant in terms of its financial cost, disruption 
in schools, and association with criminality. The effects of the disease can extend to 
workplace productivity as the parents who take care of children with ADHD lose time at 
work to accompany their children to appointments with service providers and school 
officials, not to mention the exhaustion of caring for a child with special needs. 
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Methodological hurdles prevent obtaining good estimates of the cost of ADHD to society; 
however, these costs are significant (NIH Consensus Development Program 1998). Children 
with ADHD often underachieve or may need the assistance of special education. Additional 
expenditures in public schools for students with ADHD exceeded $3 billion in 1995 (NIH 
Consensus Development Program 1998). Patients also tend to have poor relationships with 
peers, teachers, and caregivers. Internally, they may have poor self-esteem and are at an 
increased risk for depression, anxiety, or criminal/offending behavior (Klassen, Miller et al. 
2004). These characteristics of children with ADHD can have far-reaching and long-term 
societal consequences. Children with ADHD are at an increased risk for criminal activities 
leading to arrest, conviction, and incarceration (Manuzza et al. 1989). Multiple studies 
examine the effect of pediatric ADHD on criminality outcomes. Satterfield and Schell (1997) 
demonstrated that children who were diagnosed with ADHD between ages 6 and 12 had 
higher juvenile arrest rates compared to unaffected controls. Patients with ADHD are twice 
as likely to be arrested compared to controls (Matza, Paramore et al. 2005). The mean total 
criminal costs were almost 26 times higher in their ADHD group ($12,868 compared to 
$498).           
Pediatric ADHD places a significant economic burden on parents and other family 
members (Swensen et al. 2003). Using claims from a large U.S. company between 1996 and 
1998, researchers found that family members of children with ADHD had 1.6 times as many 
medical claims as matched controls (by age, gender, location, and employment status). 
Indirect costs related to disability and absenteeism operated in a similar fashion; family 
members of patients with ADHD had $888 in indirect costs per year, while controls had 
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$551 (Swensen et al. 2003). In sum, children with ADHD consume an uneven share of 
resources and attention from the health care system, schools, and the criminal justice 
system. Effective modeling of societal costs must take into account both the direct medical 
costs and indirect costs (e.g., special education and juvenile justice), as well as lost 
productivity of caregivers.   
 
 2.4 Effective treatments are available for ADHD. 
Pharmacological management of ADHD symptoms is effective and considered the 
foundation for treatment of moderate to severe symptoms (Madaan et al. 2008). Drug 
therapy can enhance the school, home, and social activities of the child. The clinical 
decision of which drug to choose is based on a number of factors. Clinicians must factor in 
the empirical evidence of drug efficacy, side-effect profiles, parental/patient preferences, 
child’s age, comorbid disorders, effectiveness of prior treatments, and financial resources 
of the parent (Madaan et al. 2008). Stimulants remain the hallmark of ADHD medication 
treatment, but atomoxetine is now an available and efficacious non-stimulant option.   
There are a number of behavioral, educational, and psychological treatments that 
can be helpful for children and adolescents with ADHD (Smith et al. 2000). The scope of 
these interventions is quite broad. Psychosocial treatment of ADHD includes several 
behavioral strategies. For example, contingency management (e.g., a point reward system 
or timeout) usually conducted in the classroom, parental training in which the caregivers 
are taught child management skills, clinical behavior management where the 
teacher/caregivers are taught to use the contingency management procedures, and 
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cognitive-behavioral treatment (e.g., self monitoring, verbal self-instruction, problem-
solving strategies, self-reinforcement), each can mitigate the typical symptoms of ADHD 
(Smith et al, 2000). Tables 2 and 3 contain detailed information about specific medication 
and behavioral treatments for ADHD.  
 
Table 2: Common Medication Treatments for ADHD 
Drug Approval Date Indication Mechanism of 
Action 
Doses (mg) Duration (h) 
MPH-IR 
(Ritalin) 
12/5/1955 ADHD, 
Narcolepsy; 
patients age 
6+ 
Blocks 
reuptake of 
dopamine in 
brain 
5, 10, 20 3 – 4 
MPH-ER 
(Concerta) 
8/1/2000 ADHD; 
patients age 6 
- 65  
Blocks 
reuptake of 
dopamine in 
brain 
18, 27, 36, 54 12 
DEX-SR 
(Dexedrine) 
8/2/1976 ADHD, 
Narcolepsy; 
patients age 
6+ 
Blocks 
reuptake of 
dopamine and 
norepinephrine 
from synapse 
5, 10, 15 8 – 12 
MAS-IR 
(Adderall) 
1/19/1960 ADHD, 
Narcolepsy; 
patients age 
6+ 
Promotes 
presynaptic 
release of 
dopamine 
5, 7.5, 10, 
12.5, 15, 20, 
30 
4 – 6 
MAS-XR 
(Adderall XR) 
10/11/2001 ADHD, 
Narcolepsy; 
patients age 
6+ 
Promotes 
presynaptic 
release of 
dopamine 
5, 10, 15, 20, 
25, 30 
12 
ATM 
(Strattera) 
11/26/2002 ADHD; 
patients age 
6+ 
Selective 
inhibition of 
noradrenaline 
reuptake 
10, 18, 25, 
40, 60 
6 – 12 
      
MPH = Methylphenidate; DEX = Dexedrine; MAS = Mixed Amphetamine Salts; ATM = Atomoxetine; IR = 
Immediate Release; ER/XR = Extended Release; SR = Sustained Release; mg = Milligrams; h = Hours 
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Table 3: General and Comparative Effectiveness Medication Studies 
Authors N Drugs Tx Length Outcome 
Measure/s 
Efficacy 
Results 
Biederman et 
al. (2003) 
 
136 MPH-ER 
Placebo 
2 weeks CADS-Teacher MPH > 
Placebo*** 
Findling et al. 
(2008) 
 
282 MPH-OROS 
Placebo 
7 weeks ADHD-RS MPH-OROS > 
Placebo*** 
Greenhill, 
Findling, and 
Swanson 
(2002) 
 
321 MPH-ER 
Placebo 
3 weeks CGI-Teacher MPH-ER > 
Placebo*** 
Wolraich et 
al. (2001) 
282 MPH-OROS 
MPH-IR 
Placebo 
3 weeks IOWA-Teacher MPH-OROS > 
Placebo*; 
MPH-IR > 
Placebo*; 
MPH-OROS = 
MPH-IR 
Biederman et 
al. (2002) 
563 MAS-XR 10mg 
MAS-XR 20mg 
MAS-XR 30mg 
Placebo 
3 weeks CGI-Teacher MAS 10mg > 
Placebo***;     
MAS 20mg > 
Placebo***; 
MAS 30mg > 
Placebo*** 
Efron, Jarman, 
and Barker 
(1997) 
 
125 DEX           
MPH-IR 
2-week 
crossover 
Connors-
Teacher 
MPH-IR > 
DEX** 
Findling, 
Short, and 
Manos (2001) 
177 MAS-IR     
MPH-IR     
Placebo 
1-week 
crossover 
ASQ-
Parent/Teacher 
MAS-IR > 
Placebo***; 
MPH-IR > 
Placebo*** 
Pelham et al. 
(1990) 
22 DEX-SR      
MPH-IR     
MPH-ER  
Placebo 
3 – 6-day 
crossover 
CPT DEX-SR > 
Placebo**; 
MPH-IR > 
Placebo**; 
MPH-ER > 
Placebo** 
Pliszka et al. 
(2000) 
58 MAS-IR     
MPH-IR     
Placebo 
3 weeks Connors-
Teacher 
MAS-IR > 
Placebo*; 
MPH-IR > 
Placebo*; 
MAS-IR >  
MPH-IR* 
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Authors N Drugs Tx Length Outcome 
Measure/s 
Efficacy 
Results 
Biederman et 
al. (2007) 
 
 
52 MAS-XR   
Placebo 
1-week 
crossover 
SKAMP MAS-XR > 
Placebo*** 
Kelsey et al. 
(2004) 
 
197 ATM      
Placebo 
8 weeks ADHD-RS ATM > 
Placebo* 
Michelson et 
al. (2001) 
297 ATM .5mg/kg  
ATM 
1.2mg/kg  
ATM 
1.8mg/kg  
Placebo 
8 weeks ADHD-RS ATM .5mg/kg 
= Placebo;    
ATM 1.2mg/kg 
>Placebo*; 
ATM 1.8mg/kg 
> Placebo* 
Kratochvil et 
al. (2002) 
 
228 MPH-IR      
ATM 
10 weeks ADHD-RS MPH-IR = ATM 
Wigal et al. 
(2005) 
 
 
215 MAS-XR     
ATM 
18 days SKAMP MAS-XR > 
ATM*** 
MPH = Methylphenidate; MAS = Mixed Amphetamine Salts; DEX = Dexedrine; ATM = Atomoxetine;  ER/XR = 
Extended Release; IR = Immediate Release; OROS = Osmotic Controlled Release System;  CADS = Connors 
ADHD Scale; ADHD-RS = ADHD Rating Scale; CGI = Connors Global Index Scale;     IOWA = 
Inattention/Overactivity with Aggression Connors Scale; ASQ = Abbreviated Symptom Questionnaire; CPT = 
Continuous Performance Task; SKAMP = Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale; mg = 
Milligrams; kg = Kilograms; N = Sample Size  ***p<=.001; **p<=.01; *p<=.05     
 
2.5 The majority of research on ADHD focuses on boys. 
Clinicians’ and researchers’ understanding of issues surrounding ADHD and gender 
has changed greatly, thanks to a growing body of literature (Quinn 2008). Still, ADHD 
research has been conducted much more often in samples of boys than girls, or in mixed 
groups without stringent efforts to determine sex differences in symptoms and/or response 
to treatment (Staller and Faraone 2006). As a result, the idea of possible sex differences in 
ADHD is quite blurred.  Males and females with ADHD are more similar than different, yet 
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small differences can affect the course of disease and the utilization of services, making it 
necessary to model boys and girls separately.     
 
     2.5.1 ADHD manifests itself differently among boys and girls. 
In pediatric samples, boys historically have had an increased incidence of diagnosis; 
estimates currently are in the range of 2.5:1 to 3:1 across all subtypes (Quinn 2008). As the 
pediatric population ages, the disparity between genders is thought to decrease, indicating 
that women may represent a higher proportion of adults with ADHD than previously 
estimated (Faraone et al. 2000). Prevalence estimates (gender ratios) vary from 3:1 to 9:1, 
depending on the study setting (i.e., clinic-referred as opposed to community sample) 
(Gaub and Carlson 1997). That said, recent studies demonstrate the gap is decreasing 
(Robison et al. 2002). 
 
          2.5.1.1 Boys are more impaired than girls in some domains, while girls are more   
           impaired than boys in others. 
 
In a meta-analysis on gender differences in ADHD, non-clinic-referred boys with 
ADHD seemed to be more impaired than non-clinic-referred girls with ADHD (Gaub and 
Carlson 1997). In a population-based study from Australia, researchers found that boys 
with hyperactive/impulsive or combined subtypes of ADHD were more clinically impaired 
than girls of the same subtypes; however, girls with the inattentive subtype were typically 
more impaired than inattentive boys (Graetz, Sawyer et al. 2005). In school settings, girls 
and boys with ADHD show comparable academic performance (Gaub and Carlson 1997); 
however, in social situations, girls were more impaired during their leisure time and less 
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impaired on the School Behavior subscale (Greene et al. 2001). Finally, empirical evidence 
indicates greater intellectual impairment in girls with ADHD compared to boys; however, 
researchers have stated that the differences are not clinically significant (Gaub and Carlson 
1997; Biederman et al. 2002; Greene et al. 2001). 
 
          2.5.1.2 The ADHD developmental patterns of girls and boys appear to differ. 
 
Little research addresses developmental patterns in studies of gender differences in 
ADHD (Gaub and Carlson 1997). As children with ADHD age, the deficits of girls increase 
compared to boys (Brown, Madan-Swain et al. 1991). Girls perform more poorly on 
neurocognitive tasks and are less popular among their peers. Boys, on the other hand, 
improve on neurocognitive tasks, and their peer ratings do not change as they age (Brown, 
Madan-Swain et al. 1991).  An older study made similar assertions: As girls with ADHD age, 
they increasingly are rejected by peers, while boys’ ratings are unchanged (Berry, Shaywitz 
et al. 1985). Finally, the prevalence rate for boys wanes by 20 percent per year from age 10 
to 20, while girls’ rates remained constant over the same ages (Cohen et al. 1993). 
2.6 Comorbidities are quite prevalent among children with ADHD. 
ADHD is associated with the presence of major psychiatric disorders. As many as two 
out of three children with ADHD in the general population meet DSM-IV criteria for a 
psychiatric comorbidity (Jensen et al. 2001). Comorbid psychiatric disorders can be divided 
into two groups characterized by internalizing or externalizing behaviors. Some emotional 
or behavioral disorders manifest themselves outwardly. Externalizing behaviors constitute 
acting-out style that could be described as aggressive, impulsive, coercive, and 
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noncompliant. Other disorders are more accurately described as "inward." Internalizing 
behaviors are typical of an inhibited style that could be described as withdrawn, lonely, 
depressed, and anxious.    
 
2.7 Comorbidities can complicate treatment for ADHD. 
Comorbid disorders can complicate the assessment of treatment effectiveness yet 
are important in predicting the long-term outcome of a child with ADHD. Comorbidities can 
strengthen the link between ADHD and service utilization as well as intensify the risk for 
poor long-term outcomes, moderating the cost-effectiveness of alternative treatments 
(Foster et al. 2007). To effectively model ADHD, the effects of comorbidities must be 
factored in to account for these issues. The most common externalizing comorbidities are 
oppositional-defiant disorder and conduct disorder. Common internalizing comorbidities 
include depression, anxiety disorders, and bipolar disorder (Banaschewski et al. 2007; 
Steinhausen et al. 2006). See Appendix C for descriptions, details, and the prevalence of 
specific comorbidities.  
 
2.8 Comorbid conditions can be quite different in boys compared to girls. 
The literature firmly establishes that ADHD is associated with significant 
comorbidity. Comorbid disorders in girls with ADHD can be quite different from those seen 
in boys. A large, multisite, placebo-controlled study of adults found that despite popular 
opinion, more women had ADHD combined type than men (Robison et al. 2002). In 
addition, women had more affective symptoms (e.g., anxiety or depression). The 
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researchers concluded that women with ADHD were more impaired than men. Other 
studies have found conflicting results. Biederman et al. (2004) reported that the only 
gender disparities in comorbidities were a lower rate of conduct disorder and of antisocial 
personality disorder in women. Clinicians generally agree that males have more 
externalizing (i.e., behavior) disorders on average, whereas females have more internalizing 
disorders (e.g., anxiety or depression). Rucklidge and Tannock (2001) found that adolescent 
girls with ADHD displayed greater psychological distress than their male counterparts. The 
girls more often reported anxiety, overall distress, and depression, and were at greater risk 
for future psychiatric hospitalizations.   
 
 
2.9 The limited literature on cost-effectiveness of alternative treatments for ADHD. 
      The literature on cost-effectiveness of different treatment modalities is quite sparse, 
and most studies lack methodological considerations characteristic of an economic analysis 
of a chronic condition, particularly ADHD. Among the limitations of the cost-effectiveness 
studies are their short time horizons, a lack of comprehensive treatment alternatives (i.e., 
non-drug therapies are not evaluated), lack of variation in treatment efficacy based on 
severity levels and gender, and failure to factor in compliance to treatment (King et al. 
2006). Descriptions of each study are provided below; summary tables of each study are 
found in Table 4.     
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     2.9.1 Lord and Paisley (2000)    
 Lord and Paisley (2000) performed a cost-effectiveness analysis for NICE, comparing 
combined MPH + BT verses BT in isolation using the MTA data. The time horizon was 14 
months and under the perspective of the National Health Service (NHS). The authors used 
only the costs of MPH, assuming that the BT costs were equivalent in both treatments 
options. During the first month, 94 percent of the patients were titrated, averaging 10 mg of 
MPH per day. During the remaining 13 months, 70 percent of the children took an average 
of 30 mg per day. The treatment costs for the combination arm included a 30-minute 
consultation with a pharmacotherapist. The authors assumed that two outpatient visits 
were made during the titration period, with monthly visits during the maintenance period. 
Also, the authors assumed that 6 percent of the children did not start with titration and that 
7percent remained unmedicated during the maintenance period. The results indicated that 
combination therapy cost $2,540 per one standard deviation improvement in the SNAP-IV 
(Swanson, Nolan, and Pelham-IV) index, based on teacher rating of ADHD symptoms. 
Sensitivity analyses showed the incremental cost-effectiveness ratio (ICER) ranged from 
$1,111 to $7,146. 
 Lord and Paisley (2000) used a short time horizon that could not capture the long-
term costs characteristic of a chronic condition. Additionally, they modeled only behavioral 
therapy and combination therapy, which didn’t address the first-line treatment of 
medication management consistent with clinical practice. Finally, by not factoring in gender 
or comorbidities into their analyses, they failed to attend to important aspects of ADHD that 
could affect treatment effectiveness or utilization of resources.      
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     2.9.2 Zupancic et al. (1998) 
 Zupancic et al. (1998) performed a cost-effectiveness analysis comparing five 
interventions for ADHD: MPH-IR, DEX, behavioral therapy (BT), combination MPH-IR + BT, 
and no treatment. The analysis was over a one-year time horizon from the Canadian health 
care payer perspective. The authors used the Abbreviated CTRS with estimates from clinical 
trials’ meta-analyses. They presented outcomes as a cost per one- and six-point reductions 
in the mean CTRS score.      
The costs of medical care included the costs of the interventions (drugs/BT), 
physician visits, and hospitalizations. The medical resource use was based on available data 
from the peer-reviewed literature as well as expert opinion. Patients on MPH-IR were 
assumed to have four physician visits, two specialist visits, and two lab tests (at baseline and 
one year). Patients on DEX were assumed to have three physician visits and two specialist 
visits. BT was composed of 16 hours of counseling, eight hours of parental training, and two 
hours of teacher training. Patients receiving no treatment were assumed to have four more 
office visits than children without ADHD. The results showed that MPH-IR was the most 
cost-effective option at $64 for a one-point gain and $384 for a six-point (1 SD) gain in the 
CTRS.   
In a critique, King et al. (2006) stated: “It is not clear, from the presentation of the 
results, whether the distribution of change in CTRS is normal and, unless this is so, 
estimating the number of patients experiencing a six-point reduction using the reported 
overall mean CTRS will not be accurate. Therefore, it may be appropriate to estimate 
response on an individual, patient-level basis.” According to King et al. (2006), significant 
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heterogeneity in the efficacy studies and the paucity of BT effectiveness diminished the 
reliability of their estimates. The authors also assumed medication efficacy is constant 
across baseline levels of ADHD severity; however, the efficacy of stimulants has been found 
to be dependent on the severity of symptoms (King et al. 2006). Finally, by failing to 
incorporate gender and comorbidity into their model, as well as a longer-term time horizon, 
their analyses fall short of providing the necessary details to assess the cost-effectiveness of 
treatments for ADHD. 
 
     2.9.3 Jensen et al. (2005) and Foster et al. (2007) 
 Jensen et al. (2005) conducted a cost-effectiveness study based on the results of the 
MTA trial. They employed a societal perspective and evaluated the treatment options (i.e., 
medication management, behavioral therapy, combination therapy, routine community 
care) over a one-year time horizon. The costs of medications were garnered from the 
National Drug Data File Plus, while resource utilization (including teachers’ time) were 
calculated by determining hourly wages based on each respective salaries. The cost-
effectiveness was based on a simple formula: 
 
average cost of new treatment – average cost of usual treatment 
------------------------------------------------------------------------------------------- 
average effectiveness of new treatment – average effectiveness of usual treatment 
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This equation represented the ICER, with the SNAP-IV parent and teacher scale as the 
effectiveness measure. Sensitivity analyses were performed varying the cost estimates 
found.     
 The authors presented their results in comorbidity subgroups (i.e., ADHD only, ADHD 
+ internalizing disorders, ADHD + externalizing disorders, ADHD + both types of disorders). 
When comparing medication management and community care, each subgroup was cost-
effective, with the highest ICER estimated at $988 (both types of comorbidities subgroup). 
When comparing behavioral therapy with community care at a $50,000 threshold 
willingness to pay, behavioral therapy is cost-effective in only the ADHD + internalizing 
disorders (ICER = $31,690) and ADHD + both types of disorders (ICER = $26,480) subgroups, 
while both more expensive and less effective than community care. The combined therapy 
was cost-effective across all subgroups compared to community care, with the highest ICER 
for ADHD + externalizing disorder ($17,691). The combined treatment arm was generally 
not cost-effective compared to medication management; however, it was cost-effective in 
the ADHD + both types of disorders subgroup (ICER = $29,840). The combined treatment 
arm was cost-effective compared to behavioral treatment across all subgroups, with the 
highest ICER associated with the ADHD + internalizing disorder subgroup ($4,896). Finally, 
across all subgroups, behavioral therapy was both more expensive and less effective than 
medication management.   
 Foster et al. (2007) used the same mathematical methodology as Jensen et al. 
(2005). The cost-effectiveness acceptability curve of the entire MTA cohort showed 
medication management with the highest probability of being the optimal treatment until 
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the threshold willingness to pay reached approximately $50,000. At this point, combination 
therapy appeared to have the highest probability of being the optimal treatment. The cost-
effectiveness acceptability curves stratified by comorbidity (i.e., ADHD only, ADHD + 
anxiety, ADHD + conduct disorder, all three) indicated several differences. First, medication 
management always had the highest probability of being the optimal treatment in patients 
with only ADHD. For patients with comorbid conduct disorder, medication management 
had the highest probability of being the optimal treatment until the threshold willingness to 
pay reached approximately $25,000, at which point combination therapy had the highest 
probability of being the optimal treatment. In patients with comorbid anxiety, community 
care was the best choice until the threshold willingness to pay reached approximately 
$1,000. Then, the best choice became medication management until the threshold reached 
approximately $10,000, at which point the best option became behavioral therapy. Finally, 
in patients with all three disorders, medication management had the highest probability of 
being the optimal choice until the threshold reached approximately $30,000, at which point 
combination therapy became the best choice. The take away message from both studies is 
that comorbidity status certainly has a role in determining which treatment is most cost-
effective. 
 These two studies employed a more sound methodology for estimating the ICERs 
compared to Lord and Paisley (2000) and Zupancic (1998). They incorporated comorbidity 
into their analyses, which could capture an important aspect of ADHD and treatment 
effectiveness. However, they did not evaluate the cost-effectiveness over a longer-term 
time horizon, which failed to capture the costs associated with the chronic condition. 
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Neither did they address ADHD severity, which also plays a role in treatment effectiveness. 
Ultimately, readers were left wondering how each of these factors affected the ICERs. 
      
     2.9.4 Gilmore and Milne (2001) 
 Gilmore and Milne (2001) evaluated the cost-utility of MPH compared to placebo for 
children with hyperkinetic disorder, which falls under the broader umbrella of ADHD. They 
conducted the study under the perspective of the NHS.  Their resource use inputs included 
dosage of MPH and the average number of outpatient clinic visits. All follow-up was 
assumed to be hospital-based, and those who terminated treatment or non-responders 
were assumed to be treated for only six weeks. In addition, those who remained in the 
analysis for the entire one-year time horizon received five outpatient clinician 
appointments. The incremental cost per QALY (quality-adjusted life year) ratio of MPH over 
placebo totaled $14,573 (with a range from $9,472 to $22,589) when a 70 percent response 
rate was used. Sensitivity analyses, varying input estimates simultaneously, raised the ratio 
to $46,135 under the most pessimistic scenario.      
 King et al. (2006) raised a couple of concerns regarding methodology. First, they 
provided little information on how they garnered their resource information from experts’ 
opinions. The reliability of these estimates is paramount to the validity of the final cost-
utility ratios. Second, they compared the treatment to placebo, which failed to include 
other relevant therapies, although King et al. (2006) recognized that head-to-head data may 
not have been present in 2001. In addition to not modeling alternative treatments, the 
authors did not address gender, comorbidity, and ADHD severity. Together with the short, 
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one-year time horizon, these limitations produce results that are not very helpful in making 
efficient treatment decisions.          
       
     2.9.5 Janssen-Cilag NICE Submission (King et al. 2006) 
 The Janssen-Cilag submission compared methylphenidate-ER with methylphenidate-
IR, atomoxetine, and behavioral therapy for children diagnosed with severe ADHD in a cost-
utility analysis. The analysis was parameterized with data from two randomized trials, 
including the MTA trial. The model took the form of a decision tree with a one-year time 
horizon and was conducted from the NHS perspective. The outcome measure was response 
to treatment, based on the parent-rated SNAP-IV scale; however, for the comparison of 
methylphenidate-ER with atomoxetine, the effectiveness data were taken from another 
trial. The resource utilization and costs associated with treating ADHD were based on peer-
reviewed literature as well as expert opinion. The results of the study showed that 
methylphenidate-ER dominated all other treatment options, with the exception of 
methylphenidate-IR; however, the incremental cost-effectiveness ratio in this case was 
$7.928/QALY, which is well within the bounds of cost-effectiveness using conventional 
thresholds of willingness to pay.  
 The authors’ methodology did have some limitations. First, the time horizon was 
short with no mention of comorbidity, severity, or gender, making it difficult to determine 
the cost-utility of alternative treatment options over the course of the disease. Second, the 
cost-utility model did not make good use of the available literature, using only two trials 
from a relatively large body of research. Further, the response rates to BT were taken from 
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the MTA trial, and when single arms of trials are used, it breaks the randomization and 
assumes that the baseline characteristics from the two trials are the same. Next, the model 
assumes equivalent response to combination therapy regardless of the medication used in 
treatment, which is most likely not appropriate. Finally, a decision tree was used to model 
the disease, which can be problematic because trees require mutually exclusive outcomes 
and do not consider time. 
 
 
     2.9.6 Celltech NICE Submission (King et al. 2006).  
 The Celltech submission compared methylphenidate-ER in a cohort of children 
unable to comply with twice-daily methylphenidate-IR. The authors performed a cost-utility 
analysis from the NHS perspective, based on reviews of treatment for ADHD. They 
employed a decision tree with a time horizon of one year. The model made assumptions 
regarding compliance to morning and afternoon doses of methylphenidate-IR, with 
uncertainty built around each estimate. The authors also assumed a higher compliance rate 
with methylphenidate-ER because the medication is taken only once daily (in the morning). 
Though the authors did not provide a definition of response, they assumed the response 
rates of each drug would be equal, based on the findings of prior studies. The medication 
costs were based on published pricing lists for the UK, while resource utilization was based 
on expert opinion. The model did not include any treatment costs associated with side 
effects. Utility data were based on prior studies’ estimates, using the EQ-5D (generic quality 
of life questionnaire).   
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 The comparator for methylphenidate-ER was no treatment, because the cohort was 
already taking methylphenidate-IR but not compliant. The authors calculated a 
$23,276/QALY ICER for methylphenidate-ER. With the threshold willingness to pay set at 
$47,000, the cost-effectiveness acceptability curve indicated that methylphenidate-ER was 
cost-effective in 100 percent of the simulations. In sensitivity analyses, the ICER was in the 
range of $19,000 to $27,000. 
 The methodological limitations appeared immediately. First, the authors did not 
explore the full range of treatment options, though they did specify a specific population for 
study — patients who were not compliant with twice-daily methylphenidate-IR. Second, as 
with most of the other studies, the authors set the time horizon to a short one-year, making 
it difficult to assess the long-term nature of the disease. Third, the model was extremely 
sensitive to assumptions made regarding compliance rates, and unfortunately, these were 
acquired via expert consultations. Furthermore, the authors assumed that compliant non-
responders would be moved to a different treatment, while non-compliers would not be 
deemed non-responders, even though they cannot respond to a treatment that they are 
not taking appropriately. Finally, the model did not consider comorbidities, gender, ADHD 
severity, or non-drug therapies, leaving the reader to wonder how these variables affected 
the cost-effectiveness of treatments.  
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     2.9.7 Eli Lilly NICE Submission (Cottrell et al, 2008) 
 The Eli Lilly submission used a Markov model to estimate the cost-utility of adding 
atomoxetine to an existing strategy of medication management, using a one-year time 
horizon under the perspective of the NHS. The authors created five subgroups: 
1. Stimulant naïve patients with no contraindications to any treatment. 
2. Stimulant naïve patients with contraindications to stimulants. 
3. Stimulant exposed patients who have failed on methylphenidate. 
4. Stimulant exposed patients with contraindications to stimulants. 
5. Stimulant exposed patients with no contraindications to any treatment, and 
who have not failed on previous therapy. 
For Groups 1 and 5, the treatment strategies compared methylphenidate, followed by 
dextroamphetamine, followed by no treatment, with and without atomoxetine preceding 
methylphenidate. Groups 2 and 4 compared strategies of no treatment, with or without 
atomoxetine as first-line therapy. For Group 3, they compared dextroamphetamine 
followed by no treatment, with or without atomoxetine as first-line therapy. The response 
rates were calculated from a metaregression of several clinical trials comparing 
atomoxetine with methylphenidate. Response to treatment was defined as a ≥25% 
reduction in parental-rated ADHD-RS scores. The probability of response for patients who 
previously failed on methylphenidate was taken from a crossover trial comparing 
methylphenidate and dextroamphetamine. The resource utilization and cost information 
included only medication-related costs, taken from published sources. The utility data were 
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based on a previous study that gathered utilities during a standard gamble interview based 
on parental preferences (proxy for children’s responses). Dextroamphetamine was not 
included in the utility study; therefore, the authors assumed that the values would be 
equivalent to those who were on methylphenidate. The results illustrated that adding 
atomoxetine as a first-line therapy is cost-effective using generally accepted thresholds for 
willingness to pay. The ICERs ranged from a low of $18,300 for Group 2 to $24,385 for the 
immediate release version of methylphenidate. The main limitations of this model mirror 
the limitations of the previous models mentioned: the short time horizon and failure to 
consider longer-term consequences, the lack of a non-drug treatment, and a failure to 
include comorbidities, gender, and ADHD severity in their model.  
 
     
     2.9.8 King et al. (2006) 
 The King et al. (2006) model assessed the cost-utility of methylphenidate-IR, 
methylphenidate-ER, dextroamphetamine, atomoxetine, and combination therapies with 
each of the aforementioned medications. The model was probabilistic in nature, used a 
hypothetical cohort of children 6 years of age, and was based on the perspective of the NHS 
during a one-year time horizon. The authors also extended the time horizon in a secondary 
analysis to age 18. Their model described alternative sequences of treatments; patients 
who fail to respond or discontinue treatment are assumed to move to the next therapy, 
until they reach no therapy at the end. There were six different treatment sequences; 
however, this number ballooned to 37 after the inclusion of the three formulations of 
methylphenidate, behavioral therapy combinations, and no treatment (6 X 3 X 2 = 36 + 1 = 
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37).  In the long-term extrapolation of the patient to age 18, the model assumes that each 
patient will have a two-week drug holiday each year to determine whether the disease is in 
remission, and this is built into the model using data on the age-related decline in ADHD 
symptoms. The authors used several different clinical response definitions (i.e., Clinical 
Global Impression Improvement subscale, the Clinical Global Impression Severity subscale, 
ADHD-RS, SNAP-IV). The resource utilization estimates were drawn from a Delphi panel of 
experts and the uncertainty around these estimates were modeled as a gamma distribution. 
Drug prices were garnered from published UK data. As stated before, the utility data came 
from a study employing the standard gamble technique to elicit parental preferences under 
uncertainty. The uncertainty around these estimates was modeled as a beta distribution, 
with values not falling below 0.   
 In the base case analysis (no combination treatment, 19 options), they found that a 
strategy of dextroamphetamine to methylphenidate-IR to atomoxetine to no treatment 
would be the most cost-effective, dominating all other drug options. When the full range of 
study comparators was included, the aforementioned strategy was still the most cost-
effective; however, more recent information indicates it does not continue to dominate all 
strategies. The only alternative not ruled out by dominance or extended dominance is 
combination therapy with dextroamphetamine to atomoxetine to methylphenidate-ER to 
no treatment. The ICER for the latter strategy compared to the former is $1,971,737/QALY, 
which is obviously not cost-effective. That said, the decision uncertainty among 37 options 
is higher than the original 19 options, and under a $47,000 threshold willingness to pay, the 
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combination strategy has a 40 percent chance of being the most cost-effective, compared 
to a 60 percent chance for the strategy without the behavioral therapy element. 
 The King et al. (2006) model is the most comprehensive among the ADHD treatment 
cost-effectiveness literature. The authors address many of the current unanswered 
questions in the literature. They factor in comorbidities, include a comprehensive list of 
treatment options, and use a long-term time horizon. However, they do not include gender 
or ADHD severity in their estimates of costs and response to treatment.   
 
     2.9.9 Marchetti et al. (2001) 
 Marchetti et al. (2001) examined the expected direct costs for six medication 
treatments directed toward school-age children with ADHD. The authors compared the 
costs associated with MPH-ER (generic), MPH-ER (branded-Metadate CD), MPH-ER 
(branded-Concerta), MPH-IR (generic), MPH-IR (branded-Ritalin), and MAS-IR. The analysis 
was performed from the U.S. payer perspective but included school-related costs. 
Probabilities of parameters (e.g., treatment success/failure) were accrued from the peer-
reviewed literature. Clinical experts estimated that it took four weeks (on average) to 
evaluate the response to medication; therefore, the evaluation period for the model was 
four weeks. Metadate CD had the lowest total expected cost per year at $1,487, while MAS-
IR had the highest annual expected total cost at $2,232. One key omission from the 
methodology was the inclusion of medication compliance. Low compliance associated with 
multiple daily dosing generally results in higher costs, due to increased accidents, 
hospitalizations, etc. Perhaps the most glaring oversights in methodology were not factoring 
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in comorbidities, gender, or ADHD severity when determining total direct costs.  As stated 
earlier, each variable can alter the costs and response to treatments for ADHD. 
 
     2.9.10 Vanoverbeke et al. (2003) 
 Vanoverbeke et al. (2003) modeled the costs for ADHD treatment in patients 6 to 16 
years old in the UK. They compared starting treatment with MPH-IR (one to three times 
daily), MPH-ER (branded-Concerta), or BT over a one-year time horizon. The authors 
employed a decision tree analysis with parameter estimates gleaned from the peer-
reviewed literature. The probabilities for parameters related to two-line treatment were 
gathered from an expert panel. Costs (e.g., medications, lab tests, clinician/school 
involvement in BT) were also based on published prices in 2001 dollars, and outcomes were 
garnered from the MTA trial. The cost of initiating treatment with MPH-IR ($2,115) was 
slightly lower than with Concerta ($2,163), while BT was the most expensive initial 
treatment $3,049). However, the probability of treatment success was highest with 
Concerta. King et al. (2006) noted that because data were used from different trials, the 
randomization in each trial was broken. Also, the response rates could be called into 
question because the Concerta rates were based on a small short-term study.   
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2.10 The design limitations of the literature are similar across studies. 
 In sum, almost all cost-effectiveness studies were based on a one-year time horizon; 
the Lord and Paisley (2000) and King et al. (2006) studies were two exceptions (14-month 
time horizon and 12-year time horizon, respectively). Even though ADHD and treatment for 
the disorder are known to last for many years, the vast majority of studies fail to consider 
the long-term costs or response to treatment. In addition, no study evaluated a complete 
set of treatment alternatives. While Zupancic et al. (1998) compared several treatments; 
the authors did not consider atomoxetine, which is a newer non-stimulant medication that 
can be used by those with contraindications to stimulants (e.g., anxiety, tic disorders). Only 
two studies modeled compliance and no study addressed the role of gender in cost-
effectiveness. See Table 4 for a comprehensive list of cost/cost-effectiveness studies 
outlining the weaknesses. 
 
2.11 Gaps in the Literature and Contributions of Proposed Research 
 I have outlined several gaps in the literature that my project answers. First, I was 
able to fill the gaps in ADHD cost-effectiveness methodology by extending the time horizon 
to eight years (age 7 to age 15) to capture longer-term costs and consequences of a 
particular ADHD therapy, and by including medication and combination treatments from 
which to make comparisons. Second, of the few cost-effectiveness studies of ADHD 
treatment, even fewer took into account comorbid conditions that could alter the 
course/outcomes of treatment, and no study examined the effect gender has on treatment 
cost-effectiveness. While the effects of gender, in and of itself, is a welcomed addition to 
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the literature, my literature review shows that comorbidity and its effects on ADHD can vary 
by gender and may or may not have a differential impact on treatment effectiveness. 
Therefore, by exploring the interaction of gender and comorbidity status, I was able to 
inform clinicians and payers who should receive what treatment, based on cost-
effectiveness. My hope is that the information garnered from this study, in addition to other 
studies encompassing other therapeutic areas, will assist in ushering in a new era of cost-
conscious clinical guidelines. Given that clinical guidelines appear to focus on issues of 
effectiveness, broader issues such as cost have not been explicitly entertained. I expect that 
the role of decision analysis in the development of clinical guidelines will become more 
prominent in the U.S. as health care costs continue to rise. 
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Table 4: Cost/Cost-Effectiveness Studies on Pediatric ADHD   
Authors 
 
Gilmore and Milne 
(2001) 
Lord and Paisley 
(2000) 
Zupancic et al. (1998) 
Study Type 
 
CUA CEA CEA 
Population 
 
Children Children Children 
Perspective 
 
NHS NHS Canadian Payer 
Time Horizon 
 
12 months 14 months 12 Months 
Treatment/s MPH BT; MPH-IR + BT MPH-IR; DEX; BT;   
MPH-IR + BT; No Tx 
Findings $11,750 - $14,600 per 
QALY 
ICER for Combined 
Treatment = 
$2,540/1SD increase in 
SNAP-IV 
MPH-IR Dominates all 
other options; 
$384/1SD increase in 
CTRS 
Weaknesses Short Time Horizon;     
No Alternative Options 
Analyzed  
Short Time Horizon; 
Lack of Full Range of 
Comparators 
Estimated Response 
Using Overall Mean 
(Not Patient-Level); 
Short Time Horizon; 
Lack of Full Range of 
Comparators; 
Heterogeneity of 
Efficacy Studies 
CUA = Cost-Utility Analysis; CEA = Cost-Effectiveness Analysis; NHS = National Health Service; MPH = 
Methylphenidate; DEX = Dexedrine; BT = Behavioral Therapy; Tx = Treatment; IR = Immediate Release; QALY 
= Quality-Adjusted Life Year; ICER = Incremental Cost-Effectiveness Ratio; SNAP = Swanson, Nolan, and 
Pelham Rating Scale; SD = Standard Deviation; CTRS = Connors Teacher Rating Scale  
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Table 4 cont’d: Cost/Cost-Effectiveness Studies on Pediatric ADHD   
Authors Marchetti et al. (2001) Vanoverbeke et al. 
(2003) 
NICE – Janssen  
Study Type 
 
Expected Direct Costs Cost of Management CUA 
Population 
 
School-Aged Children 6 – 16 year olds Children & 
Adolescents 
Perspective 
 
US Payer UK NHS 
Time Horizon 
 
12 Months 12 Months 12 Months 
Treatment/s MPH-ER; MPH-IR;   
MAS-IR 
MPH-IR; MPH-ER; BT Concerta; MPH-IR; 
ATM; MPH-ER; BT 
Findings MPH-ER = Lowest 
Expected Costs 
($1487); MAS-IR = 
Highest Expected Costs 
($2232) 
Lowest Cost Treatment 
Initiation = MPH-IR 
($2,115); Highest Cost 
= BT ($3,409) 
Concerta Dominates 
All Other Options; 
$7,927 per QALY 
Weaknesses Short Time Horizon; 
Lack of Full Range of 
Comparators; 
Comorbid Conditions 
Not Factored in Model 
Data From Different 
Trials Breaks 
Randomization 
(Response Rates 
Questionable); Short 
Time Horizon; Lack of 
Full Range of 
Comparators 
Short Time Horizon; 
Effectiveness Based 
Off Only Three Trials; 
Lack of Full Range of 
Comparators 
CUA = Cost-Utility Analysis; UK = United Kingdom; NHS = National Health Service; MPH = Methylphenidate; 
MAS = Mixed Amphetamine Salts; ATM = Atomoxetine; BT = Behavioral Therapy; IR/ER = Immediate/ 
Extended Release; QALY = Quality-Adjusted Life Year 
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Table 4 cont'd: Cost/Cost-Effectiveness Studies on Pediatric ADHD 
Authors NICE - Celltech King et al.     (2006)  Cottrell et al. (2008) 
Study Type 
 
CUA CUA CUA 
Population Children Unable to 
Comply With MPH-IR 
Children & Adolescents Children 
Perspective 
 
NHS NHS NHS 
Time Horizon 
 
12 Months 12 Months 12 Months 
Treatment/s MPH-ER; MPH-IR; No 
Tx 
MPH-IR; MPH-ER; DEX; 
ATM 
ATM; MPH-IR; MPH-
ER; DEX-IR; No Tx 
Findings MPH-ER ICER = 
$23,275 per QALY; 
Always Most C/E 
Strategy if WTP = 
$47,000 per QALY 
$11,320 per QALY 
When the Order of Tx 
is MPH-IR---DEX---
ATM---No Tx 
Adding ATM to a Tx 
Algorithm is C/E; 
Costliest = Stimulant-
Averse Patients 
($25,215 per QALY) 
Weaknesses Lack of Full Range of 
Comparators; Short 
Time Horizon; Model 
Very Dependent on 
Compliance 
Assumptions 
Short Time Horizon 
(Although Longer 
Horizon is Proposed); 
Lack of Full Range of 
Comparators 
Short Time Horizon; 
Lack of Full Range of 
Comparators; Utilities 
Not Estimated From 
Patient Perspective 
CUA = Cost-Utility Analysis; NHS = National Health Service; MPH = Methylphenidate; MAS = Mixed 
Amphetamine Salts; DEX = Dexedrine; ATM = Atomoxetine; BT = Behavioral Therapy; Tx = Treatment; IR/ER 
= Immediate/ Extended Release; QALY = Quality-Adjusted Life Year; ICER = Incremental Cost-Effectiveness 
Ratio; C/E = Cost-Effective; WTP = Threshold Willingness to Pay 
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Table 4 cont'd: Cost/Cost-Effectiveness Studies on Pediatric ADHD 
Authors 
 
Faber et al. (2008) Foster et al. (2007) Jensen et al. (2005) 
Study Type 
 
CUA CEA CEA 
Population Children (8 – 18) Sub-
optimally Controlled 
With MPH-IR 
7 – 9.9 Year-Olds 7 – 9.9 Year-Olds 
Perspective 
 
Societal (Dutch) US Payer US Payer 
Time Horizon 
 
10 Years 14 Months 14 Months 
Treatment/s MPH MPH-IR; Routine 
Community Care; BT; 
MPH-IR + BT 
MPH-IR; Routine 
Community Care; BT; 
MPH-IR + BT 
Findings ICER = $3,110 per 
QALY; Estimate is 
Sensitive to Several 
Assumptions 
Best Option Varies 
Based on Comorbidity 
Status and Threshold 
WTP 
Best Option varies 
Based on Comorbidity 
Status; BT Always 
Dominated By MPH-IR 
Weaknesses QALYs Garnered From 
1 UK Utility Study (Not 
a Dutch Study); Lack of 
Full Range of 
Comparators 
Short Time Horizon Short Time Horizon 
CUA = Cost-Utility Analysis; CEA = Cost-Effectiveness Analysis; UK = United Kingdom; MPH = 
Methylphenidate; BT = Behavioral Therapy; IR/ER = Immediate/ Extended Release; QALY = Quality-Adjusted 
Life Year; ICER = Incremental Cost-Effectiveness Ratio; WTP = Threshold Willingness to Pay 
 
 
 
 
 
 
 
 
 
  
Chapter 3: Methods 
 This study addresses the question of which ADHD treatments are most cost-effective 
for boys and girls stratified by comorbidity. Decision analytic methods provide a vehicle to 
compare two or more alternative treatments. These methods can serve as a guide to 
optimize health care resource allocation in a standardized and scientifically grounded 
manner. We can distinguish several types of decision analytic tools for economic evaluation: 
cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis, and cost-utility 
analysis.  
 Cost-minimization analysis is used when the effectiveness of two treatments are 
equivalent (Cunningham 2001). Cost-minimization studies identify the lowest-cost 
treatment. Since effectiveness has already been demonstrated, no requirement to find a 
common efficacy denominator is necessary. Cost-minimization analyses typically have great 
appeal to analysts and decision-makers who want to keep studies and evidence simple. But 
often the two treatments under consideration are not similarly effective. Even when data 
are known, cost-minimization analysis is rarely the appropriate method of analysis (Briggs 
and Obrien 2001).  
 Cost-benefit analysis compares alternative treatments by using a generic monetary 
outcome (e.g., dollars). Both benefits and costs are expressed in monetary terms and are 
adjusted for the time value of money, so that all flows of benefits and costs are expressed in 
terms of their present value. Generally, techniques like ‘willingness-to-pay’ are used to 
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make individual assessments about the value of the health outcomes associated with the 
treatment (Robinson 1993). Willingness to pay can be determined in several ways, one of 
which is contingent valuation. With this technique, individuals are asked to state the most 
they would be willing to pay to assure the outcome of a treatment (Robinson 1993). This 
amount, deemed the ‘value’ of the given outcome, allows analysts to determine the 
desirability of the treatment. 
 Cost-effectiveness analyses compare alternative treatments by using an outcome 
measured in natural units (Cunningham 2001). The level of outcomes varies but can be 
expressed by metrics such as blood pressure reduction or another measure of treatment 
response. Results are normally expressed as the incremental costs per incremental unit of 
effect (incremental cost-effectiveness ratio). Cost-effectiveness analyses are useful for 
comparing treatments whose effects are measured in the same units.  It is not possible to 
compare treatments or interventions that have several types of clinical effects. This 
disadvantage led to the development of cost-utility analyses (Cunningham 2001).  
 Cost-utility analyses are used when quality of life is an important outcome 
(Cunningham 2001). It is also an ideal method when a treatment impacts both morbidity 
and mortality – or when treatments have multiple outcomes and need a common metric 
(Cunningham 2001). Utility is a term used by economists that represents a patient’s level of 
well-being while in specified health states (Cunningham 2001). Utility-based measures are 
typically expressed in terms of quality-adjusted life years (QALYs), which are metrics based 
on both the quality and length of life experienced.  
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 Cost-effectiveness analysis provides the best vehicle to answer my study questions 
for several reasons. First, the treatments in my study appear to yield differential rates of 
response, thus ruling out cost-minimization analysis (MTA Cooperative Group 1999).  I also 
lack sufficient data on the health-related quality of life associated with providing treatments 
for ADHD, which would be necessary to carry out a cost-utility analysis. Only two studies 
utilize health-related quality of life to calculate QALYs (King et al. 2006). Both studies lack 
the methodological considerations that would justify their use in my study. One study uses 
physician experts to calculate utilities (not the patients or caregivers themselves), while the 
other study garners utility estimates from UK populations that may not be representative of 
U.S. patients (King et al. 2006). Finally, I do not have a measure of societal willingness to 
pay, or another way to place the benefits of treatments into dollar terms, rendering a cost-
benefit analysis inappropriate. Therefore, cost-effectiveness analysis appears to be the clear 
method of choice, allowing me to measure the costs per treatment response over time. 
 The remaining sections of this chapter detail the key steps to conducting a cost-
effectiveness analysis; a discussion of discrete-event simulation, the method I chose to carry 
out the cost-effectiveness analysis; and a comprehensive review of the components of my 
discrete-event simulation model.   
 
3.1 Key Steps to a Cost-Effectiveness Analysis 
 A cost-effectiveness analysis has six steps (Royal Tropical Institute KIT 2008): 
defining the scope of study treatments, choosing the time horizon, selecting the 
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perspective, identifying the costs, delineating effectiveness indicators, and identifying 
disease or treatment states that must be modeled over time.   
     
     3.1.1 Step 1: Defining the Scope of Treatments 
 In order for policymakers to interpret the results of a cost-effectiveness analysis, the 
intervention should be accurately described. For example, policymakers would like to know 
the specific treatments evaluated, as well as the target population. The treatment model I 
use is based in large part on the Multimodal Treatment Study of Children with ADHD and is 
described in detail below. 
      
          3.1.1.1 The Multimodal Treatment Study of Children with ADHD (MTA) 
The MTA trial (MTA Cooperative Group 1999) assigned 579 children with ADHD-
combined-type, age 7 to 9 years old at baseline, at six sites to one of four treatment groups: 
14 months of medication management, intensive behavioral therapy, combination therapy, 
or standard community care (treatment by community providers, which may include any of 
the other treatments). Six major outcome domains were assessed before and during 
treatment, as well as at the study endpoint (MTA Cooperative Group 1999). ADHD 
symptoms were measured using the parent and teacher subscales of the ADHD SNAP-IV.  
The ensuing subsections detail the two treatment arms found superior by the MTA 
Cooperative Group (1999).    
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               3.1.1.1.1 Medication Management (MTA Cooperative Group 1999) 
 
Children in the medication management arm received medication treatment only. 
This began with evaluating the effects of four different doses (5, 10, 15, and 20mg) of 
methylphenidate during a 28-day, double-blind, placebo-controlled trial (MTA Cooperative 
Group, 1999). Children received a full dose at breakfast and lunch, and then a half-dose in 
the afternoon. Experienced clinicians compared parent and teacher ratings of the children's 
behavior on each dose, and then selected the best dose for each child. For children not 
obtaining an adequate response to methylphenidate during this titration trial, clinicians 
tested alternate medications using non-double-blind procedures in the following order – 
dextroamphetamine, pemoline, and imipramine – until a satisfactory medication and dose 
for the child was found.  
Of 289 participants initially assigned to receive medication in the medication 
management arm or the combined therapy arm (described below), 256 (88.6%) successfully 
completed this initial titration period. For the remaining children, parents either refused to 
try their child on medication, there were intolerable side effects, or parents could not 
cooperate with the titration procedures. For 69 percent of the children completing the 
initial medication trial, an adequate response was obtained with at least one of the doses of 
methylphenidate, and those children began their treatment on this dose. Twenty-six 
children who did not respond to methylphenidate were found to do well on 
dextroamphetamine and began this medication. The final 32 did not begin any medication 
because they had such a strong placebo response that no clear benefits of medication 
would be demonstrated.  
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After titration, providers reviewed the child’s behavior as reported by parents and 
teachers each month. After carefully reviewing this information, providers adjusted dosage 
according to guidelines. Adjustments that involved increases or decreases of more than 10 
mg/dose needed approval by a cross-site panel of experts.  
By the end of the 14-month study, 74 percent of participants were successfully 
maintained on methylphenidate, 10 percent on dextroamphetamine, and just over 1 
percent on pemoline. Only two children were on any other type of medication. Clinicians 
also monitored side effects monthly. Over 85 percent of the sample reported tolerable or 
no side effects.  
 
               3.1.1.1.2 Combination Therapy (MTA Cooperative Group 1999) 
 The combination therapy treatment arm consisted of medication management and 
intensive behavioral therapy. Behavioral therapy comprised parent training, child-focused 
treatment, and a school-based intervention. Parent training involved 27 group sessions and 
eight individual sessions per family. The training focused on teaching parents specific 
behavioral strategies to deal with the challenges that children with ADHD often encounter. 
The child-focused treatment was a summer treatment program that children attended for 
eight weeks, five days a week. This program employed intensive behavioral interventions 
administered by counselors and aides who were supervised by the therapists conducting 
the parent training. Children were able to earn various rewards based on their ability to 
follow rules and meet certain behavioral expectations. Counselors also provided social skills 
training and specialized academic instruction. The school-based treatment had two 
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components: 10 to 16 sessions of biweekly teacher consultation focused on classroom 
behavior management strategies, and 12 weeks of a part-time paraprofessional aide 
working directly in the classroom with the child. A Daily Report Card, a one-page, teacher-
completed rating of the child's success on specific behaviors, linked the child's behavior at 
school to consequences at home. . Parents reviewed the report card and provided rewards 
for a successful outcome. Consistent with what occurs in actual clinical practice, the family’s 
and child's involvement in behavioral treatment was reduced gradually over the 14-month 
period. 
Children in the combined treatment group received each treatment outlined above. 
Individuals supervising the child's behavioral and medication treatments conferred regularly 
to guide overall treatment decisions. By the end of the study, children in the combined 
group were maintained on lower daily doses of methylphenidate than children who 
received medication alone.   
 
          3.1.1.2 MTA Study Questions and Results  
 The MTA results answered three specific study questions (MTA Cooperative Group 
1999) about which treatment type was most effective. The first question was, “Do 
participants assigned to combined treatment show higher levels of improvement in overall 
functioning in pertinent outcome domains than those assigned to either medication 
management or behavioral treatment at the end of treatment?” Combination therapy and 
medication management did not differ significantly in any symptom domain (MTA 
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Cooperative Group 1999). However, combination therapy was superior to behavioral 
therapy, based on ADHD SNAP-IV scale, as well as parent-rated internalizing symptoms.  
Next, the study asked, “Do medication and behavioral treatments result in 
comparable levels of improvement in pertinent outcomes at the end of treatment?” 
Medication management was superior to behavioral therapy, especially under the parents’ 
and teachers’ SNAP-IV ratings of inattention and teachers’ ratings of 
hyperactivity/impulsivity (MTA Cooperative Group 1999). Medication management and 
behavioral therapy did not differ significantly in any other domain.  
Finally, the study asked, “Do participants assigned to each of the three MTA 
treatments show greater improvement over 14 months than those assigned to community 
care?” Using the SNAP-IV, combination therapy and medication management were superior 
to community care, while behavioral therapy was not (MTA Cooperative Group 1999). 
Medication management or behavioral therapy was superior to community care in teacher-
reported social skills and parent-child relations. Combination therapy was superior to 
community care in every measured non-ADHD domain. In sum, all four groups showed 
reductions in symptoms over time, with significant differences in the magnitude of change 
among treatments. Combination therapy and medication management were clinically and 
significantly superior to behavioral therapy or community care; therefore, my study models 
the costs and effects of these two treatments.  
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     3.1.2 Step 2: Choosing the Time Horizon and Target Population for Treatment 
 
In order to assess the long-term costs and outcomes characteristic of a chronic 
illness such as pediatric ADHD, I employed a time horizon of eight years to capture the costs 
and benefits of ADHD treatment from childhood well into adolescence (7 to 15 years of 
age). As stated earlier, the vast majority of cost-effectiveness analyses of treatments for 
ADHD use a one-year time horizon. The results of a study with such a short time horizon 
must be interpreted with caution because ADHD can impair patients for many years, and 
short-term studies cannot show the full impact of treatments for an illness that begins in 
childhood. 
 
     3.1.3 Step 3: Choosing the Perspective 
Determining the true cost of a treatment depends on the perspective of the study’s 
audience. Readers can draw different conclusions from the study, depending on which costs 
and outcomes are included in the analysis. For example, when a study applies only to a 
health care payer, it assumes a health care payer perspective. When a study applies to 
society as a whole, it assumes a societal/taxpayer perspective. The choice of perspective 
can have important consequences for the results of the cost-effectiveness analyses. For 
instance, from the health care payer perspective, Treatment A may be more cost-effective 
than Treatment B because it is associated with fewer costly psychiatric hospitalizations. 
However, if family members forced to stay home from work replaces hospital care, the 
costs of lost productivity at work must be included in the societal/taxpayer perspective. 
Therefore, from the societal/taxpayer perspective, Treatment A could be less cost-effective 
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than Treatment B, from the societal perspective if the cost of lost workforce productivity 
outweighs the cost savings associated with fewer psychiatric hospitalizations.  
I consider both perspectives in this study. Because health care payers define 
coverage and help drive the utilization of health services, I believe their interests are 
important to cover. And because ADHD can affect the utilization of services outside the 
health care arena, such as in special education and juvenile justice, including the 
societal/taxpayer perspective helps inform decisions about the allocation of limited 
resources. 
 
     3.1.4 Step 4: Identifying the Costs 
Costs in economic evaluations are divided into tangibles and intangibles (Graff 
1989). The perspective dictates which costs to include, as well as what value to put on the 
quantities. My study encompasses tangible costs consistent with societal and payer 
perspectives. Tangible costs can include direct medical and nonmedical costs, lost 
productivity costs, and indirect costs. Intangible costs are the costs of pain and suffering, 
which are extremely hard to quantify and are not necessarily important for a cost-
effectiveness analysis. Any costs of pain and suffering that resulted in medical care 
utilization (such as a psychiatric hospitalization) would be recorded as direct medical costs, 
thus considered a tangible cost. But measuring intangible costs incorporated into a measure 
of quality of life is beyond the scope of my study.  
The project’s specific costs are selected based on common domains of impairment in 
ADHD (Table 5) and follow the framework in Pelham, Foster et al. (2007). My study includes 
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treatment and non-treatment costs. Treatment costs (in both payer and societal/taxpayer 
perspectives) include the costs of medications, teacher and clinician time, and inpatient 
psychiatric hospitalizations. Non-treatment costs (in societal/taxpayer perspective only) 
include entry into the juvenile justice and special education systems, and parental work 
absenteeism. Because the MTA data cites costs in 2000 dollars, all costs are discounted or 
inflated to 2000 dollars by using the appropriate inflation rate from the Consumer Price 
Index.  
 
Table 5: Cost Parameters 
Specific Costs 
 
Domain of 
Impairment 
Origin of Utilization Data Origin of Cost Per Unit 
Data 
Treatment 
 
   
   Medication  
   (Compliance) 
Health MTA  
 
 
 
MTA 
   Clinician/Teacher 
   (Doctor, Teacher, Camp) 
 
Health MTA  
 
Bureau of Labor 
Statistics 
   Hospital 
 
Health MTA  
 
H-CUP Brief (2007) 
Non-Treatment 
 
   
   Juvenile Justice Criminality 
 
MTA  
 
Pelham, Foster, and 
Robb (2007) 
   Special Education Academic 
 
MTA  
 
Pelham, Foster and 
Robb (2007); 
Parrish (2003) 
    
   Absenteeism 
 
Family 
Occupational 
Literature Swensen et al. (2003) 
Roijen et al. (2007) 
MTA = Multimodal Treatment Study of Children with ADHD (MTA Cooperative Group, 1999); H-CUP = Health 
Care Cost and Utilization Project 
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     3.1.5 Step 5: Identifying the Effectiveness Indicator 
  
Following the MTA Cooperative Group (1999) design, I use parent ratings from the 
SNAP-IV rating scale, a 26-item questionnaire intended to assess ADHD core symptoms of 
hyperactivity/impulsivity (9 items), inattention (9 items), and oppositional defiant disorder 
(8 items) (Bussing et al. 2008). Items are rated on a four-point scale from (0) not at all to (3) 
very much. The SNAP-IV measure, which determines whether the disease has been 
normalized by the treatment provided, has been used by many other treatment studies 
(Bussing et al. 2008).  Normalization is a term used by the MTA Cooperative Group to 
indicate that a patient responded successfully to treatment. Average rating indices are 
constructed for inattentive, hyperactive/impulsive, combined ADHD, and ODD subscales. 
Scores above the 95th percentile are labeled clinically relevant.  
Bussing et al. (2008) explored the psychometric properties of the SNAP-IV, including 
internal reliability, inter-rater reliability, and factor structure. Coefficient alpha for the 
overall parent ratings was 0.94, while domain-specific estimates were 0.90 for inattentive, 
0.79 for hyperactive/impulsive, and 0.89 for ODD. The teacher ratings were 0.97 overall, 
0.96 for inattentive, 0.92 for hyperactive/impulsive, and 0.96 for ODD. The results showed 
no significant variations in internal consistency by gender or race. Inter-rater reliability 
between parents and teachers was 0.49 for inattention, 0.43 for hyperactivity/impulsivity, 
and 0.47for ODD. Internal consistency estimates did not increase when any item was 
removed. The findings indicated no need for age-specific normative cutoff points among the 
patient population. Additionally, gender and race differences in SNAP-IV scores were small, 
which supported the non-stratified cutoff point methodology. In sum, authors found 
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internal consistency, item selection, and factor structure of the SNAP-IV adequate and 
reliable with the concepts published in the DSM-IV. 
 
3.1.6 Step 6: Identify Measures of Health/Treatment States and How They                   
    Change Over Time 
  
A key component of cost-effectiveness analyses is to determine the different health 
or treatment states that require modeling transitions between states. My study includes 
two state transitions – ADHD severity and treatment compliance.  
 
          3.1.6.1 ADHD Severity States 
  
As a moderator of treatment response, severe ADHD is associated with decreased 
rates of response (Owens et al. 2003). ADHD severity can rise and fall over the course of the 
disease. So to adequately model the cost-effectiveness of ADHD, transitions among ADHD 
severity states must be factored in to produce meaningful results. To assess severity, I use 
the Columbia Impairment Scale (CIS) from the MTA. The CIS is a 13-item scale covering four 
major areas of global functioning: 1) interpersonal relations; 2) broad areas of 
psychopathology; 3) functioning at school or work; and 4) use of leisure time (Bird et al. 
1993). Items are scored from zero (no problem) to four (a very bad problem) (Bird et al. 
1993). The CIS can be administered to the child’s parent by a trained lay interviewer.  
The instrument’s psychometric properties demonstrate good reliability, as well as 
good construct, discriminant and concurrent validity (Bird et al. 1993, 1996). The optimal 
threshold ≥ 16 distinguishes those with definite impairment from all others (Bird et al. 
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1996). Therefore, I classify a patient with a total score of 16 or higher as having severe 
ADHD.  
       
          3.1.6.2 Treatment Compliance States 
 Effective modeling of the cost-effectiveness of treatments for ADHD must take into 
account the possibility of treatment noncompliance. As with all medications, treatment 
compliance is essential to garner the most benefit from therapy. Inadequate compliance is a 
problem in treating ADHD (Swanson 2003), but the extent of noncompliance is mixed. An 
ADHD patient’s need for multiple medication doses during the day, along with the long 
duration of both behavioral and medication treatment, can erode treatment compliance 
and lead to a reduction in treatment effectiveness (Swanson 2003). In a study of treatment 
compliance over 14 months for ADHD in children ages 6 to 9, only 80 percent of children 
were taking medications as prescribed by month 4, and compliance had dropped to 56 
percent by month 10 (Firestone 1982). These results compare unfavorably to MTA patients, 
who took approximately 85 percent of medications as prescribed at month 14, the study’s 
endpoint.  
Few studies measure compliance with behavioral therapy. Brown et al. (1987) 
conducted a three-month study and found that patients were much more likely to comply 
with psychosocial treatment than medication management. No long-term studies of 
psychosocial treatment compliance for ADHD exist.  
 Because different studies often use different definitions of what constitutes 
adherence, estimating treatment compliance can be complicated. Some studies define a 
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minimal cutoff point of the percentage of medication taken. Other studies determine 
compliance by the number of days each week patients took the medication as prescribed 
(Adler and Nierenberg 2010). Ibrahim (2002) stated that patients who took at least 70 
percent of their medication as prescribed had “very high adherence.”  Pappadopulos et al. 
(2009) used an adherence rate cutoff of 50 percent to determine compliers.  
The MTA measures medication compliance in its 14-month trial, which The MTA 
defined medication treatment compliers as patients who received medication throughout 
the 14 months – and took their medication at least 80 percent of the time. The MTA also 
provided a structure to measure compliance in the follow-up data. In a sensitivity analysis 
(described later), I varied my medication compliance definition to 50 percent to test the 
robustness of my results. Because the MTA provided the 14-month trial complier variable, I 
needed only to calculate compliance for the remaining time horizon of seven years. To do 
so, I used the variable – ‘percent of the total number of days in this interval that any 
stimulant or non-stimulant medication was taken for ADHD’ – to create a medication 
compliance variable. Those with a percentage ≥ 80 percent were labeled compliers.  
 Similar parameters must be set to measure compliance with other forms of therapy. 
The MTA defined psychosocial treatment complier as a patient/parent who completed at 
least 75 percent of parental group training sessions, 77 percent of summer treatment camp 
attendance, and 75 percent of school classroom aide and teacher consultations conducted. 
If any of these requirements were not met, the patient was considered a non-complier.  
Behavioral therapy compliance is defined similarly in the literature.  For instance, Pavuluri 
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et al. (2004) defined compliance to child- and family-focused cognitive behavioral therapy 
as attending 12 out of 15 sessions (75 percent).   
After the controlled portion of the MTA trial was over, the patients were free to be 
treated as needed in the community. Therefore, to measure compliance to behavioral 
therapy beyond 14 months, as I do in my study, I calculate compliance using the variable 
called ‘global hours per year of therapy or counseling.’  For those patients on combination 
therapy after 14 months, the behavioral therapy compliers visited their clinicians at least 
three hours per year, which represents 75 percent compliance, assuming quarterly one-
hour appointments (three kept appointments out of four available), and follows the metrics 
of the MTA. A patient on combination therapy must meet the compliance requirements for 
both behavioral therapy and medication management to be classified as a complier. 
 
3.2 Selecting the Method to Carry Out the Cost-Effectiveness Analysis 
To further explore the issues of health states and time, I evaluated three methods of 
modeling the cost-effectiveness of alternative treatments for ADHD – decision trees, 
Markov models, and discrete-event simulation. Most economic models involve health 
states; historically, these states were modeled using a decision tree, but this became 
difficult in instances where health states recur. Because that structure only allows progress 
of a patient through the model in one direction (they are read from left to right), patients 
are not allowed to move back and forth between states. Thus, decision trees might not be 
very suitable for evaluating health conditions with recurrent events.  
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 The inability of decision trees to handle recurring events and health states led to the 
application of Markov models, which can better represent complex processes happening 
over time. Markov models assume that the patient is always in one of a finite number of 
states of health, referred to as Markov states (Sonnenberg and Beck 1993). All events are 
modeled as transitions from one state to another over time. However, Markov models 
make strong assumptions about these transitions, and they assume the patient population 
is homogeneous. Markov models assume that the probability of transitioning from one 
state to another does not take into account the history of the patient before the arrival at a 
given health state – the so-called memoryless property (Caro 2005).  Heterogeneity and 
patient history are quite important to researchers and decision-makers, therefore 
necessitating a more flexible method. 
 One way to overcome these problems involves simulating the processes involved in 
the system. Banks et al. (2010) puts it this way: “A simulation is the imitation of the 
operation of a real-world process or system over time. Whether done by hand or on a 
computer, simulation involves the generation of an artificial history of the system and the 
observation of that artificial history to draw inferences concerning the operating 
characteristics of the real system. The behavior of a system as it evolves over time is studied 
by developing a simulation model. The model usually takes the form of a set of assumptions 
concerning the operation of the system.”  One use for simulation is to learn the properties 
of the Markov model, allowing one to relax the memoryless assumption. Additionally, 
knowing the rate at which a patient might enter a state and leave it enables mathematical 
formulas to be used to calculate the percent of time spent in the state. Over time, 
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simulation methods have developed an added range of other features, such as entering 
services and leaving services, which grew out of a literature on queuing methods in 
operations research that also worked with Markov models. Over time, these methods have 
been labeled discrete-event simulation. 
 
3.3 Discrete-Event Simulation 
Caro, Moller et al. (2010) notes: “In a discrete-event simulation, the experience of 
individuals is modeled over time in terms of the events that occur and the consequences of 
those events.” Modeling disease in this fashion allows addressing the dynamic (or time-
dependent) characteristics of the condition (Lay et al. 2006). In cost-effectiveness studies, 
discrete-event simulation models have been used in disease areas of cancer, renal disease, 
drug abuse, HIV transmission, and liver transplants (Lay et al. 2006). To my knowledge, 
discrete-event simulation has not been used to model ADHD. The three key principles 
involved in discrete-event simulation modeling are entities, events, and time.  
Entities refer to patients who evolve through the simulation. In discrete-event 
simulation models, individual patients are assigned attributes (e.g., age, gender, disease 
severity, compliance with prescribed therapy) with a point estimate and measure of 
variability for each. These values are specified as the simulation begins and may be updated 
if indicated (Lay et al. 2006). For instance, a patient’s age increases with the passage of 
time, and disease severity levels may increase or decrease.  
Events are defined as anything that can happen during a simulation (Lay et al. 2006). 
Examples of events in my model include clinical response to ADHD treatment, visits to the 
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clinician, and changes in severity and/or compliance states. Events can occur simultaneously 
and/or recur, altering a patient’s course by affecting that patient’s attributes and the 
incidence of future events. The rates at which events transpire can depend on any patient 
attribute.  
Time informs both entities and events. A simulation clock keeps track of the passage 
of time, making it possible to designate the start and end of the eight-year simulation (Lay 
et al. 2006). Discrete-event simulation, by keeping track of time in the model, handles time 
much more easily than in Markov models (Lay et al. 2006).   
Discrete-event simulation models offer several advantages over Markov models for 
modeling of experiences of patients with ADHD. First, discrete-event simulation models 
allow analysts to relax the memoryless assumption of Markov models. Throughout the 
simulation, new information can be tracked and stored in a temporary variable, allowing 
future events to vary, and reflecting patients’ new clinical profiles (Lay et al. 2006). Markov 
models do not allow future state transitions to be based on what has happened in the past. 
Second, discrete-event simulations can address patient heterogeneity. Rather than 
following an entire (homogeneous) cohort through a model by assigning proportions to 
different states, discrete-event simulation can model the pathway of a population of 
patients who are assigned different profiles of characteristics (Lay et al. 2006). Ultimately, 
discrete-event simulation is superior to Markov models for the modeling of experiences of 
patients with ADHD.  
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3.4 Data Sources 
 In my study, I primarily used the MTA data to populate the parameters of the model. 
The MTA Cooperative Group collected follow-up data over the past 10 years since the 
primary endpoint of the study, and I have access to eight years of data. These data were 
collected at regular intervals throughout the follow-up portion of the trial (Table 6). I used 
nine data files to populate the parameters of my model (Table 7). However, the MTA did 
not include all the information I needed to fully parameterize my model. The parameters 
not covered by the MTA principally revolved around cost estimates. Table 5 illustrates that, 
with the exception of parental work absenteeism, all utilization data were garnered from 
the MTA. The costs of utilization of these services, with the exception of medications, were 
all taken from the literature. Therefore, I exercised the flexibility of discrete-event 
simulation models by incorporating multiple data sources.  
 
 
  
64 
 
Table 6: MTA Data Collection Points Where Parameters Were Measured 
Variables 14 
Months 
24 
Months 
36 
Months 
48 
Months 
60 
Months 
72 
Months 
84 
Months 
96 
Months 
 
Response to 
Treatment 
 
X 
 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
ADHD Severity 
 
X 
 
X 
 
X 
 
 
 
 
 
X 
 
 
 
X 
 
Comorbidity 
Status 
 
X 
 
X 
 
X 
   
X 
  
X 
 
Compliance with 
Medications  
and 
Combination 
Therapy 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
 
X 
 
 
Juvenile Justice  
Utilization 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
Special 
Education  
Utilization 
 
X 
 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
Productivity 
Losses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication  
Utilization  
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
Clinician  
Utilization 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
Hospitalization  
Utilization 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
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Table 7: MTA Datasets Used to Populate Parameters of the Model 
Dataset Name         Parameter/s 
 
Columbia Impairment Score 
 
• ADHD Severity 
 
 
Summary Medication Variables 
 
• Medication Utilization 
• Medication Compliance (post-14 months) 
 
 
Cost Data 
 
• Clinician/Teacher Costs (through 14 months) 
• Medication Cost 
 
 
SNAP-IV  
(Parent Version) 
 
 
• Response to Treatment 
 
 
Diagnoses and Symptoms 
 
• Comorbidities 
 
 
Justice System Contact  
 
• Arrests/police contact 
 
 
Summary School Services 
 
• Special education 
 
 
Subject Therapy Variables 
 
• Behavioral therapy 
• Behavioral therapy compliance (post-14 months) 
• Psychiatric Hospitalizations 
 
 
Master Data File 
 
• Gender 
• Medication Compliance (at 14 months) 
• Behavioral Therapy Compliance (at 14 months) 
 
MTA = Multimodal Treatment Study of Children with ADHD; SNAP-IV = Swanson, Nolan, and Pelham ADHD 
Rating Scale 
 
   3.4.1 MTA Sample Characteristics by Treatment Arm  
  
The MTA was essentially a two-part trial. The first part was the tightly controlled, 14-
month randomized controlled trial, in which patients were assigned to a specific treatment. 
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The second part was an observational follow-up study. After 14 months, patients were free 
to receive any treatment provided by their community clinician/s. Patients could change 
therapies or drop out of the follow-up portion of the study.  
To create combination therapy and medication management cohorts after 14 
months, I used data from all 579 randomized patients, regardless of which MTA treatment 
they received. Patients who received only medications during a given year were classified as 
medication management, while those receiving both medications and behavioral therapy 
were classified as combination therapy. If a patient either received no therapy or only 
behavioral therapy for a given year, they were dropped from the analysis for that year. I 
dropped these patients because the combination therapy cohort for a given period must 
only contain patients who received both medication management and behavioral therapy. 
The resulting dynamically evolving cohorts changed in both size and composition as time 
progressed. Appendix A contains information about the MTA samples over time, including 
patients who switch therapies or drop out of the follow-up study, as well as demographic 
and clinical characteristics of the sample as time progressed.   
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Table 8: Treatment Sample Sizes at Each Time Point 
Treatment/Time Sample Size 
 
Combination Therapy 
 
   14 Months 145 
   24 Months 120 
   36 Months 107 
   48 Months 46 
   60 Months 60 
   72 Months 80 
   84 Months 73 
   96 Months 61 
 
Medication Management 
 
   14 Months 144 
   24 Months 318 
   36 Months 325 
   48 Months 352 
   60 Months 312 
   72 Months 277 
   84 Months 256 
   96 Months 244 
 
 
    
     3.4.2 Missing Data 
  
Statistical analysis of data sets with missing data is a frequent problem in health 
outcomes research. Missing data can have two major negative effects.  First, they can 
negatively impact statistical power through listwise deletion (using only complete cases), 
and second, missing data may cause biased parameter estimates (Tsikriktsis 2005).  
Therefore, accounting for missing data is important to produce robust parameter estimates 
for my model.   
Understanding the processes behind the underlying missing data is an important 
first step in addressing any missing data issues (Tsikriktsis 2005). In my study, the missing 
MTA data came from three sources: missing by design, missing by attrition, and missing by 
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omission. A portion of the MTA data was missing by design, because all model parameters 
were not collected by the MTA Cooperative Group at each data collection point (Table 6). 
For instance, treatment response was collected at each data collection point; however, 
severity was only collected at 14-, 24-, 36-, 72-, and 96-months. Similar to other long-term 
longitudinal studies, patients dropped out (missing by attrition) of the MTA project over the 
eight-year time horizon, creating empty data cells (Appendix B). Lastly, some patients or 
caregivers still participating in the follow-up portion did not reply to every question, leaving 
the variables associated to the omitted questions missing. 
The missing MTA data prompts two questions: 
1. How much of the data are missing?   
2. Is the pattern of missing observations random or not? 
There is no apparent rule as to how much missing data is too much, but prior research 
states that 5 percent to 10 percent of missing data on a given variable is not too large 
(Tsikriktsis, 2005). Appendix B illustrates the extent of missing MTA data by treatment arm. 
Generally, the later time points have more missing data than the earlier time points. 
Interestingly, the medication management cohort is more likely to have missing data over 
each variable-time point pair, indicating that the extent of missing data may be a function of 
the MTA treatment arm.   
 More important than the amount, the randomness of missing data plays a large role 
in prescribing a remedy for the problem. Little and Rubin (1987) distinguished between data 
that are missing at random (MAR) and those that are missing not at random (NMAR). MAR 
indicates that the probability of a patient’s missing observation is independent of the true 
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value of that observation. Better stated, patients with a missing observation on a given 
variable differ only by chance from patients who have values for that variable (Tsikriktsis 
2005). Consequently, estimations based on data from patients with non-missing data should 
be generalizable to patients with missing data. However, when data are NMAR, a systematic 
relationship between variables with and without missing data exists. Most remedies for 
missing data cannot alleviate the problems if the data are NMAR, but imputations can 
theoretically be constructed to account for the specific NMAR missing data mechanism.   
 There are several ways to evaluate the MAR assumption. Little and Rubin (1987) 
suggested assessing the missing data for a given variable by forming two groups – one with 
missing values and one with valid values for that variable. If significant differences are found 
between the two groups over other variables in the dataset, the data would be NMAR. Little 
and Rubin (1987) mention that some differences will occur by chance, but the key is to look 
for an underlying pattern.   
I chose to evaluate the randomness of missing values for ADHD severity, 
comorbidities, medication compliance, and behavioral therapy compliance. I tested the 
variables over demographic variables that had no missing data. Those demographics were 
gender, race, grade at baseline, urban/rural status, mother’s education, and family income 
(Appendix B). No systematic patterns of significant differences by demographic variable 
appear; however, significant differences become more likely as time progresses, suggesting 
(but not confirming) the possibility of non-random missing data over time. Because my 
study lacks overwhelming evidence of NMAR, I am comfortable with the assumption that 
the data are MAR.     
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Under the assumption of MAR, various methods are available to handle the missing 
data, avoiding biased parameter estimates and improving their precision. To circumvent the 
biases associated with complete case analysis, I used multiple imputation in STATA™ (Stata 
Corp. 2007) to fill in the missing data cells. Instead of imputing missing values to create a 
single imputed dataset, multiple imputation constructs several imputed data sets, each of 
which contains different imputed values (Stata Library). The analysis of the statistical model 
is performed on each of the data sets, and the multiple analyses are then combined to yield 
a single set of results (Stata Library). “The major advantage of multiple imputation over 
single imputation is that it produces standard errors that reflect the degree of uncertainty 
due to the imputation of missing values” (Stata Library). Appendix B contains more 
information about the specific imputation equations for each variable. 
 
3.5 Study Aim 1 
 The first study aim was to develop a natural disease history model that describes 
patients’ experiences in the health care system. I was guided by a psychiatrist and consulted 
with a panel of four physicians to create conceptual models depicting the movement of 
pediatric patients with ADHD through the health care system. The conceptual models took 
form through the process described below, with layers of complexity being added at each 
meeting.  
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      3.5.1 Creating the Conceptual Models – Physician Consultations 
 
In order to create a simulation model, I first drafted a conceptual model from which 
to base the simulation. Each conceptual model had to be verified by content experts to 
ensure the validity of the simulation results. The process to create my conceptual models 
contained two steps: a one-on-one interview with a psychiatrist to draft the models, and 
review by a panel of physicians to validate the models.  
First, I interviewed a psychiatrist with experience in treating patients with ADHD. 
Together we drafted a conceptual model depicting how patients on each treatment would 
flow through the health care system. He pointed out several different factors that must be 
accounted for in my models. Frequency of patient/physician interaction matters. Patients 
generally visit their physician on a monthly basis to obtain a prescription refill. Compliance 
with treatment, severity of symptoms, and the presence of comorbidities also have an 
important impact on response to treatment. After our meeting, we finalized a conceptual 
model, which I presented to a panel of four psychiatrists who are key opinion leaders in 
pediatric ADHD. Panel members thought the model was sufficiently valid, and their only 
recommendation was that I not extend the intensive behavioral therapy beyond 14 months. 
Instead, they thought it more reasonable to model the behavioral therapy component of 
combination therapy (post-14 months) as quarterly booster therapy sessions to supplement 
what was learned during the first 14 months. Adding another layer of experts to evaluate 
the model gave me more confidence in the validity of the models’ structure.       
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      3.5.2 Conceptual Models  
 
 The main model parameters correspond to the probability of events that occur 
during the course of treatment as well as cost data, many of which were found in the MTA 
trial data and others in the literature. In the ensuing subsections, I describe the details of 
each model.  
 
          3.5.2.1 Medication Management Model 
 This conceptual model (Figure 1) begins with a hypothetical cohort of 7-year-old 
children with ADHD, each of whom is randomly assigned attributes including: gender; ADHD 
severity; and comorbidity statuses. Each characteristic dictates how the child moves 
through the model. The hypothetical cohort of 7-year-olds is then assigned to begin 
titration for drug therapy. Very soon after treatment initiation side effects may appear. If 
intolerable, the treatment is adjusted until the side effects go away or become tolerable. 
 The patient in the hypothetical cohort begins a monthly cycle through the model 
corresponding to the central region of the diagram. The cycle is one month long because 
patients on medication are required by law to return to the clinician monthly to obtain a 
refill, because the stimulants are controlled substances. At the beginning of the monthly 
cycle, the clinician checks the child for treatment response, defined as an item mean of ≤1.0 
on the SNAP-IV composite scale. If the child is not responding, the treatment is adjusted 
until clinical response is attained.  
On a yearly basis, the model recognizes that a child’s ADHD severity may change 
over time. Changes in severity also can depend on environmental factors, severity of 
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comorbidities, and side effects, among other factors. Compliance status may change over 
time as well. Therefore, I allow the patient’s ADHD severity and compliance level to ‘update’ 
during every visit to the clinician. Once the hypothetical child’s ADHD severity and 
compliance have been updated, the child re-enters the monthly cycle with each clinician 
visit. The only way for a child to exit the model is to reach the age of 15.  
 
7 yr olds
Medication
Management
Treatment 
adjustment
Clinician 
Visit:  
check for 
response
Age 15?
If yes
If intolerable
Side 
Effects?
ADHD 
Severity 
Update 
(once per 
year)
If 
tolerable
Exit 
Model
If no
Monthly Cycle
Figure 1 : Conceptual Model for 
Medication Management
 
          
          3.5.2.2 Combination Therapy Model 
The combination therapy model (Figure 2) contains all the components of the 
medication management model, plus a 14-month comprehensive behavioral therapy 
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component and booster behavioral therapy sessions beyond 14 months. The conceptual 
model begins the same way as the medication management model: The hypothetical cohort 
of 7-year-olds is assigned attributes and titrated to an appropriate dose of medication. 
However, in addition to the medication management protocol, the combination therapy 
patients and their parents begin a detailed 14-month behavioral therapy regimen.  
The first component of the behavioral therapy regimen, parental training, contains 
27 group sessions and eight individual sessions that begin weekly and taper off overtime. 
Parental training teaches parents effective behavioral management strategies for their 
child. The second component, child-focused treatment, is an eight-week summer treatment 
camp that provides intensive behavioral interventions delivered in a group-based 
recreational setting. The third component, school-based intervention, involves 10 to 16 
biweekly sessions of teacher consultation. In addition, once the student returns to school in 
the fall, paraprofessional aides work with students and teachers to help reinforce the tactics 
the student learned during the summer camp. After the 14-month intensive behavioral 
therapy, the patient begins a quarterly booster behavioral therapy regimen that continues 
until the child reaches the age of 15. These sessions help the child progress through 
obstacles that can impede a person with ADHD.  
As with the medication management model, the behavioral therapy model allows 
for the ‘updating’ of ADHD severity and compliance to behavioral and medication therapy, 
and the only way for the child to exit the model is to reach the age of 15. 
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Severity and 
Compliance 
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Visit
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7 year-olds Titration Side Effects Adjust 
Treatment
Monthly 
Medication 
Visit
Severity and 
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Intervention Quarterly 
Booster 
Session
Age 15?
Exit 
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Combination Therapy
Intolerable
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After 14 
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Age 15
Not age 15
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3.6 Model Implementation 
 To estimate the parameters for the model, I used MTA trial data and cost estimates 
from the literature. In the ensuing subsections, I describe specific parameters and 
estimation techniques in more depth. 
 
     3.6.1 Specific Parameters and Data Analysis 
 All MTA data were analyzed through STATA™ (Stata Corp. 2007). The parameters in 
the model are categorized into disease/treatment variables and cost variables. The 
disease/treatment variables included comorbidities, ADHD severity, compliance to 
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treatment/s, and response to treatment/s. I categorized comorbidities into internalizing, 
externalizing, both, or neither. Severe ADHD referred to a total score of at least 16 on the 
Columbia Impairment Scale. Compliance to medications indicated that a patient was taking 
at least 80 percent of prescribed medication, while compliance to the behavioral therapy 
referred to attending at least 75 percent of all components, both following the metrics 
created by the MTA Cooperative Group (1999). Finally, I defined response to therapy as an 
average score of at most 1 on the SNAP-IV-parent version, a definition used in numerous 
other studies (MTA Cooperative Group 1999). Table 9 illustrates each model parameter, the 
variable/s used to estimate each parameter, whether a non-MTA reference was used, and 
the distributional assumptions regarding the uncertainty of each estimate. The rationale for 
my choice of parameter distributions is presented in Appendix C. 
 The conceptual models highlight the impact of ADHD severity compliance to 
treatment on treatment response and costs.  In the next subsections, I discuss how I 
calculated estimates of each of these.      
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Table 9: Time-Varying Parameters and Distributional Assumptions 
Time-Varying  
Parameters 
Vary 
By: 
Gender Comorbidity Severity Comply Tx Non-MTA 
Reference/s 
Distributional 
Assumption 
 
Response to 
Treatment 
  
X 
 
X 
 
X 
 
X 
 
X 
 
 
 
Normal 
 
ADHD Severity 
  
 
    
X 
  
Normal 
 
Compliance with 
Medications and 
Combination 
Therapy 
      
 
 
X 
  
 
 
Normal 
 
Juvenile Justice 
Utilization and 
Costs 
      
 
X 
 
 
X 
 
 
Triangular 
 
Special 
Education 
Utilization and 
Costs 
      
 
X 
 
 
X 
 
 
Triangular 
 
Productivity 
Losses 
       
X 
 
Triangular 
 
Medication 
Utilization and 
Costs 
     
 
X 
 
 
X 
  
 
Triangular 
 
Clinician 
Utilization and 
Costs 
     
 
X 
 
 
X 
 
 
X 
 
 
Triangular 
 
Teacher 
Utilization and 
Costs 
     
 
X 
 
 
X 
  
 
Triangular 
 
 
Hospitalization 
Utilization and 
Costs 
      
 
X 
 
 
X 
 
 
Triangular 
Tx = Treatment; MTA = Multimodal Treatment Study of Children with ADHD; Non-MTA Reference/s = 
References (in Whole or Partially) Garnered From the Literature; Comply = Compliance 
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          3.6.1.1 Disease/Treatment Variables: ADHD Severity and Compliance 
 To calculate the transition probabilities between states of severity and compliance, I 
used the counting method as described in Diehr et al. (1998) and Diehr and Patrick (2001).  
Using two-by-two cross-tabulations (matricies), I counted the number of transitions from 
initial states to the next periods’ states. These matrices were created for each adjacent 
time-point pair, resulting in state transitions that were input into the model (Appendix D). 
Tables 10 to 13 summarize the transition matrices for states of severity and compliance for 
both the medication and combination treatment arms. The vertical axis indicates the index 
period, and the horizontal axis the second period. For instance, Table 10 reads that 49 
percent of patients on medication management with severe ADHD at 14 months remain 
severe at 24 months, while 51 percent transition to the not severe state. Additionally, 72 
percent of patients on medication management with not severe ADHD at 14 months remain 
not severe, while 28 percent transition to the severe state. Generally, a patient is more 
likely to remain in the same severity state from the index time to the subsequent time point 
up to 48 months; however, from 60 months to 96 months, patients are likely to transition 
from one severity state to the other. Compliant and non-compliant patients at the index 
date are more likely to remain in their respective states throughout the time horizon.   
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Table 10: Severity State Transition Matrix for Medication Management 
Time 
Severity 
24m 
S 
24m 
NS 
36m 
S 
36m 
NS 
48m 
S 
48m 
NS 
60m 
S 
60m 
NS 
72m 
S 
72m 
NS 
84m 
S 
84m 
NS 
96m 
S 
96 
NS 
 
14m 
S 
 
 
 
.49 
 
 
.51 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
14m 
NS 
 
 
.28 
 
 
.72 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
S 
 
 
-- 
 
 
-- 
 
 
.67 
 
 
.33 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
NS 
 
 
-- 
 
 
-- 
 
 
.33 
 
 
.67 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.59 
 
 
.41 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.51 
 
 
.49 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.53 
 
 
.47 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.46 
 
 
.54 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.47 
 
 
.53 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.35 
 
 
.65 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
72m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.50 
 
 
.50 
 
 
-- 
 
 
-- 
 
72m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.46 
 
 
.54 
 
 
-- 
 
 
-- 
 
84m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.46 
 
 
.54 
 
84m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.52 
 
 
.48 
 
m = Months; S = Severe ADHD; NS = Not Severe ADHD 
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Table 11: Severity State Transition Matrix for Combination Therapy 
Time 
Severity 
24m 
S 
24m 
NS 
36m 
S 
36m 
NS 
48m 
S 
48m 
NS 
60m 
S 
60m 
NS 
72m 
S 
72m 
NS 
84m 
S 
84m 
NS 
96m 
S 
96 
NS 
 
14m 
S 
 
 
 
.66 
 
 
.34 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
14m 
NS 
 
 
.38 
 
 
.62 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
S 
 
 
-- 
 
 
-- 
 
 
.73 
 
 
.27 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
NS 
 
 
-- 
 
 
-- 
 
 
.50 
 
 
.50 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.50 
 
 
.50 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.56 
 
 
.44 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.56 
 
 
.44 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.56 
 
 
.44 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.56 
 
 
.44 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.79 
 
 
.21 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
72m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.68 
 
 
.32 
 
 
-- 
 
 
-- 
 
72m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.63 
 
 
.37 
 
 
-- 
 
 
-- 
 
84m 
S 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.68 
 
 
.32 
 
84m 
NS 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.63 
 
 
.37 
 
m = Month; S = Severe ADHD; NS = Not Severe ADHD 
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Table 12: Compliance State Transition Matrix for Medication Management 
Time 
Comply 
24m 
C 
24m 
NC 
36m 
C 
36m 
NC 
48m 
C 
48m 
NC 
60m 
C 
60m 
NC 
72m 
C 
72m 
NC 
84m 
C 
84m 
NC 
96m 
C 
96m 
NC 
 
14m 
C 
 
 
 
.50 
 
 
.50 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
14m 
NC 
 
 
.47 
 
 
.53 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
C 
 
 
-- 
 
 
-- 
 
 
.71 
 
 
.29 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
NC 
 
 
-- 
 
 
-- 
 
 
.46 
 
 
.54 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.66 
 
 
.34 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.39 
 
 
.61 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.73 
 
 
.27 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.36 
 
 
.64 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.61 
 
 
.39 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.39 
 
 
.61 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
72m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.51 
 
 
.49 
 
 
-- 
 
 
-- 
 
72m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.22 
 
 
.78 
 
 
-- 
 
 
-- 
 
84m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.61 
 
 
.39 
 
84m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.26 
 
 
.74 
 
Comply = Compliance State; m = Month; C = Medication Complier; NC = Medication Non-Complier 
  
82 
 
Table 13: Compliance State Transition Matrix for Combination Therapy 
Time 
Comply 
24m 
C 
24m 
NC 
36m 
C 
36m 
NC 
48m 
C 
48m 
NC 
60m 
C 
60m 
NC 
72m 
C 
72m 
NC 
84m 
C 
84m 
NC 
96m 
C 
96m 
NC 
 
14m 
C 
 
 
 
.37 
 
 
.63 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
 
 
-- 
 
14m 
NC 
 
 
.46 
 
 
.54 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
C 
 
 
-- 
 
 
-- 
 
 
.74 
 
 
.26 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
24m 
NC 
 
 
-- 
 
 
-- 
 
 
.39 
 
 
.61 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.80 
 
 
.20 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
36m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.20 
 
 
.80 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.25 
 
 
.75 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
48m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.33 
 
 
.67 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.55 
 
 
.45 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
60m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.29 
 
 
.71 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
72m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.61 
 
 
.39 
 
 
-- 
 
 
-- 
 
72m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.41 
 
 
.59 
 
 
-- 
 
 
-- 
 
84m 
C 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.50 
 
 
.50 
 
84m 
NC 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
-- 
 
 
.11 
 
 
.89 
 
Comply = Compliance State; m = Month; C = Combination Therapy Complier; NC = Combination Therapy 
Non-Complier  
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          3.6.1.2 Disease/Treatment Variables: Response 
 
 I estimated response to therapy as a function of gender, comorbidity status, 
treatment, ADHD severity, and treatment compliance, with the mathematical specification 
below: 
|	
		    
     	 
	 	
	    
 
Therefore, I estimated response rates for 32 groups of patients corresponding to the groups 
of compliance, gender, severity, and comorbidity status. However, the MTA had few 
patients in the medication and combined treatment arms (Table 8), which created very low 
group membership in several of the groups. In order to robustly estimate response based 
on these factors, I used mixed effects logistic regression. Mixed effects logistic regression, 
or hierarchical modeling, is a robust method for testing the association between potential 
risk factors and disease outcomes with the presence of intra-group correlation of disease 
status (Atwill et al. 1995).  According to Bailley and Alimadhi (2007), “This general class of 
models is expressed as both a function of fixed effects …, [or] parameters corresponding to 
the entire population …, and random effects, [or] parameters corresponding to [individuals] 
drawn at random from a population.” Because each of the 32 groups has a relatively small 
size, the groups’ mixed effects logit response predictions effectively ‘borrow’ information 
from the given treatment arm’s overall mean response, which smoothes the group 
estimates and provides a more realistic estimate of treatment response. Table 14 provides 
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the group numbers (1 to 32) to evaluate Tables 15 through 18. Tables 15 and 16 present the 
MTA sample size for each patient type by treatment arm over time. Table 17 contains the 
predicted response rates for children on medication management, while Table 18 displays 
the predicted response rates for children on combination therapy.  The unadjusted 
response rates for patients on medication management and combination therapy, as well as 
the statistical output from the response models, are presented in Appendix E.    
 The two main statistical assumptions for mixed effects logistic regression models are 
that the residuals at the lowest (fixed) level have a normal distribution with a mean of zero 
and that the residuals at the second (cluster) level have a normal distribution with a mean 
of zero (Singer and Willett 2003). To test these assumptions, I plot both the fixed + random 
and random Pearson Residuals against the standardized normal probability plot. Plots for 
each model approximated normality (e.g., Figures 3 and 4), although the normality 
assumption does not fit perfectly. The mean of the fixed + random portions of the residuals 
deviated from zero more than the random portions.  However, the fixed portions of the 
Pearson Residuals generally hovered around |0.20|.   
 While the residuals at both the fixed and clustered levels of the model appear to 
resemble normality, they are not perfectly normal.  Non-normal residuals at the clustered 
level have little effect on the fixed parameter estimates (Maas and Hox 2004).  The 
parameter estimates are unbiased and the robust standard errors are correct (Maas and 
Hox 2004).  However, non-normal residuals at the clustered level do affect the parameter 
estimates in the random part of the model (Maas and Hox 2004).  But according to Mass 
and Hox (2004), “…using [maximum likelihood] methods for the analysis of multilevel data 
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with non-normally distributed group level residual errors only causes problems when one is 
interested in the significance or in the confidence intervals…at the second [clustered] level.”       
 
Figure 3: Standardized Normal Probability Plot: Fixed + Random Pearson Residuals 
 
Normal F[(Pearson2-m)/s] = Ordered Pearson Residuals; Empirical P[i]=i/(N+1) = Normal Order Statistic 
Means 
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Figure 4: Standardized Normal Probability Plot: Random Portion of Pearson Residuals
 
Normal F[(Pearson2-m)/s] = Ordered Pearson Residuals; Empirical P[i]=i/(N+1) = Normal Order Statistic 
Means 
 
Response to treatment in Tables 17 and 18 varies substantially between treatments 
and patient groups. For instance, estimated response rates at 24 months for patients on 
medication management are between 0.227 (Group 15 – girls without comorbidity, with 
severe ADHD, and who do not comply with treatment) and 0.677 (Group 13 – girls without 
comorbidity, with not severe ADHD, and who do not comply with treatment). The same 
patient groups on combination therapy have response rates of 0.526 and 0.817, 
respectively. Interestingly, some patient groups’ response rates actually improve after the 
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tightly controlled portion of the trial ended, which is contrary to common logic. One would 
expect to see response rates suffer when the patients return to the community because, 
hypothetically, compliance to medications and clinician visits would be more of a hurdle. 
That said, groups 6, 10, 13, 15, 19, 21, 23, 28, and 31 on combination therapy actually saw 
an increase in response rates after the trial ended. Groups 4, 12, 13, 17, 18, 21, 26, and 31 
on medication management saw the same peculiar pattern.   
Overall, with the exception of higher response rates during the first 14 months of 
controlled treatment, each group’s response rates appear to vary in a non-systematic way. 
For instance, girls in Group 1 on combination therapy have the highest predicted probability 
of response (post 14 months) at 60 months, while the lowest is at 84 months (Table 17). 
Girls in Group 1 on medication management have the second-lowest predicted probability 
of response at 60 months and the third-highest at 84 months. Presumably, the 
nonsystematic variances in response rates are a function of the small sample sizes of each 
group, where the element of chance plays a strong role. The small sample sizes also are 
reflected in the standard errors, particularly patients on combination therapy and girls 
overall. The only statistically significant estimates of response are among several of the 
groups of boys without comorbidity. The remaining groups’ estimates of response do not 
differ significantly from zero. The implications of the large standard errors and small sample 
sizes are discussed in Chapter 5.    
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Table 14: Patient Group Numbers for Response to Treatment Tables 
Patient  
Characteristics 
Patient Group 
Number (Females)  
Patient Group 
Number (Males) 
   
Both Comorbidities   
   Not Severe   
        Non-Complier 1 17 
        Complier 2 18 
   Severe   
        Non-Complier 3 19 
        Complier 
 
 
4 20 
Internalizing    
   Not Severe   
        Non-Complier 5 21 
        Complier 6 22 
   Severe   
        Non-Complier 7 23 
        Complier 
 
 
8 24 
Externalizing    
   Not Severe   
        Non-Complier 9 25 
        Complier 10 26 
   Severe   
        Non-Complier 11 27 
        Complier 
 
 
12 28 
No Comorbidities   
   Not Severe   
        Non-Complier 13 29 
        Complier 14 30 
   Severe   
        Non-Complier 15 31 
        Complier 16 32 
   
Both = Internalizing + Externalizing Comorbidities; Internalizing = Internalizing        
Comorbidities; Externalizing = Externalizing Comorbidities 
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Table 15: Sample Sizes for Patients on Medication Management across Time Points 
Patient Group 14 
months 
24 
months 
36 
months 
48 
months 
60 
months 
72 
months 
84 
Months 
96 
months 
 
Girls 
        
1 3 10 9 22 16 8 12 1 
2 16 5 11 1 12 8 13 16 
3 1 15 16 3 19 22 2 1 
4 2 1 1 2 2 1 2 1 
5 6 4 2 2 2 8 1 8 
6 2 1 2 3 2 2 3 16 
7 2 1 3 1 4 1 5 3 
8 5 2 3 9 4 1 1 1 
9 3 2 2 1 1 1 1 8 
10 16 5 11 2 1 2 1 16 
11 1 1 1 2 3 2 2 6 
12 2 4 2 4 3 4 3 1 
13 3 23 15 10 10 5 12 6 
14 14 14 14 14 16 18 6 9 
15 2 3 7 6 5 5 4 6 
16 1 3 3 7 7 2 6 5 
 
Boys 
        
17 9 3 1 6 3 4 4 5 
18 7 2 3 9 4 2 5 2 
19 4 9 7 12 8 10 8 13 
20 7 6 20 13 10 7 4 3 
21 2 10 7 2 5 4 7 3 
22 11 8 6 8 4 56 5 5 
23 1 6 4 10 16 4 44 12 
24 8 10 16 22 13 9 9 3 
25 1 4 1 8 3 2 3 3 
26 2 5 4 6 7 6 1 2 
27 1 15 14 15 12 20 20 18 
28 8 10 18 17 14 16 3 14 
29 6 58 52 36 40 63 51 46 
30 50 57 68 50 62 44 31 37 
31 2 29 27 35 25 22 33 23 
32 3 27 22 36 26 20 12 16 
         
MTA = Multimodal Treatment Study of Children with ADHD 
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Table 16: MTA Sample Sizes for Patients on Combination Therapy across Time Points 
Patient Group 14 
months 
24 
months 
36 
months 
48 
months 
60 
months 
72 
months 
84 
Months 
96 
months 
 
Girls 
        
1 7 3 4 1 4 6 2 4 
2 1 8 11 1 3 6 3 8 
3 13 2 4 2 1 2 2 3 
4 1 1 2 1 1 2 2 5 
5 7 3 1 1 4 6 2 4 
6 2 8 2 1 3 6 3 8 
7 1 1 2 2 2 2 2 1 
8 1 1 1 3 2 1 4 1 
9 7 3 4 1 4 6 2 1 
10 6 8 1 1 1 6 1 8 
11 1 2 2 2 1 2 2 3 
12 5 1 3 3 1 2 4 5 
13 5 5 2 3 2 1 2 4 
14 10 5 4 1 3 2 1 8 
15 4 3 3 1 1 2 1 1 
16 5 5 1 3 2 1 4 3 
 
Boys 
        
17 34 1 24 4 10 16 2 1 
18 1 32 20 7 15 27 1 20 
19 5 10 2 1 4 7 1 3 
20 6 8 5 3 3 3 2 1 
21 3 1 3 3 2 1 18 1 
22 4 2 3 7 15 4 1 2 
23 5 8 5 3 3 2 6 2 
24 10 3 1 4 1 14 6 1 
25 2 2 2 1 10 2 18 1 
26 1 4 20 7 2 1 23 20 
27 3 7 5 1 1 10 7 6 
28 3 6 10 2 4 8 2 1 
29 19 26 16 5 20 11 9 9 
30 29 8 14 5 1 3 8 4 
31 8 7 8 2 10 8 9 9 
32 15 6 8 5 2 5 8 3 
         
MTA = Multimodal Treatment Study of Children with ADHD 
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Table 17: Mean Estimates of Response to Medication Management 
Patient 
Group 
14 Mo 
Smoothed 
Mean (SE) 
24 Mo 
Smoothed 
Mean (SE) 
36 Mo 
Smoothed 
Mean (SE) 
48 Mo 
Smoothed 
Mean (SE) 
60 Mo 
Smoothed 
Mean (SE) 
72 Mo 
Smoothed 
Mean (SE) 
84 Mo 
Smoothed 
Mean (SE) 
96 Mo 
Smoothed 
Mean (SE) 
 
 
Girls 
         
1 .541 
(.708) 
.348 
(.525) 
.367 
(.557) 
.210 
(.402) 
.185 
(.510) 
.141 
(.697) 
.279 
(.525) 
.193 
(1.02) 
 
2 .726 
(.475) 
.239 
(.664) 
.321 
(.532) 
.251 
(.755) 
.221 
(.535) 
.205 
(.646) 
.166 
(.577) 
.160 
(.527) 
 
3 .302 
(1.09) 
.239 
(.664) 
.321 
(.532) 
.209 
(.696) 
.221 
(.535) 
.205 
(.646) 
.181 
(.930) 
.193 
(1.02) 
 
4 .243 
(1.00) 
.297 
(.884) 
.292 
(.934) 
.228 
(.722) 
.175 
(.916) 
.199 
(.670) 
.181 
(.930) 
.193 
(1.02) 
 
5 .541 
(.708) 
.425 
(.699) 
.580 
(.837) 
.445 
(.696) 
.318 
(.865) 
.141 
(.697) 
.403 
(.953) 
.440 
(.541) 
 
6 .668 
(.967) 
.297 
(.884) 
.580 
(.837) 
.297 
(.675) 
.175 
(.916) 
.174 
(.916) 
.285 
(.824) 
.545 
(.521) 
 
7 .476 
(.756) 
.297 
(.884) 
.349 
(.786) 
.371 
(.745) 
.243 
(.781) 
.199 
(.670) 
.134 
(.833) 
.149 
(.915) 
 
8 .337 
(.650) 
.256 
(.830) 
.219 
(.830) 
.195 
(.579) 
.142 
(.848) 
.199 
(.670) 
.209 
(.988) 
.391 
(.975) 
 
9 .541 
(.708) 
.401 
(.803) 
.407 
(.839) 
.371 
(.745) 
.200 
(.970) 
.199 
(.670) 
.209 
(.988) 
.440 
(.541) 
 
10 .726 
(.475) 
.239 
(.664) 
.321 
(.532) 
.329 
(.705) 
.200 
(.970) 
.317 
(.865) 
.209 
(.988) 
.160 
(.527) 
 
11 .578 
(1.07) 
.297 
(.884) 
.292 
(.934) 
.228 
(.722) 
.156 
(.878) 
.174 
(.916) 
.181 
(.930) 
.196 
(.754) 
 
12 .243 
(1.00) 
.309 
(.721) 
.407 
(.837) 
.194 
(.675) 
.156 
(.878) 
.142 
(.848) 
.161 
(.889) 
.391 
(.975) 
 
13 .550 
(.855) 
.677 
(.405) 
.392 
(.471) 
.351 
(.510) 
.423 
(.547) 
.435 
(.685) 
.569 
(.513) 
.396 
(.667) 
 
14 .726 
(.541) 
.520 
(.468) 
.693 
(.505) 
.428 
(.447) 
.548 
(.453) 
.590 
(.436) 
.612 
(.662) 
.543 
(.573) 
 
15 .476 
(.756) 
.227 
(.791) 
.314 
(.639) 
.305 
(.593) 
.219 
(.754) 
.219 
(.754) 
.251 
(.788) 
.115 
(.838) 
 
16 .578 
(1.07) 
.482 
(.741) 
.494 
(.769) 
.284 
(.578) 
.266 
(.664) 
.174 
(.916) 
.401 
(.659) 
.325 
(.724) 
 
 
Boys 
         
17 .188 
(.707) 
.618 
(.750) 
.292 
(.934) 
.234 
(.615) 
.156 
(.878) 
.142 
(.848) 
.146 
(.858) 
.124 
(.859) 
 
18 .223 
(.737) 
.401 
(.803) 
.349 
(.786) 
.251 
(.554) 
.243 
(.781) 
.174 
(.916) 
.449 
(.691) 
.167 
(.957) 
 
19 .270 
(.700) 
.204 
(.629) 
.229 
(.678) 
.128 
(.586) 
.107 
(.774) 
.151 
(.677) 
.109 
(.782) 
.308 
(.545) 
 
20 .321 
(.682) 
.254 
(.673) 
.153 
(.532) 
.124 
(.580) 
.097 
(.751) 
.114 
(.788) 
.146 
(.858) 
.149 
(.915) 
 
21 .450 
(.944) 
.456 
(.531) 
.496 
(.610) 
.329 
(.705) 
.436 
(.685) 
.492 
(.725) 
.364 
(.635) 
.149 
(.915) 
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22 .667 
(.571) 
.530 
(.571) 
.445 
(.643) 
.468 
(.530) 
.493 
(.725) 
.520 
(.267) 
.333 
(.713) 
.325 
(.724) 
23 .302 
(1.09) 
.174 
(.719) 
.307 
(.748) 
.237 
(.544) 
.200 
(.537) 
.243 
(.781) 
.333 
(.550) 
.082 
(.762) 
 
24 .384 
(.630) 
.319 
(.555) 
.226 
(.517) 
.242 
(.422) 
.347 
(.510) 
.301 
(.598) 
.233 
(.637) 
.149 
(.915) 
 
25 .578 
(1.07) 
.205 
(.762) 
.292 
(.934) 
.331 
(.547) 
.156 
(.876) 
.174 
(.916) 
.285 
(.824) 
.274 
(.842) 
 
26 .243 
(1.00) 
.380 
(.667) 
.559 
(.721) 
.382 
(.579) 
.542 
(.615) 
.391 
(.655) 
.209 
(.988) 
.167 
(.957) 
 
27 .302 
(1.09) 
.240 
(.512) 
.105 
(.666) 
.189 
(.509) 
.135 
(.659) 
.132 
(.559) 
.134 
(.561) 
.181 
(.536) 
 
28 .204 
(.721) 
.191 
(.191) 
.207 
(.507) 
.175 
(.499) 
.220 
(.550) 
.200 
(.537) 
.161 
(.889) 
.273 
(.528) 
 
29 .705 
(.730) 
.634 
(.634) 
.634 
(.277) 
.442 
(.309) 
.499 
(.303) 
.567 
(.247) 
.547 
(.272) 
.622 
(.293) 
 
30 .742 
(.313) 
.693 
(.693) 
.660 
(.248) 
.598 
(.271) 
.560 
(.249) 
.541 
(.291) 
.545 
(.342) 
.588 
(.320) 
 
31 .243 
(1.00) 
.347 
(.347) 
.242 
(.412) 
.332 
(.327) 
.143 
(.503) 
.157 
(.512) 
.297 
(.359) 
.331 
(.412) 
 
32 .370 
(.868) 
.306 
(.306) 
.402 
(.401) 
.302 
(.331) 
.200 
(.444) 
.239 
(.434) 
.137 
(.662) 
.152 
(.590) 
 
          
Total .546 
(.587) 
.479 
(.435) 
.441 
(.449) 
.337 
(.439) 
.345 
(.498) 
.375 
(.478) 
.362 
(.524) 
.368 
(.531) 
 
 
         
Smoothed = Smoothed Estimates from the Mixed-Effects Logit Estimation; SE = Standard Error; Mo = 
Months 
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Table 18: Mean Estimates of Response to Combination Therapy 
Patient 
Group 
14 Mo 
Smoothed 
Mean 
(SD) 
24 Mo 
Smoothed 
Mean 
(SD) 
36 Mo 
Smoothed 
Mean 
(SD) 
48 Mo 
Smoothed 
Mean 
(SD) 
60 Mo 
Smoothed 
Mean 
(SD) 
72 Mo 
Smoothed 
Mean 
(SD) 
84 Mo 
Smoothed 
Mean 
(SD) 
96 Mo 
Smoothed 
Mean 
(SD) 
 
 
Girls 
         
1 .747 
(.678) 
.554 
(.871) 
.298 
(.564) 
.271 
(.825) 
.570 
(.810) 
.275 
(1.29) 
.243 
(1.02) 
.283 
(.710) 
 
2 .741 
(1.59) 
.383 
(.637) 
.209 
(.492) 
.271 
(.825) 
.141 
(1.05) 
.275 
(1.29) 
.205 
(.964) 
.205 
(.636) 
 
3 .776 
(.567) 
.135 
(1.30) 
.263 
(.599) 
.364 
(.759) 
.179 
(1.27) 
.275 
(1.29) 
.458 
(.960) 
.175 
(.801) 
 
4 .215 
(1.64) 
.172 
(1.42) 
.308 
(.640) 
.235 
(.928) 
.487 
(1.18) 
.275 
(1.29) 
.101 
(1.69) 
.453 
(.644) 
 
5 .747 
(.678) 
.554 
(.871) 
.245 
(.675) 
.271 
(.825) 
.570 
(.810) 
.275 
(1.29) 
.243 
(1.02) 
.283 
(.710) 
 
6 .151 
(1.48) 
.383 
(.871) 
.227 
(.650) 
.271 
(.825) 
.141 
(1.05) 
.275 
(1.29) 
.205 
(.964) 
.205 
(.636) 
 
7 .741 
(1.59) 
.548 
(1.29) 
.227 
(.650) 
.364 
(.759) 
.146 
(1.18) 
.275 
(1.29) 
.457 
(.960) 
.218 
(.878) 
 
8 .741 
(1.59) 
.548 
(1.29) 
.245 
(.675) 
.440 
(.705) 
.366 
(.995) 
.275 
(1.29) 
.773 
(.881) 
.218 
(.878) 
 
9 .747 
(.678) 
.554 
(.871) 
.298 
(.564) 
.271 
(.825) 
.570 
(.810) 
.275 
(1.29) 
.800 
(1.43) 
.371 
(.857) 
 
10 .307 
(.686) 
.383 
(.637) 
.245 
(.675) 
.415 
(.904) 
.179 
(1.27) 
.275 
(1.29) 
.140 
(1.86) 
.205 
(.636) 
 
11 .215 
(1.64) 
.136 
(1.30) 
.227 
(.650) 
.364 
(.759) 
.198 
(1.19) 
.275 
(1.29) 
.101 
(1.69) 
.280 
(.760) 
 
12 .577 
(.695) 
.548 
(1.29) 
.397 
(.575) 
.440 
(.705) 
.179 
(1.27) 
.275 
(1.29) 
.773 
(.881) 
.453 
(.644) 
 
13 .578 
(.839) 
.817 
(.953) 
.400 
(.633) 
.439 
(.762) 
.363 
(1.03) 
.275 
(1.29) 
.800 
(1.43) 
.358 
(.699) 
 
14 .940 
(1.14) 
.672 
(.829) 
.337 
(.587) 
.235 
(.928) 
.141 
(1.05) 
.275 
(1.29) 
.695 
(1.62) 
.205 
(.636) 
 
15 .100 
(1.34) 
.526 
(.952) 
.211 
(.631) 
.235 
(.928) 
.198 
(1.19) 
.275 
(1.29) 
.140 
(1.86) 
.218 
(.878) 
 
16 .901 
(1.24) 
.799 
(.851) 
.245 
(.675) 
.440 
(.705) 
.617 
(1.03) 
.275 
(1.29) 
.773 
(.881) 
.280 
(.760) 
 
 
Boys 
         
17 .477 
(.327) 
.172 
(1.42) 
.243 
(.386) 
.267 
(.753) 
.078 
(.889) 
.275 
(1.29) 
.438 
(1.23) 
.218 
(.878) 
 
18 .741 
(1.59) 
.177 
(.437) 
.242 
(.409) 
.226 
(.633) 
.157 
(.629) 
.275 
(1.29) 
.140 
(1.86) 
.237 
(.666) 
 
19 .086 
(1.30) 
.129 
(.822) 
.227 
(.650) 
.235 
(.928) 
.111 
(1.07) 
.275 
(1.29) 
.695 
(1.62) 
.175 
(.801) 
 
20 .347 
(.800) 
.068 
(1.08) 
.246 
(.583) 
.183 
(.837) 
.126 
(1.12) 
.275 
(1.29) 
.101 
(1.69) 
.218 
(.878) 
 
21 .357 
(1.06) 
.548 
(1.29) 
.211 
(.631) 
.301 
(.787) 
.618 
(1.03) 
.275 
(1.29) 
.248 
(.503) 
.218 
(.878) 
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22 
 
.885 
(1.28) 
 
.389 
(1.10) 
 
.365 
(.608) 
 
.226 
(.633) 
 
.157 
(.629) 
 
.275 
(1.29) 
 
.140 
(1.86) 
 
.318 
(.800) 
 
23 .086 
(1.30) 
.153 
(.848) 
.246 
(.583) 
.183 
(.836) 
.487 
(.879) 
.275 
(1.29) 
.053 
(1.46) 
.193 
(.834) 
 
24 .496 
(.608) 
.114 
(1.23) 
.245 
(.675) 
.267 
(.753) 
.179 
(1.27) 
.275 
(1.29) 
.475 
(.775) 
.218 
(.878) 
 
25 .151 
(1.48) 
.136 
(1.30) 
.227 
(.650) 
.415 
(.904) 
.078 
(.889) 
.275 
(1.29) 
.248 
(.503) 
.371 
(.857) 
 
26 .741 
(1.59) 
.099 
(1.18) 
.242 
(.409) 
.226 
(.633) 
.363 
(1.03) 
.275 
(1.29) 
.239 
(.458) 
.153 
(.516) 
 
27 .119 
(1.39) 
.073 
(1.10) 
.246 
(.583) 
.235 
(.928) 
.179 
(1.27) 
.275 
(1.29) 
.048 
(1.43) 
.139 
(.736) 
 
28 .119 
(1.39) 
.189 
(.886) 
.235 
(.512) 
.205 
(.875) 
.111 
(1.07) 
.275 
(1.29) 
.438 
(1.23) 
.218 
(.878) 
 
29 .523 
(.450) 
.456 
(.382) 
.458 
(.409) 
.564 
(.673) 
.430 
(.431) 
.275 
(1.29) 
.740 
(.725) 
.594 
(.551) 
 
30 .716 
(.405) 
.251 
(.734) 
.499 
(.426) 
.453 
(.671) 
.487 
(1.18) 
.275 
(1.29) 
.822 
(.864) 
.358 
(.699) 
 
31 .381 
(.692) 
.395 
(.702) 
.260 
(.530) 
.348 
(.835) 
.209 
(.686) 
.275 
(1.29) 
.431 
(.649) 
.235 
(.604) 
 
32 .592 
(.511) 
.189 
(.886) 
.260 
(.530) 
.152 
(.784) 
.146 
(1.18) 
.275 
(1.29) 
.044 
(1.41) 
.280 
(.760) 
 
          
Total .536 
(.816) 
.309 
(.841) 
.319 
(.539) 
.313 
(.787) 
.305 
(.819) 
.275 
(1.29) 
.390 
(1.17) 
.299 
(.722) 
 
          
Smoothed = Smoothed Estimates from the Mixed-Effects Logit Estimation; SE = Standard Error; Mo = 
Months 
 
          3.6.1.3 Costs  
 The analyses’ perspectives framed which costs to include. I employed both the payer 
and societal/taxpayer perspectives. The payer perspective included treatment-related costs, 
while the societal/taxpayer perspective included both treatment and non-treatment related 
costs. Table 19 details the specific costs used for each perspective. Tables 20 to 26 illustrate 
the utilization and costs-parameter estimates used in the discrete-event simulation. Costs 
are reported in 2000 dollars; however, a description of the differential inflation rates over 
the past decade and how to interpret costs in 2000 dollars is located in Appendix F. 
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 I calculated costs of medications according to compliance states (Table 20). I 
assumed those who complied with their medication therapy accrued a higher medication 
cost than those who did not comply, and the MTA data confirmed this assumption. The 
average medication costs for compliers on medication management were $669, while 
average costs of compliers on combination therapy were $619. The average costs of non-
compliant patients on medication management were $428, while the average costs of non-
compliers on combination therapy were $132.   
 I determined costs of clinicians also by compliance states, as well as the costs of the 
clinicians’ time (Table 21). I assumed that compliers on medication management attended 
an average of 12.5 visits for the first 14 months, and compliers attended an average of 11 
visits per year in the follow-up periods, each one year long. Non-compliers attended, on 
average, 5.0 visits during the first 14 months and 4.5 visits during the follow-up periods. The 
costs of clinicians’ time were determined by the average half-hour wage for psychiatrists 
(U.S. Department of Labor, Bureau of Labor Statistics). Psychiatrists average approximately 
$26 per half-hour; therefore, each medication management visit cost $26.  
For the clinician and teacher costs of the intensive behavioral therapy component of 
combination therapy, I used estimates by the MTA Cooperative Group (Table 22). Average 
costs of clinicians for compliers were $7,456, while costs for non-compliers were $6,014. 
The average costs of teachers were $459 for compliers and $317 for non-compliers.   
 The clinician costs for medication management in combination therapy during the 
follow-up periods were equivalent to those of only medication management (Table 23). 
However, the additional clinician costs of booster therapy were determined by compliance 
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state and the clinicians’ time. The average number of booster therapy visits for compliers 
was 3.5, while non-compliers averaged 1.5. The average cost per visit was equivalent to the 
medication management visits because the visit’s length was a half-hour in each instance.  
 I determined the costs of inpatient psychiatric hospitalizations by the average 
number of days spent in the hospital, the average cost per day of hospitalization, and the 
percentage of patients hospitalized by treatment arm and time point (Table 24). For 
instance, 0.31 percent of patients on medication management were hospitalized during the 
first 14 months. Patients spent an average of three days in the hospital. At an average cost 
of $1,300 per day, the hospital costs for the medication management cohort at 14 months 
averaged $12. Patients on combination therapy seemed to be hospitalized considerably 
more than patients on medication management, reaching a peak of 8.7 percent at 48 
months, while the 48-month peak for those on medication management was 2.27 percent. 
Though these differences appear to be large (especially during the later time points), the 
differences are not statistically significant at any time point (Figure 5, Appendix G) and are 
likely the result of small sample sizes.      
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The costs and frequency of arrests also appeared to be much higher for patients on 
combination therapy compared to medication management patients. Arrests for patients 
on combination therapy peaked at 96 months (9.84 percent), while medication 
management patients peaked at 72 months (5.78 percent). The average costs per arrest 
were equivalent in each treatment arm and across time points at $387.96 (Table 25). But 
again, the differences in arrest rates were not statistically significant over the time horizon, 
indicating the equivalency of arrest rates among patients in each treatment arm (Figure 6, 
Appendix G).  
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The costs of special education were estimated from MTA data based on the 
percentage of patients in special education, the percent of the school year those patients 
spent in special education, and the costs of special education per year. The average costs 
per year of special education were equivalent across treatment arms and time points at 
$4,320 (Pelham et al. 2007; Parrish 2003). On average, combination therapy patients were 
more likely to spend time in special education toward the beginning and end of the time 
horizon, while those on medication management were more likely to be in special 
education during the middle time points. Differences among the two groups were 
statistically significant (Figure 7, Appendix G), indicating real differences in service 
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utilization. Among those taking part in special education, combination therapy patients 
generally spent more time in special education (Table 26), although the differences are only 
statistically significant at 14 and 24 months (Appendix G).       
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Table 19: Costs by Perspective 
Payer Perspective Societal Perspective 
Medication 
 
Medication 
Clinician 
 
Clinician 
Hospital 
 
Hospital 
 Juvenile Justice 
 
 Special Education 
 
 Work Absenteeism 
 
 
 
Table 20: Cost of Medications by Compliance State 
Treatment Average Cost of Compliers Range Average Cost of Non-Compliers Range 
 
Medication 
 
$669 
 
$0 - $1,415 
 
$428 
 
$0 - $1,078 
 
Combination 
 
$619 
 
$0 - $1,298 
 
$132 
 
$0 - $367 
Costs of Being Managed on Medications, Not Managed on a Specific Medication; All Garnered From 
Multimodal Treatment Study of Children with ADHD Data 
 
 
Table 21: Clinician Costs and Utilization by Compliance State for Medication Management 
Compliance 
State 
Average Number of 
Visits 
(14 Months) 
Range Number of 
Visits 
(post-14 
months) 
Range Cost per 
Visit 
Range 
 
Complier 
 
12.5 
 
11 – 14 
 
11 
 
10 – 12 
 
$26 
 
$25 - $27 
 
Non-Complier 
 
5 
 
0 - 10 
 
4.5 
 
0 - 9 
 
$26 
 
$25 - $27 
Costs of Medication Visits are Based on ½ Hour Visit Using Bureau of Labor Statistics Estimates of 
Psychiatrists’ Salaries; Utilization from Multimodal Treatment Study of Children With ADHD Data; post-14 
months = 12 Month Intervals 
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Table 22: Clinician and Teacher Costs by Compliance State for First 14 Months of Intensive 
Behavioral Therapy 
Compliance 
State 
Cost for Intensive BT 
(Doctors) 
Range Cost for Intensive BT 
(Teachers) 
Range 
 
Complier 
 
$7,436 
 
$3395 - $8462 
 
$459 
 
$265 - $530 
 
Non-Complier 
 
$6,014 
 
$55 - $8541 
 
$317 
 
$0 - $530 
All Garnered From Multimodal Treatment Study of Children with ADHD Data; BT = Behavioral Therapy 
 
 
Table 23: Clinician Costs and Utilization by Compliance State for Combination Therapy Post-14 
Months 
Compliance 
State 
# of 
Medication 
Visits 
Range Cost per 
Medication 
Visit  
Range # of 
Booster 
BT Visits 
Range Cost per 
Booster 
Visit 
Range 
 
Complier 
 
11 
 
 
10 – 12 
 
$26 
 
$25 - 
$27 
 
3.5 
 
3 – 4 
 
$26 
 
$25 - $27 
 
Non-
Complier 
 
4.5 
 
 
0 - 9 
 
$26 
 
$25 - 
$27 
 
1.5 
 
0 – 3  
 
$26 
 
$25 - $27 
Costs of Medication and Booster Visits are each based on ½ hour visit using BLS estimates of Psychiatrists’ 
Salaries, Utilization From Multimodal Treatment Study of Children With ADHD Data; # = number 
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Table 24: Utilization and Costs for Inpatient Psychiatric Hospitalizations 
Treatment 
Time Point 
% of Kids 
Hospitalized 
Average Days 
in Hospital 
Range Average 
Cost/Day 
Range Average Cost 
for Cohort 
 
Medication 
      
   14 Months 0.31% 3 1 - 15 $1,300 $700 - 
$1900 
$12 
   24 Months 0.31% 3 1 - 15 $1,300 $700 - 
$1900 
$12 
   36 Months 0.62% 3 1 - 15 $1,300 $700 - 
$1900 
$24 
   48 Months 2.27% 3 1 - 15 $1,300 $700 - 
$1900 
$89 
   60 Months 0.32% 3 1 - 15 $1,300 $700 - 
$1900 
$12 
   72 Months 0.72% 3 1 - 15 $1,300 $700 - 
$1900 
$28 
   84 Months 0.39% 3 1 - 15 $1,300 $700 - 
$1900 
$15 
   96 Months 1.23% 3 1 - 15 $1,300 $700 - 
$1900 
$48 
 
Combination 
      
   14 Months 0.84% 3 1 - 15 $1,300 $700 - 
$1900 
$33 
   24 Months 1.67% 3 1 - 15 $1,300 $700 - 
$1900 
$65 
   36 Months 0.93% 3 1 - 15 $1,300 $700 - 
$1900 
$36 
   48 Months 8.70% 3 1 - 15 $1,300 $700 - 
$1900 
$339 
   60 Months 3.30% 3 1 - 15 $1,300 $700 - 
$1900 
$129 
   72 Months 2.50% 3 1 - 15 $1,300 $700 - 
$1900 
$98 
   84 Months 2.50% 3 1 - 15 $1,300 $700 - 
$1900 
$98 
   96 Months 3.28% 3 1 - 15 $1,300 $700 - 
$1900 
$128 
Cost Data Garnered From H-CUP; Utilization From Multimodal Treatment Study of Children With ADHD 
Data; % = percentage; Medication = Medication Management; Combination = Combination Therapy; Time 
Point = Interval From the Previous Time Point to the One Listed 
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Table 25: Utilization and Costs of Arrests in the Juvenile Justice System 
Treatment 
Time Point 
% of Kids Arrested Mean Cost per Arrest Range 
  
 
Medication 
   
   14 Months 2.85% $387.96 $10 - $824 
   24 Months 2.20% $387.96 $10 - $824 
   36 Months 1.54% $387.96 $10 - $824 
   48 Months 0.85% $387.96 $10 - $824 
   60 Months 1.60% $387.96 $10 - $824 
   72 Months 5.78% $387.96 $10 - $824 
   84 Months 2.34% $387.96 $10 - $824 
   96 Months 2.87% $387.96 $10 - $824 
 
Combination 
   
   14 Months 3.36% $387.96 $10 - $824 
   24 Months 4.17% $387.96 $10 - $824 
   36 Months 1.87% $387.96 $10 - $824 
   48 Months 2.17% $387.96 $10 - $824 
   60 Months 6.67% $387.96 $10 - $824 
   72 Months 8.75% $387.96 $10 - $824 
   84 Months 4.11% $387.96 $10 - $824 
   96 Months 9.84% $387.96 $10 - $824 
Costs Garnered from Pelham et al. (2007); Utilization from Multimodal                        
Treatment Study of Children with ADHD Data; % = percentage;              
Medication = Medication Management; Combination = Combination                            
Therapy; Time Point = Interval From Previous Time Point to the One Listed 
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Table 26: Cost and Utilization of Special Education 
Treatment 
 
Time Point 
% of Kids 
in Special 
Education 
% of Year 
in Special 
Education 
Range Mean Cost 
per Year 
Range Mean Total 
Cost
1 
 
 
 
Medication        
   14 Months 35.13% 10.28% .05 – 96.92% $4,320 $3681 - 
$5709 
$444  
   24 Months 36.79% 13.26% .05 – 99.84% $4,320 $3681 - 
$5709 
$573  
   36 Months 29.54% 21.13% .06 – 100% $4,320 $3681 - 
$5709 
$913  
   48 Months 64.49% 14.59% .06 – 50.38% $4,320 $3681 - 
$5709 
$630  
   60 Months 68.27% 14.23% .68 – 40.78% $4,320 $3681 - 
$5709 
$615  
   72 Months 20.22% 23.27% .58 – 100% $4,320 $3681 - 
$5709 
$1,005  
   84 Months 62.50% 10.07% .028 – 43.68% $4,320 $3681 - 
$5709 
$435  
   96 Months 12.70% 3.90% .028 – 41.21% $4,320 $3681 - 
$5709 
$168  
 
Combination 
       
   14 Months 47.06% 20.65% .07 – 100% $4,360 $3681 - 
$5709 
$892  
   24 Months 52.50% 28.09% .029 – 100% $4,360 $3681 - 
$5709 
$1,213  
   36 Months 42.06% 25.76% .47 – 100% $4,360 $3681 - 
$5709 
$1,113  
   48 Months 28.26% 12.71% .38 – 56.55% $4,360 $3681 - 
$5709 
$549  
   60 Months 25.00% 18.07% 2.98 – 45.33% $4,360 $3681 - 
$5709 
$781  
   72 Months 36.25% 24.57% .005 – 100% $4,360 $3681 - 
$5709 
$1,061  
   84 Months 20.55% 15.74% 3.09 – 40.07% $4,360 $3681 - 
$5709 
$680  
   96 Months 27.87% 2.96% .002 – 34.26% $4,360 $3681 - 
$5709 
$128  
1
Mean Cost per Patient Using Special Education; Costs Garnered From Pelham et al. (2007) and Parrish 
(2003); Utilization From MTA Data; % = percentage; Time Point = Interval From Previous Time Point to the 
One Listed; % = Percentage 
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3.7 Study Aim 2 
         
My second study aim was to model the cost-effectiveness treatments for ADHD, 
focusing on the effects of gender and comorbidity. I used the estimates and distributions of 
response and costs to populate parameters in a computational discrete-event simulation 
model. The computational model simulated patients flowing through the health care system 
and captured both costs and treatment successes/failures as the children aged. The ensuing 
subsections describe the cost-effectiveness equation, the modeling software used to 
simulate patients’ experiences, and the model validation and verification processes.   
         
     3.7.1 Cost-Effectiveness Equation 
 The final metric for my study was the incremental cost-effectiveness ratio (ICER). 
Cost-effectiveness analyses do not express the benefits of treatment in dollar terms. 
Instead, ICER can be interpreted as incremental dollars spent per unit of desired outcome.  
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 Because my study employs a longer time horizon than previous cost-effectiveness 
studies of ADHD treatment, my focus was on how the children responded to treatment 
throughout the eight years of follow up. Instead of computing cost-effectiveness at a 
specific time point, I computed the cost divided by the amount of time patients spent in the 
treatment responder state. For instance, if a child responded to a given treatment four of 
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the eight years, then their denominator would be 4. One could view this metric in the same 
way as a quality-adjusted life year. I call my metric a normalized-adjusted life year (NALY). A 
person who never responds would have 0 NALYs, while a person who responded every year 
would have 8 NALYs. In the simulation, each patient begins with a zero at baseline, and each 
year they respond increases their NALY by one (or 1/8 of the time horizon).  Therefore, the 
ICER indicates the incremental cost of combination therapy per incremental year a patient 
responds to treatment. 
 A NALY is simply based on response estimates of the SNAP-IV rating scale. Because 
most ADHD studies last only one year, they have no need for a measure that indicates the 
proportion of time a patient responds to treatment over a long time horizon. Comparisons 
to the peer-reviewed literature can be tricky; however, my study results can be compared 
to others by using my 14-month estimates for response. In this case, the NALY would be 
replaced with the number of responders in each treatment arm. Then, one could compute 
the incremental effectiveness as: 
 
Responders on Combination Therapy – Responders on Medication Management 
 
Because ADHD is a chronic disease, with effects lasting well into adolescence, I believe 
longer-term studies are on the horizon, and metrics like the NALY will be used more often 
to demonstrate the long-term effectiveness of treatments.   
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 To implement the conceptual model with the parameters I estimated from MTA 
data, I turned to a discrete-event simulation modeling software called Simio. The next 
subsection describes how Simio operates.    
    
     3.7.2 Simio Discrete-Event Simulation Modeling Software 
 The Simio modeling system allowed me to create an animated simulation model, 
accurately representing pediatric patients’ progression through the health care system. 
Simio is a simulation modeling framework based on intelligent objects. An object might be a 
machine, a doctor’s office, or any other item that one might encounter in the system 
(Pegden and Sturrock 2009). Modeling in Simio begins with these base objects – it is the 
groundwork on which higher level objects are constructed. A base object in Simio is a fixed 
object (a visit to the doctor), an entity (patient), or a link (logic for which path to take) that 
has intelligence added by processes (Pegden and Sturrock 2009). “Processes give an object 
its intelligence by defining the logic that is executed in response to events (Pegden and 
Sturrock 2009).” A model is built by combining objects that represent the physical 
components of the system. 
Simio uses an object-oriented design for graphical model development. Graphical 
objects, called servers, are placed on a layout in order to define system components such as 
being placed on an ADHD treatment or visiting a clinician. In order to develop a simulation 
model using Simio, I simply clicked on and dragged a server onto the model canvas. Simio 
would then prompt me to define the logic of the server by creating a process to guide the 
server’s logic. 
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 Simio also contains certain tools valuable for completing entire simulation projects. 
The software allows the user to conduct experiments by replicating a simulation a number 
of times. Simio collects the results from the replications and creates confidence intervals to 
illustrate the uncertainty in each simulation. Additionally, Simio produces detailed reports 
on any metric that the user specifies. For example, the reports from my model included the 
treatment, non-treatment, and total costs for each of the eight combinations of gender and 
comorbidity, as well as the number of responders for those eight groups – with the cost-
effectiveness metric simply being the incremental costs divided by the incremental NALYs. 
The relative ease with which Simio replicates the simulations, in addition to generating 
reports, made the software ideal for this project. Simio also allows users to run warm-up 
analyses to reduce initial transient biases. The next subsection describes analyses in more 
detail.  
 
          3.7.2.1 Initial Transient Period Bias in Simulation 
The goal of discrete-event simulation is to estimate the steady-state parameters of 
the simulation output (Robinson and Ioannou, 2010). However, the beginning of a 
simulation usually includes a transient period prior to the model reaching a steady-state – 
the ‘initial transient’ (Robinson and Ioannou, 2010). This typically involves at least the time 
it takes for the model to fill with entities. Biased estimates of the steady-state parameters 
occur when these initial transient data are included (Robinson and Ioannou, 2010). In order 
to estimate the long-term performance of the system, I addressed the initial 
transient period with a warm-up period analysis. This analysis required that I inspect the 
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simulation output to identify the initial transient period. In order to run the warm-up period 
analysis I first decided which variables were of interest – for example, costs for medication 
responders versus non-responders in both males and females. In the first stage of the 
warm-up period analysis, I started with a low number of patients in the system. I ran the 
simulation until 500 patients entered and left the system. I then re-ran the simulation until 
1,000 patients entered and left the system. I compared the cost measures for each type of 
patient from both simulation runs, looking for a large difference in the cost variables. If a 
large difference existed, I would increase the number of patients entering and leaving the 
system. I continued this procedure until the costs began to level off. I ran the warm-up 
period analysis on 500, 1,000, 2,500, 5,000, and 7,500 patients and found that the costs 
leveled off around 2,500 patients. Therefore, I conducted the simulations on a hypothetical 
cohort of 2,500 patients. My final task was to verify the model. Details of the verification 
and validation processes are described in the next subsection.  
 
          3.7.2.2 Model Verification and Validation 
 I verified the model in several ways. First, an expert modeler in discrete-event 
simulation checked the operational aspects of my model. We checked the structure and 
programming of the model step-by-step. Applying two sets of eyes to trace the model 
helped to assure no errors were present. Second, I varied several model inputs to check for 
reasonableness. For instance, I changed the parameter estimates for special education and 
inpatient hospitalization in succession by raising the expected costs of each. Because of the 
relative infrequency of inpatient hospitalization compared to special education, I expected 
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to see the costs for each patient type rise more when I raised the costs of special education, 
and that is exactly what happened. Lastly, I inspected the animation of the simulation 
model, making sure that the timing of visits to the clinicians was accurate. For instance, the 
first patients should begin the 24-month loop approximately in March of the second year. I 
found that patients entered each loop of the model and exited at the correct times. 
 I established face validity of the model by presenting the conceptual models to 
clinical experts. Predictive validity was difficult to establish because no other similar study 
has utilized a time horizon as long as my model. I partially checked predictive validity by 
comparing my 14-month costs results for patients with no comorbitities to the results in 
Foster et al. (2007),  who found the treatment costs of medication management were $979 
per patient (95 percent confidence interval: $807 - $1,151). My model’s 14-month 
treatment costs for medication management were $825, well within the Foster et al. (2007) 
95 percent confidence interval. Foster et al. found treatment costs for combination therapy 
to be $7,064 (95 percent confidence interval: $6,815 - $7,314), while my model’s treatment 
costs were $6,683 – below the Foster et al. estimate, but quite plausible. The model results 
have not been validated with external datasets.    
 
 
 
  
Chapter 4: Results 
One advantage of discrete-event simulation is that probabilistic sensitivity analyses 
are automatically performed, which addresses the impact of varying multiple parameters on 
outcomes (Simpson 2009). In order to assure the stability of my results, and to reach a 
tolerance (precision) level of 5 percent, I performed 50 replications of 2,500 patients for all 
analyses. All reported results are the mean and 95 percent confidence intervals across the 
50 replications. 
 
4.1 Organization and Presentation of Results 
  
 Because of the abundance of results and tables, I present a detailed discussion of a 
representative set of results and touch on the high points for other results. The results are 
organized as follows: 
1. A discussion of treatment, non-treatment, and total costs, including trends over time, 
comparisons between genders, and comparisons between treatments. 
2. A discussion of treatment response, including trends over time, comparisons between 
genders, and comparisons between treatments.   
3. A discussion of the cost-effectiveness of combination therapy compared to 
medication management for the treatment of pediatric ADHD, including the percent of 
time normalized (and NALYs), by treatment type, cost per patient-type, incremental 
costs and NALYs, and the incremental cost-effectiveness ratio (ICER).
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4.2 Treatment Costs 
 
 Treatment costs included costs of medications, clinician and teacher time, and 
inpatient psychiatric hospitalizations. These costs in isolation represent the health care 
payer perspective and are the first cost component of the societal/taxpayer perspective. 
     
     4.2.1 Trends over Time 
 The treatment costs for boys and girls on medication management trended upward 
over time (Table 27).  For instance, treatment costs for boys on medication management 
with internalizing comorbidities from baseline to 14 months were $839; from 36 to 48 
months, treatment costs were $1,095; and from 84 to 96 months, treatment costs were 
$1,252. Treatment costs for girls on medication management with internalizing 
comorbidities were $823 from baseline to 14 months, $1,091 from 36 to 48 months, and 
$1,255 from 84 to 96 months. Similar trends over time appeared for both boys and girls 
with each comorbidity type.   
Treatment costs for boys and girls on combination therapy operated in a different 
fashion. Costs for boys and girls on combination therapy, regardless of comorbidity, were 
very high from baseline to 14 months, due to the intensity of the behavioral therapy 
component (Table 27). These costs for both boys and girls, regardless of comorbidity, were 
just over $6,700. After 14 months, the intensity of behavioral therapy receded, patients 
returned to the community (quarterly booster BT sessions), and costs fell accordingly. 
During the period from 14 to 24 months, treatment costs for all patients on combination 
therapy rose steadily at a higher rate than treatment costs for patients on medication 
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management. For instance, boys on combination therapy with internalizing comorbidities 
from 14 to 24 months had treatment costs of $1,188; $2,055 from 36 to 48 months; and 
$2,890 from 84 to 96 months – a 2.4-fold increase over that time span. Girls with 
internalizing comorbidities from 14 to 24 months accrued treatment costs of $1,175; $1,980 
from 36 to 48 months; and $2,866 from 84 to 96 months – also a 2.4-fold increase. In 
comparison, both boys and girls with internalizing comorbidities on medication 
management experienced a 1.5-fold increase over the same time periods (Table 27). The 
largest jump in combination therapy treatment costs, across comorbidity types and 
genders, occurred between the 24 to 36 months and 36 to 48 months time points. For 
instance, treatment costs for girls with externalizing comorbidities increased from $1,341 to 
$2,055 (a 53 percent increase), while treatment costs for boys increased from $1,351 to 
$2,044 (a 51 percent increase). The next-highest increase in treatment costs for girls and 
boys was between the 36 to 48 months and 48 to 60 months time periods, both increasing 
by approximately 23 percent (boys, $2,034 to $2,510; girls, $2,055 to $2,571). I found very 
similar increases for boys and girls with externalizing comorbidities, both internalizing and 
externalizing comorbitities, and no comorbidities over time. 
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Table 27: Mean Treatment Costs per Entity Over Time 
Comorbidity/ 
Time Point 
Boys - Medications Girls - Medications Boys - Combination Girls – 
Combination 
 
Intern 
 
 
   
     14 Months $839 $823 $6,723 $6,713 
     24 Months $850 $838 $1,188 $1,175 
     36 Months $936 $917 $1,349 $1,326 
     48 Months $1,095 $1,091 $2,055 $1,980 
     60 Months $1,147 $1,141 $2,496 $2,458 
     72 Months $1,197 $1,179 $2,590 $2,548 
     84 Months $1,171 $1,149 $2,801 $2,780 
     96 Months $1,252 $1,255 $2,890 $2,866 
 
Extern 
    
     14 Months $831 $828 $6,711 $6,722 
     24 Months $849 $840 $1,186 $1,173 
     36 Months $939 $919 $1,351 $1,341 
     48 Months $1,113 $1,064 $2,034 $2,055 
     60 Months $1,173 $1,114 $2,510 $2,571 
     72 Months $1,228 $1,147 $2,622 $2,672 
     84 Months $1,202 $1,129 $2,844 $2,882 
     96 Months $1,310 $1,244 $2,913 $2,948 
 
Both 
    
     14 Months $828 $838 $6,707 $6,720 
     24 Months $838 $863 $1,219 $1,180 
     36 Months $922 $949 $1,386 $1,344 
     48 Months $1,098 $1,090 $2,063 $2,050 
     60 Months $1,160 $1,135 $2,512 $2,508 
     72 Months $1,190 $1,182 $2,599 $2,616 
     84 Months $1,180 $1,157 $2,836 $2,813 
     96 Months $1,287 $1,254 $2,908 $2,887 
 
Neither 
    
     14 Months $827 $835 $6,703 $6,724 
     24 Months $834 $854 $1,194 $1,171 
     36 Months $918 $945 $1,353 $1,329 
     48 Months $1,087 $1,108 $2,068 $2,008 
     60 Months $1,142 $1,155 $2,554 $2,471 
     72 Months $1,199 $1,179 $2,669 $2,567 
     84 Months $1,173 $1,171 $2,910 $2,768 
     96 Months $1,302 $1,275 $2,990 $2,868 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither = No 
Comorbidities; Medications = Medication Management; Combination = Combination Therapy; Time Point = 
Interval From Previous Time Point to the One Listed 
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     4.2.2 Comparison between Genders 
 
Treatment costs for girls and boys, regardless of comorbidity, were very similar 
within treatment arms at each time point, and they were clearly economically equivalent 
(Table 27). Additionally, all confidence intervals for boys and girls overlapped within 
treatment and time points, which indicates that treatment costs were statistically 
equivalent (Tables 28, 29, 30 and 31). Treatment costs for boys compared to girls over time 
varied among treatment types for those with comorbidity types of externalizing, both 
internalizing and externalizing, and neither (Table 27). For instance, boys with externalizing 
comorbidities on medication management from 36 to 48 months had 5 percent higher 
treatment costs than their female counterparts ($1,113 compared to $1,064). However, 
boys with externalizing comorbidities on combination therapy from 36 to 48 months had 1 
percent fewer treatment costs than their female counterparts ($2,034 compared to $2,055). 
The same trend appeared at 60-, 72-, 84-, and 96-month marks, with boys on medication 
management accruing more treatment costs than girls, while amassing fewer treatment 
costs on combination therapy. Girls on medication management with both comorbidity 
types amassed higher treatment costs than boys from 14 to 24 months (3 percent higher; 
$863 compared to $838) and 24 to 36 months (3 percent higher; $949 compared to $922). 
Girls on combination therapy had 3 percent lower treatment costs from 14 to 24 months 
($1,180 compared to $1,219) and 24 to 36 months ($1,344 compared to $1,386). Finally, 
treatment costs for boys without comorbidity on medication management were lower than 
their female counterparts from 14 to 60 months, while treatment costs for boys without 
comorbidity on combination therapy were higher than females over the same time period. 
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Table 28: Boys’ Treatment Costs over Time – Medication Management 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.6 
    
    14 Months  $263,966 $257,189 $270,742 $839 
    24 Months  $267,398 $260,286 $274,510 $850 
    36 Months  $294,323 $285,730 $302,916 $936 
    48 Months  $344,459 $334,458 $354,461 $1,095 
    60 Months  $360,720 $350,155 $371,285 $1,147 
    72 Months  $376,439 $364,932 $387,947 $1,197 
    84 Months  $368,430 $356,381 $380,479 $1,171  
    96 Months  $393,938 $380,810 $407,066 $1,252 
 
Extern 
 
307.2 
    
    14 Months  $255,198 $248,798 $261,597 $831 
    24 Months  $260,699 $252,434 $268,963 $849 
    36 Months  $288,438 $277,016 $299,861 $939 
    48 Months  $341,967 $323,876 $360,058 $1,113 
    60 Months  $360,357 $340,627 $380,087 $1,173 
    72 Months  $377,194 $355,838 $398,550 $1,228 
    84 Months  $369,251 $349,770 $388,731 $1,202 
    96 Months  $402,409 $383,617 $421,202 $1,310 
 
Both 
 
310.1 
    
    14 Months  $256,680 $250,319 $263,042 $828 
    24 Months  $260,018 $253,449 $266,587 $838 
    36 Months  $286,026 $278,390 $293,662 $922 
    48 Months  $340,572 $326,894 $354,249 $1,098 
    60 Months  $359,751 $345,088 $374,413 $1,160 
    72 Months  $368,895 $353,813 $383,978 $1,190 
    84 Months  $365,997 $350,653 $381,342 $1,180 
    96 Months  $399,214 $383,622 $414,807 $1,287 
 
Neither 
 
313.1 
    
    14 Months  $258,826 $252,347 $265,305 $827 
    24 Months  $261,220 $252,995 $269,445 $834 
    36 Months  $287,300 $279,090 $295,511 $918 
    48 Months  $340,327 $327,327 $353,327 $1,087 
    60 Months  $357,408 $346,358 $368,458 $1,142 
    72 Months  $375,550 $361,954 $389,146 $1,199 
    84 Months  $367,154 $353,275 $381,032 $1,173 
    96 Months  $407,706 $388,074 $427,338 $1,302 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One              
Listed; N = Sample Size 
  
117 
 
Table 29: Girls’ Treatment Costs over Time – Medication Management 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.1 
    
    14 Months  $258,647 $252,661 $264,633 $823 
    24 Months  $263,312 $256,449 $270,174 $838 
    36 Months  $288,024 $280,537 $295,510 $917 
    48 Months  $342,709 $332,602 $352,816 $1,091 
    60 Months  $358,418 $346,674 $370,163 $1,141 
    72 Months  $370,178 $357,464 $382,893 $1,179 
    84 Months  $360,880 $347,078 $374,681 $1,149  
    96 Months  $394,090 $379,106 $409,074 $1,255 
 
Extern 
 
320.1 
    
    14 Months  $265,170 $257,738 $272,602 $828 
    24 Months  $268,734 $260,256 $277,213 $840 
    36 Months  $294,244 $284,726 $303,762 $919 
    48 Months  $340,467 $325,325 $355,609 $1,064 
    60 Months  $356,448 $339,829 $373,066 $1,114 
    72 Months  $367,201 $350,836 $383,566 $1,147 
    84 Months  $361,525 $346,648 $376,403 $1,129 
    96 Months  $398,335 $381,628 $415,042 $1,244 
 
Both 
 
308.9 
    
    14 Months  $258,795 $252,251 $265,340 $838 
    24 Months  $266,655 $258,667 $274,643 $863 
    36 Months  $293,253 $283,335 $303,171 $949 
    48 Months  $336,770 $322,695 $350,845 $1,090 
    60 Months  $350,596 $335,025 $366,168 $1,135 
    72 Months  $365,023 $348,099 $381,947 $1,182 
    84 Months  $357,425 $339,963 $374,886 $1,157 
    96 Months  $387,286 $367,350 $407,222 $1,254 
 
Neither 
 
312.0 
    
    14 Months  $260,504 $251,843 $269,165 $835 
    24 Months  $266,554 $257,521 $275,587 $854 
    36 Months  $294,694 $282,786 $306,601 $945 
    48 Months  $345,704 $328,219 $363,189 $1,108 
    60 Months  $360,293 $344,063 $376,523 $1,155 
    72 Months  $367,958 $352,145 $383,770 $1,179 
    84 Months  $365,267 $346,997 $383,536 $1,171 
    96 Months  $397,877 $379,232 $416,521 $1,275 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
  
118 
 
Table 30: Boys Treatment Costs over Time – Combination Therapy 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
306.8 
    
   14 Months  $2,062,609 $2,010,295 $2,114,922 $6,723 
   24 Months  $364,368 $349,804 $378,931 $1,188 
   36 Months  $413,996 $398,088 $429,903 $1,349 
   48 Months  $630,528 $599,015 $662,041 $2,055 
   60 Months  $765,685 $730,958 $800,412 $2,496 
   72 Months  $794,518 $760,258 $828,778 $2,590 
   84 Months  $859,403 $823,302 $895,504 $2,801  
   96 Months  $886,645 $848,205 $925,086 $2,890 
 
Extern 
 
315.5 
    
   14 Months  $2,117,439 $2,076,918 $2,157,959 $6,711 
   24 Months  $374,177 $361,596 $386,759 $1,186 
   36 Months  $426,090 $409,946 $442,233 $1,351 
   48 Months  $641,877 $611,909 $671,846 $2,034 
   60 Months  $791,776 $754,434 $829,117 $2,510 
   72 Months  $827,213 $789,927 $864,498 $2,622 
   84 Months  $897,374 $856,289 $938,460 $2,844 
   96 Months  $918,930 $873,380 $964,479 $2,913 
 
Both 
 
316.0 
    
   14 Months  $2,119,426 $2,060,363 $2,178,489 $6,707 
   24 Months  $385,216 $371,900 $398,532 $1,219 
   36 Months  $437,993 $418,776 $457,210 $1,386 
   48 Months  $651,910 $618,353 $685,468 $2,063 
   60 Months  $793,727 $756,869 $830,584 $2,512 
   72 Months  $821,294 $782,340 $860,248 $2,599 
   84 Months  $896,252 $858,715 $933,789 $2,836 
   96 Months  $919,079 $879,562 $958,595 $2,908 
 
Neither 
 
308.9 
    
   14 Months  $2,070,605 $2,020,512 $2,120,698 $6,703 
   24 Months  $368,774 $349,864 $387,684 $1,194 
   36 Months  $417,877 $397,668 $438,087 $1,353 
   48 Months  $638,834 $609,863 $667,806 $2,068 
   60 Months  $788,884 $751,139 $826,629 $2,554 
   72 Months  $824,504 $785,845 $863,164 $2,669 
   84 Months  $898,984 $859,819 $938,149 $2,910 
   96 Months  $923,462 $880,261 $966,664 $2,990 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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Table 31: Girls Treatment Costs over Time – Combination Therapy 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.3 
    
    14 Months  $2,109,937 $2,065,634 $2,154,240 $6,713 
    24 Months  $369,209 $355,913 $382,505 $1,175 
    36 Months  $416,850 $401,811 $431,889 $1,326 
    48 Months  $622,405 $597,912 $646,898 $1,980 
    60 Months  $772,480 $743,298 $801,663 $2,458 
    72 Months  $800,892 $769,397 $832,387 $2,548 
    84 Months  $873,753 $840,326 $907,181 $2,780  
    96 Months  $900,842 $866,448 $935,236 $2,866 
 
Extern 
 
311.9 
    
    14 Months  $2,096,540 $2,055,790 $2,137,290 $6,722 
    24 Months  $366,009 $354,231 $377,786 $1,173 
    36 Months  $418,108 $404,350 $431,866 $1,341 
    48 Months  $641,095 $615,257 $666,934 $2,055 
    60 Months  $801,889 $769,241 $834,536 $2,571 
    72 Months  $833,372 $799,261 $867,483 $2,672 
    84 Months  $898,852 $863,246 $934,458 $2,882 
    96 Months  $919,414 $883,773 $955,054 $2,948 
 
Both 
 
311.2 
    
    14 Months  $2,091,365 $2,038,854 $2,143,875 $6,720 
    24 Months  $367,242 $352,853 $381,632 $1,180 
    36 Months  $418,250 $402,210 $434,290 $1,344 
    48 Months  $638,044 $617,373 $658,715 $2,050 
    60 Months  $780,364 $752,524 $808,204 $2,508 
    72 Months  $814,182 $784,228 $844,137 $2,616 
    84 Months  $875,523 $844,199 $906,847 $2,813 
    96 Months  $898,336 $866,911 $929,761 $2,887 
 
Neither 
 
315.5 
    
    14 Months  $2,121,574 $2,069,964 $2,173,185 $6,724 
    24 Months  $369,330 $357,527 $381,132 $1,171 
    36 Months  $419,260 $405,419 $433,101 $1,329 
    48 Months  $633,451 $608,775 $658,127 $2,008 
    60 Months  $779,697 $749,831 $809,563 $2,471 
    72 Months  $809,879 $780,483 $839,275 $2,567 
    84 Months  $873,414 $840,086 $906,742 $2,768 
    96 Months  $904,728 $874,330 $935,126 $2,868 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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     4.2.3 Comparison Among Treatments 
  
 Treatment costs were much higher for patients on combination therapy regardless 
of gender, comorbidity, or time point (Table 27). The treatment costs for boys and girls on 
combination therapy were higher from baseline to 14 months, due to the intensity of the 
behavioral treatments. For instance, treatment costs for boys and girls on medication 
management ranged from $823 to $839 over comorbidity and time points, while 
combination therapy costs ranged from $6,703 to $6,724. 
 After 14 months, the intensive behavioral therapy ended, and quarterly booster 
therapy sessions began. Combination therapy treatment costs remained much higher than 
medication management treatment costs, regardless of gender, comorbidity, or time point. 
For instance, treatment costs of combination therapy were at least 37 percent higher than 
medication management (girls with both comorbidity types from 14 to 24 months; $1,180 
compared to $863), and as much as 155 percent higher (girls with externalizing 
comorbidities from 72 to 84 months; $2,882 compared to $1,129). Confidence intervals 
between treatment arms and within time points never intersect, indicating that treatment 
costs of combination therapy were always significantly higher than treatment costs of 
medication management (Tables 28, 29, 30, and 31).    
 
 
4.3 Non-Treatment Costs 
 
 Non-treatment costs included parental absenteeism, entry into the juvenile justice 
system, and special education classes. These costs were the second cost component of the 
societal/taxpayer perspective. 
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     4.3.1 Trends Over Time 
 
 Both treatment arms’ non-treatment costs (Table 32), regardless of gender or 
comorbidity, displayed a general trend upward from baseline to 36 months, trending 
downward from 36 months to 60 months, and trending upward to plateau at 72 or 84 
months. For instance, boys with externalizing comorbidities on medication management 
accrued $1,357 of non-treatment costs from baseline to 14 months, rose to $2,058 from 24 
to 36 months, decreased to $1,667 from 48 to 60 months, and plateaued at $1,901 from 72 
to 84 months. Girls with externalizing comorbidities on medication management had $1,356 
of non-treatment costs from baseline to 14 months, which rose to $2,048 from 24 to 36 
months, decreased to $1,663 from 48 to 60 months, and plateaued at $1,903 from 72 to 84 
months. Boys with externalizing comorbidities on combination therapy had $1,644 non-
treatment costs from baseline to14 months, which rose to $2,430 from 24 to 36 months, 
decreased to $2,133 from 48 to 60 months, and plateaued at $2,372 from 60 to 72 months. 
Girls with externalizing comorbidities on combination therapy had $1,625 non-treatment 
costs from baseline to 14 months, which rose to $2,444 from 24 to 36 months, decreased to 
$2,115 from 48 to 60 months, and non-treatment costs plateaued at $2,388 from 60 to 72 
months. These same trends over time were evident for entities on either treatment with 
internalizing comorbidities, both types of comorbidities, or no comorbidities (Table 32). 
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Table 32: Mean Non-Treatment Costs per Patient Over Time 
Comorbidity/ 
Time Point 
Boys - Medications Girls - Medications Boys - Combination Girls – 
Combination 
 
Intern 
 
 
   
    14 Months $1,363 $1,339 $1,642 $1,622 
    24 Months $1,801 $1,757 $2,234 $2,204 
    36 Months $2,039 $2,025 $2,445 $2,422 
    48 Months $1,883 $1,878 $2,280 $2,284 
    60 Months $1,669 $1,665 $2,119 $2,114 
    72 Months $1,897 $1,879 $2,372 $2,374 
    84 Months $1,906 $1,900 $2,251 $2,268 
    96 Months $1,882 $1,866 $2,067 $2,063 
 
Extern 
    
    14 Months $1,357 $1,356 $1,644 $1,625 
    24 Months $1,803 $1,801 $2,238 $2,219 
    36 Months $2,058 $2,048 $2,430 $2,444 
    48 Months $1,883 $1,866 $2,268 $2,275 
    60 Months $1,667 $1,663 $2,133 $2,115 
    72 Months $1,895 $1,893 $2,372 $2,379 
    84 Months $1,901 $1,903 $2,268 $2,274 
    96 Months $1,869 $1,867 $2,051 $2,075 
 
Both 
    
    14 Months $1,337 $1,370 $1,647 $1,626 
    24 Months $1,752 $1,768 $2,209 $2,231 
    36 Months $2,015 $2,041 $2,419 $2,443 
    48 Months $1,868 $1,883 $2,273 $2,292 
    60 Months $1,656 $1,668 $2,123 $2,115 
    72 Months $1,887 $1,899 $2,368 $2,388 
    84 Months $1,911 $1,917 $2,261 $2,266 
    96 Months $1,853 $1,858 $2,073 $2,084 
 
Neither 
    
    14 Months $1,356 $1,416 $1,617 $1,619 
    24 Months $1,762 $1,796 $2,240 $2,216 
    36 Months $2,018 $2,029 $2,478 $2,431 
    48 Months $1,876 $1,851 $2,298 $2,267 
    60 Months $1,669 $1,662 $2,137 $2,106 
    72 Months $1,895 $1,902 $2,376 $2,366 
    84 Months $1,912 $1,917 $2,255 $2,251 
    96 Months $1,864 $1,874 $2,049 $2,077 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither = No 
Comorbidities; Medication = Medication Management; Combination = Combination Therapy; Time Point = 
Interval From Previous Time Point to the One Listed 
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     4.3.2 Comparisons Between Genders 
 
 Boys and girls, by treatment type and time points, had very similar non-treatment 
costs. In the medication management arm, for instance, the non-treatment costs for girls 
compared to boys were generally within 2 percent of each other (Tables 33 and 34). The 
three exceptions were: 
1. Boys with internalizing comorbidities from 14 to 24 months had 2.47 percent 
higher non-treatment costs than their female counterparts ($1,801 compared to 
$1,757). 
2. Boys with both types of comorbidities from baseline to 14 months had 2.46 
percent fewer non-treatment costs than their female counterparts ($1,337 
compared to $1,370). 
3. Boys without comorbidity from baseline to 14 months had 2.24 percent higher 
non-treatment costs than their female counterparts ($1,356 compared to 
$1,326). 
The differences between boys and girls with internalizing comorbidities reached their peak 
from 14 to 24 months ($1,801 for boys compared to $1,757 for girls). Non-treatment costs 
were most similar among the same cohort from 48 to 60 months ($1,669 for boys compared 
to $1,665 for girls). The 95 percent confidence intervals overlap such that these differences 
were not statistically significant (Tables 33 and 34). Additionally, because the costs for boys 
compared to girls during a given year varied no more than $44 (internalizing comorbidities 
from 14 to 24 months), the differences were not economically significant. The non-
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treatment costs of combination therapy for girls compared to boys varied even less than 
those for medication management; the largest difference was among boys and girls without 
comorbidity from 24 to 36 months ($2,478 for boys compared to $2,431 for girls) (Tables 
32).    
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Table 33: Boys Non-Treatment Costs over Time – Medication Management 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.6 
    
    14 Months  $428,952 $414,292 $443,612 $1,363 
    24 Months  $566,515 $552,506 $580,523 $1,801 
    36 Months  $641,359 $626,730 $655,988 $2,039 
    48 Months  $592,249 $578,111 $606,387 $1,883 
    60 Months  $525,116 $513,604 $536,627 $1,669 
    72 Months  $596,724 $583,862 $609,586 $1,897 
    84 Months  $599,783 $588,024 $611,541 $1,906  
    96 Months  $592,215 $580,068 $604,363 $1,882 
 
Extern 
 
307.2 
    
    14 Months  $416,965 $401,791 $432,139 $1,357 
    24 Months  $553,898 $538,745 $569,050 $1,803 
    36 Months  $632,311 $617,367 $647,254 $2,058 
    48 Months  $578,308 $565,298 $591,317 $1,883 
    60 Months  $512,078 $500,038 $524,119 $1,667 
    72 Months  $582,133 $568,599 $595,667 $1,895 
    84 Months  $584,052 $570,566 $597,538 $1,901 
    96 Months  $574,185 $560,170 $588,199 $1,869 
 
Both 
 
310.1 
    
    14 Months  $414,471 $404,679 $424,264 $1,337 
    24 Months  $543,201 $527,781 $558,622 $1,752 
    36 Months  $624,877 $607,391 $642,363 $2,015 
    48 Months  $579,224 $565,335 $593,113 $1,868 
    60 Months  $513,654 $502,731 $524,577 $1,656 
    72 Months  $585,259 $573,021 $597,496 $1,887 
    84 Months  $592,472 $580,705 $604,239 $1,911 
    96 Months  $574,696 $562,472 $586,921 $1,853 
 
Neither 
 
313.1 
    
    14 Months  $424,447 $410,011 $438,884 $1,356 
    24 Months  $551,705 $534,855 $568,556 $1,762 
    36 Months  $631,898 $614,512 $649,285 $2,018 
    48 Months  $587,224 $572,404 $602,043 $1,876 
    60 Months  $522,414 $510,032 $534,795 $1,669 
    72 Months  $593,396 $580,048 $606,745 $1,895 
    84 Months  $598,683 $584,880 $612,486 $1,912 
    96 Months  $583,475 $569,960 $596,990 $1,864 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Non-Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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Table 34: Girls Non-Treatment Costs over Time – Medication Management 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.1 
    
    14 Months  $420,668 $410,278 $431,058 $1,339 
    24 Months  $551,964 $539,936 $563,992 $1,757 
    36 Months  $636,021 $620,526 $651,517 $2,025 
    48 Months  $589,926 $575,266 $604,585 $1,878 
    60 Months  $522,964 $510,953 $534,976 $1,665 
    72 Months  $590,239 $576,103 $604,375 $1,879 
    84 Months  $596,915 $584,429 $609,400 $1,900  
    96 Months  $585,987 $573,029 $598,944 $1,866 
 
Extern 
 
320.1 
    
    14 Months  $434,193 $420,563 $447,822 $1,356 
    24 Months  $576,345 $560,997 $591,694 $1,801 
    36 Months  $655,588 $639,715 $671,461 $2,048 
    48 Months  $597,221 $582,923 $611,519 $1,866 
    60 Months  $532,441 $520,863 $544,019 $1,663 
    72 Months  $605,974 $591,510 $620,439 $1,893 
    84 Months  $609,135 $594,675 $623,595 $1,903 
    96 Months  $597,524 $582,901 $612,148 $1,867 
 
Both 
 
308.9 
    
    14 Months  $423,289 $413,334 $433,244 $1,370 
    24 Months  $546,202 $533,852 $558,552 $1,768 
    36 Months  $630,483 $615,413 $645,554 $2,041 
    48 Months  $581,729 $569,813 $593,646 $1,883 
    60 Months  $515,192 $505,771 $524,613 $1,668 
    72 Months  $586,553 $572,869 $600,237 $1,899 
    84 Months  $592,262 $581,237 $603,288 $1,917 
    96 Months  $574,037 $561,644 $586,431 $1,858 
 
Neither 
 
312.0 
    
    14 Months  $413,677 $402,681 $424,674 $1,326 
    24 Months  $547,649 $530,808 $564,490 $1,755 
    36 Months  $627,284 $606,743 $647,825 $2,011 
    48 Months  $579,657 $565,046 $594,267 $1,858 
    60 Months  $521,890 $507,796 $535,984 $1,673 
    72 Months  $586,816 $572,978 $600,654 $1,881 
    84 Months  $597,102 $584,500 $609,704 $1,914 
    96 Months  $581,740 $568,619 $594,860 $1,865 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Non-Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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     4.3.3 Comparisons Between Treatments 
 
 Interestingly, boys and girls on combination therapy had considerably higher non-
treatment costs than their counterparts on medication management (matched by 
comorbidity and time). For instance, boys and girls with both comorbidity types on 
combination therapy from baseline to 14 months had non-treatment costs of $1,647 (boys) 
and $1,625 (girls) (Table 32). Boys and girls with both comorbidity types on medication 
management from baseline to 14 months had non-treatment costs of $1,337 (boys) and 
$1,370 (girls). Therefore, in children with both comorbidity types, boys on combination 
therapy had 23 percent higher non-treatment costs [($1,647 - $1,337)/$1,337] than boys on 
medication management, while with girls the difference between the two treatments was 
greater than 18 percent [(1,625 - $1,370)/$1,370]. Moreover, the differences between 
treatment arms by gender, comorbidity, and time points operated in the same manner, and 
the 95 percent confidence intervals (Tables 33, 34, 35 and 36) did not overlap, 
demonstrating statistically significant differences. Finally, across all time points, 
comorbidities, and genders, combination therapy yielded between 10 percent (boys with 
internalizing comorbidites from 84 to 96 months) and 28 percent (boys with both 
comorbidity types from 48 to 60 months) higher non-treatment costs than their 
counterparts on medication management. 
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Table 35: Boys Non-Treatment Costs over Time– Combination Therapy 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
306.8 
    
    14 Months  $503,621 $491,808 $515,434 $1,642 
    24 Months  $685,372 $667,184 $703,561 $2,234 
    36 Months  $750,056 $728,729 $771,383 $2,445 
    48 Months  $699,444 $680,870 $718,018 $2,280 
    60 Months  $650,041 $634,874 $665,207 $2,119 
    72 Months  $727,818 $710,423 $745,213 $2,372 
    84 Months  $690,609 $675,013 $706,206 $2,251  
    96 Months  $634,201 $618,217 $650,185 $2,067 
 
Extern 
 
315.5 
    
    14 Months  $518,733 $508,621 $528,846 $1,644 
    24 Months  $706,063 $693,892 $718,235 $2,238 
    36 Months  $766,517 $750,756 $782,278 $2,430 
    48 Months  $715,480 $699,362 $731,597 $2,268 
    60 Months  $672,887 $659,800 $685,973 $2,133 
    72 Months  $748,371 $731,579 $765,164 $2,372 
    84 Months  $715,638 $699,103 $732,174 $2,268 
    96 Months  $647,026 $631,321 $662,732 $2,051 
 
Both 
 
316.0 
    
    14 Months  $520,495 $503,665 $537,325 $1,647 
    24 Months  $698,162 $678,014 $718,310 $2,209 
    36 Months  $764,346 $744,183 $784,509 $2,419 
    48 Months  $718,333 $698,838 $737,829 $2,273 
    60 Months  $671,013 $651,825 $690,201 $2,123 
    72 Months  $748,330 $727,317 $769,343 $2,368 
    84 Months  $714,549 $694,258 $734,840 $2,261 
    96 Months  $654,955 $637,355 $672,555 $2,073 
 
Neither 
 
308.9 
    
    14 Months  $499,499 $485,507 $513,491 $1,617 
    24 Months  $691,929 $672,507 $711,351 $2,240 
    36 Months  $765,459 $744,111 $786,806 $2,478 
    48 Months  $709,704 $690,665 $728,743 $2,298 
    60 Months  $660,107 $641,565 $678,649 $2,137 
    72 Months  $734,054 $715,414 $752,695 $2,376 
    84 Months  $696,678 $678,319 $715,038 $2,255 
    96 Months  $633,040 $617,726 $648,355 $2,049 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Non-Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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Table 36: Girls Non-Treatment Costs over Time – Combination Therapy 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.3 
    
    14 Months  $509,688 $496,085 $523,291 $1,622 
    24 Months  $692,858 $675,657 $710,059 $2,204 
    36 Months  $761,087 $742,266 $779,908 $2,422 
    48 Months  $717,909 $701,081 $734,738 $2,284 
    60 Months  $664,433 $647,643 $681,223 $2,114 
    72 Months  $746,057 $727,197 $764,916 $2,374 
    84 Months  $712,947 $694,457 $731,438 $2,268  
    96 Months  $648,540 $632,626 $664,454 $2,063 
 
Extern 
 
311.9 
    
    14 Months  $506,929 $493,642 $520,217 $1,625 
    24 Months  $692,194 $675,288 $709,100 $2,219 
    36 Months  $762,329 $745,664 $778,994 $2,444 
    48 Months  $709,645 $694,710 $724,581 $2,275 
    60 Months  $659,662 $646,306 $673,017 $2,115 
    72 Months  $741,966 $729,502 $754,430 $2,379 
    84 Months  $709,112 $696,113 $722,112 $2,274 
    96 Months  $647,282 $634,545 $660,018 $2,075 
 
Both 
 
311.2 
    
    14 Months  $506,112 $489,494 $522,731 $1,626 
    24 Months  $694,436 $674,290 $714,583 $2,231 
    36 Months  $760,173 $739,520 $780,827 $2,443 
    48 Months  $713,147 $693,482 $732,812 $2,292 
    60 Months  $658,199 $638,634 $677,763 $2,115 
    72 Months  $743,127 $724,530 $761,724 $2,388 
    84 Months  $705,147 $686,902 $723,392 $2,266 
    96 Months  $648,565 $630,883 $666,248 $2,084 
 
Neither 
 
315.5 
    
    14 Months  $510,729 $497,840 $523,617 $1,619 
    24 Months  $699,137 $680,033 $718,240 $2,216 
    36 Months  $767,010 $747,281 $786,740 $2,431 
    48 Months  $715,359 $697,191 $733,527 $2,267 
    60 Months  $664,360 $649,468 $679,251 $2,106 
    72 Months  $746,586 $727,221 $765,951 $2,366 
    84 Months  $710,209 $689,872 $730,546 $2,251 
    96 Months  $655,168 $636,465 $673,872 $2,077 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Non-Treatment Costs; Low & High = 95% Confidence Interval;                                                          
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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4.4 Total Costs 
  
 Total costs included all treatment and non-treatment costs, and they represented 
the costs associated with the societal/taxpayer perspective.   
 
 
     4.4.1 Trends Over Time 
 
 Total costs of both treatment arms, regardless of gender or comorbidity, followed a 
similar pattern. Treatment-related costs of intensive behavioral therapy accounted for the 
bulk of the total costs of combination therapy for boys and girls of each comorbidity type 
from baseline to 14 months. Consequently, the total costs of combination therapy were 
more than three times higher than those of medication management, regardless of gender 
or comorbidity. For example, boys with no comorbidities on combination therapy had total 
costs more than 3.8 times higher than boys on medication management ($8,320 compared 
to $2,182); while girls had total costs 3.9 times higher ($8,343 compared to $2,161) (Table 
37). 
 After 14 months, the total costs of combination therapy fell considerably, and then 
rose steadily over time. For instance, boys with externalizing comorbidities accrued $8,354 
in total costs from baseline to 14 months then dropped to $3,428 from 14 to 24 months 
(Table 37). Their total costs rose progressively and plateaued from 72 to 84 months 
($5,097). The total costs of each gender-comorbidity pair operated in the same fashion. 
After 14 months, the total costs of medication management also rose steadily, and then 
plateaued around 84 months.   
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Table 37: Mean Total Costs per Patient over Time 
Comorbidity/ 
Time Point 
Boys - 
Medications 
Girls - 
Medications 
Boys - Combination Girls – Combination 
 
Intern 
 
 
   
    14 Months $2,203 $2,163 $8,365 $8,335 
    24 Months $2,651 $2,596 $3,422 $3,379 
    36 Months $2,974 $2,942 $3,794 $3,748 
    48 Months $2,977 $2,969 $4,335 $4,264 
    60 Months $2,816 $2,806 $4,614 $4,572 
    72 Months $3,093 $3,058 $4,962 $4,922 
    84 Months $3,078 $3,049 $5,052 $5,048 
    96 Months $3,135 $3,120 $4,957 $4,930 
 
Extern 
    
    14 Months $2,188 $2,185 $8,356 $8,347 
    24 Months $2,652 $2,640 $3,424 $3,393 
    36 Months $2,997 $2,967 $3,780 $3,785 
    48 Months $2,996 $2,929 $4,302 $4,331 
    60 Months $2,840 $2,777 $4,642 $4,686 
    72 Months $3,123 $3,040 $4,994 $5,051 
    84 Months $3,103 $3,032 $5,113 $5,155 
    96 Months $3,179 $3,111 $4,963 $5,023 
 
Both 
    
    14 Months $2,164 $2,208 $8,354 $8,347 
    24 Months $2,590 $2,631 $3,428 $3,412 
    36 Months $2,937 $2,990 $3,805 $3,787 
    48 Months $2,966 $2,973 $4,336 $4,342 
    60 Months $2,817 $2,803 $4,635 $4,623 
    72 Months $3,077 $3,081 $4,967 $5,004 
    84 Months $3,091 $3,074 $5,097 $5,079 
    96 Months $3,141 $3,112 $4,981 $4,971 
 
Neither 
    
    14 Months $2,182 $2,161 $8,320 $8,343 
    24 Months $2,596 $2,610 $3,434 $3,387 
    36 Months $2,936 $2,955 $3,831 $3,760 
    48 Months $2,962 $2,966 $4,366 $4,275 
    60 Months $2,810 $2,828 $4,691 $4,577 
    72 Months $3,095 $3,060 $5,046 $4,933 
    84 Months $3,085 $3,085 $5,166 $5,019 
    96 Months $3,166 $3,140 $5,039 $4,944 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither = No 
Comorbidities; Medications = Medication Management; Combination = Combination Therapy; Time Point = 
Interval From Previous Time Point to the One Listed 
  
132 
 
     4.4.2 Comparison Between Genders 
 
 The total costs of medication management for boys with internalizing or 
externalizing comorbidities at each time point were slightly higher than for their female 
counterparts (Table 37). However, their 95 percent confidence intervals overlapped, 
indicating statistical equivalence (Tables 38 and 39). The differences between total costs of 
medication management for boys and girls with both or neither types of comorbidities 
varied in an unsystematic manner. Boys with both types of comorbidities had higher total 
costs of medication management from 48 to 60 months ($2,817 compared to $2,803), from 
72 to 84 months ($3,091 compared to $3,074), and from 84 to 96 months ($3,141 
compared to $3,112). Girls with both types of comorbidities had slightly higher total costs 
than their male counterparts from baseline to 48 months and from 60 to 72 months (Table 
37). The 95 percent confidence intervals, however, suggested that the total costs of 
medication management between boys and girls with both or neither types of 
comorbidities also were statistically equivalent (Tables 38 and 39).  
 The total costs of combination therapy for boys compared to for girls revealed 
similar themes. Generally, boys with internalizing, neither, or both comorbidities accrued 
slightly higher costs than their female counterparts, while girls with internalizing 
comorbidities accumulated slightly higher costs than their male counterparts (Table 36). Yet 
95 percent confidence intervals for each gender-comorbidity pair overlapped, indicating 
statistically equivalent costs (Tables 40 and 41).     
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    4.4.3 Comparison Between Treatments 
 
 While combination therapy continued to be more costly than medication 
management when the intensive behavioral therapy ends, the magnitude of the total cost 
difference was smaller. Over all time points, comorbidity types, and genders, total costs of 
combination therapy were higher than the total costs of medication management. The 
differential ranged from 26 percent higher (boys with externalizing comorbidities from 24 to 
36 months; $3,424 compared to $2,652) and 70 percent higher (girls with externalizing 
comorbidity from 72 to 84 months; $5,155 compared to $3,032) (Table 37). The 95 percent 
confidence intervals between treatments and within genders, comorbidity types, and time 
points never intersected, indicating significantly higher costs among those on combination 
therapy (Tables 38, 39, 40, and 41).  
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Table 38: Boys Total Costs over Time– Medication Management 
Comorbidity/ 
Time Point 
N Mean Low High Mean 
Per 
Patient 
 
Intern 
 
314.6 
    
    14 Months  $692,918 $673,798 $712,038 $2,203 
    24 Months  $833,913 $815,742 $852,083 $2,651 
    36 Months  $935,682 $914,697 $956,666 $2,974 
    48 Months  $936,708 $916,442 $956,975 $2,977 
    60 Months  $885,835 $867,558 $904,113 $2,816 
    72 Months  $973,164 $953,319 $993,008 $3,093 
    84 Months  $968,212 $948,210 $988,214 $3,078  
    96 Months  $986,153 $966,389 $1,005,917 $3,135 
 
Extern 
 
307.2 
    
    14 Months  $672,163 $652,239 $692,087 $2,188 
    24 Months  $814,597 $792,793 $836,400 $2,652 
    36 Months  $920,749 $897,505 $943,993 $2,997 
    48 Months  $920,275 $892,694 $947,855 $2,996 
    60 Months  $872,436 $845,648 $899,223 $2,840 
    72 Months  $959,326 $929,568 $989,085 $3,123 
    84 Months  $953,302 $925,092 $981,513 $3,103 
    96 Months  $976,594 $948,401 $1,004,786 $3,179 
 
Both 
 
310.1 
    
    14 Months  $671,152 $656,579 $685,725 $2,164 
    24 Months  $803,220 $783,807 $822,632 $2,590 
    36 Months  $910,903 $888,043 $933,763 $2,937 
    48 Months  $919,796 $896,270 $943,321 $2,966 
    60 Months  $873,404 $853,012 $893,797 $2,817 
    72 Months  $954,154 $931,984 $976,324 $3,077 
    84 Months  $958,470 $936,420 $980,520 $3,091 
    96 Months  $973,911 $951,179 $996,642 $3,141 
 
Neither 
 
313.1 
    
    14 Months  $683,273 $663,035 $703,511 $2,182 
    24 Months  $812,925 $789,005 $836,845 $2,596 
    36 Months  $919,198 $895,741 $942,656 $2,936 
    48 Months  $927,550 $903,835 $951,266 $2,962 
    60 Months  $879,822 $860,196 $899,448 $2,810 
    72 Months  $968,946 $946,009 $991,884 $3,095 
    84 Months  $965,837 $942,497 $989,178 $3,085 
    96 Months  $991,181 $962,746 $1,019,615 $3,166 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Total Costs; Low & High = 95% Confidence Interval;                                                                  
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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Table 39: Girls Total Costs over Time – Medication Management 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.1 
    
    14 Months  $679,315 $664,331 $694,298 $2,163 
    24 Months  $815,276 $798,019 $832,533 $2,596 
    36 Months  $924,045 $903,969 $944,121 $2,942 
    48 Months  $932,635 $912,704 $952,565 $2,969 
    60 Months  $881,383 $861,132 $901,633 $2,806 
    72 Months  $960,417 $938,447 $982,387 $3,058 
    84 Months  $957,794 $934,485 $981,103 $3,049  
    96 Months  $980,077 $956,981 $1,003,173 $3,120 
 
Extern 
 
320.1 
    
    14 Months  $699,363 $681,495 $717,230 $2,185 
    24 Months  $845,080 $823,476 $866,683 $2,640 
    36 Months  $949,832 $927,369 $972,295 $2,967 
    48 Months  $937,688 $912,772 $962,604 $2,929 
    60 Months  $888,889 $864,517 $913,261 $2,777 
    72 Months  $973,176 $946,290 $1,000,061 $3,040 
    84 Months  $970,660 $945,436 $995,885 $3,032 
    96 Months  $995,859 $968,258 $1,023,459 $3,111 
 
Both 
 
308.9 
    
    14 Months  $682,084 $669,232 $694,937 $2,208 
    24 Months  $812,857 $796,033 $829,681 $2,631 
    36 Months  $923,736 $902,038 $945,435 $2,990 
    48 Months  $918,499 $895,450 $941,548 $2,973 
    60 Months  $865,788 $844,055 $887,521 $2,803 
    72 Months  $951,576 $926,566 $976,585 $3,081 
    84 Months  $949,687 $927,301 $972,073 $3,074 
    96 Months  $961,323 $936,704 $985,942 $3,112 
 
Neither 
 
312.0 
    
    14 Months  $674,181 $655,862 $692,501 $2,161 
    24 Months  $814,203 $790,166 $838,239 $2,610 
    36 Months  $921,978 $891,469 $952,486 $2,955 
    48 Months  $925,360 $898,517 $952,204 $2,966 
    60 Months  $882,183 $855,802 $908,564 $2,828 
    72 Months  $954,774 $929,933 $979,614 $3,060 
    84 Months  $962,369 $937,014 $987,724 $3,085 
    96 Months  $979,616 $952,830 $1,006,403 $3,140 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Total Costs; Low & High = 95% Confidence Interval;                                                                  
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
  
136 
 
Table 40: Boys Total Costs over Time – Combination Therapy 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
306.8 
    
    14 Months  $2,566,230 $2,504,381 $2,628,079 $8,365 
    24 Months  $1,049,740 $1,020,894 $1,078,586 $3,422 
    36 Months  $1,164,052 $1,132,234 $1,195,870 $3,794 
    48 Months  $1,329,972 $1,286,407 $1,373,537 $4,335 
    60 Months  $1,415,726 $1,375,149 $1,456,303 $4,614 
    72 Months  $1,522,336 $1,479,827 $1,564,844 $4,962 
    84 Months  $1,550,013 $1,504,024 $1,596,001 $5,052  
    96 Months  $1,520,846 $1,473,568 $1,568,124 $4,957 
 
Extern 
 
315.5 
    
    14 Months  $2,636,172 $2,590,323 $2,682,021 $8,356 
    24 Months  $1,080,241 $1,059,743 $1,100,739 $3,424 
    36 Months  $1,192,607 $1,163,816 $1,221,398 $3,780 
    48 Months  $1,357,357 $1,319,592 $1,395,122 $4,302 
    60 Months  $1,464,662 $1,421,987 $1,507,337 $4,642 
    72 Months  $1,575,584 $1,529,255 $1,621,912 $4,994 
    84 Months  $1,613,013 $1,563,794 $1,662,232 $5,113 
    96 Months  $1,565,956 $1,512,759 $1,619,153 $4,963 
 
Both 
 
316.0 
    
    14 Months  $2,639,921 $2,565,927 $2,713,915 $8,354 
    24 Months  $1,083,378 $1,052,339 $1,114,416 $3,428 
    36 Months  $1,202,339 $1,166,644 $1,238,035 $3,805 
    48 Months  $1,370,244 $1,321,623 $1,418,865 $4,336 
    60 Months  $1,464,740 $1,414,088 $1,515,391 $4,635 
    72 Months  $1,569,624 $1,515,211 $1,624,038 $4,967 
    84 Months  $1,610,801 $1,557,244 $1,664,358 $5,097 
    96 Months  $1,574,034 $1,519,909 $1,628,158 $4,981 
 
Neither 
 
308.9 
    
    14 Months  $2,570,104 $2,509,151 $2,631,057 $8,320 
    24 Months  $1,060,703 $1,026,239 $1,095,167 $3,434 
    36 Months  $1,183,336 $1,146,618 $1,220,054 $3,831 
    48 Months  $1,348,539 $1,305,770 $1,391,307 $4,366 
    60 Months  $1,448,991 $1,398,996 $1,498,986 $4,691 
    72 Months  $1,558,559 $1,506,904 $1,610,213 $5,046 
    84 Months  $1,595,662 $1,544,586 $1,646,739 $5,166 
    96 Months  $1,556,502 $1,502,228 $1,610,776 $5,039 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Total Costs; Low & High = 95% Confidence Interval;                                                                  
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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Table 41: Girls Total Costs over Time – Combination Therapy 
Comorbidity/ 
Time Point 
N Mean Low High Mean Per 
Patient 
 
Intern 
 
314.3 
    
    14 Months  $2,619,625 $2,564,645 $2,674,604 $8,335 
    24 Months  $1,062,067 $1,036,333 $1,087,800 $3,379 
    36 Months  $1,177,937 $1,147,787 $1,208,087 $3,748 
    48 Months  $1,340,314 $1,304,508 $1,376,120 $4,264 
    60 Months  $1,436,913 $1,396,546 $1,477,280 $4,572 
    72 Months  $1,546,948 $1,502,510 $1,591,386 $4,922 
    84 Months  $1,586,701 $1,540,796 $1,632,605 $5,048  
    96 Months  $1,549,382 $1,504,642 $1,594,122 $4,930 
 
Extern 
 
311.9 
    
    14 Months  $2,603,469 $2,553,608 $2,653,330 $8,347 
    24 Months  $1,058,203 $1,032,142 $1,084,264 $3,393 
    36 Months  $1,180,437 $1,152,650 $1,208,224 $3,785 
    48 Months  $1,350,741 $1,315,321 $1,386,160 $4,331 
    60 Months  $1,461,550 $1,421,095 $1,502,006 $4,686 
    72 Months  $1,575,338 $1,532,124 $1,618,552 $5,051 
    84 Months  $1,607,964 $1,563,525 $1,652,403 $5,155 
    96 Months  $1,566,695 $1,523,388 $1,610,002 $5,023 
 
Both 
 
311.2 
    
    14 Months  $2,597,477 $2,530,362 $2,664,592 $8,347 
    24 Months  $1,061,679 $1,029,736 $1,093,621 $3,412 
    36 Months  $1,178,423 $1,144,544 $1,212,302 $3,787 
    48 Months  $1,351,191 $1,316,086 $1,386,297 $4,342 
    60 Months  $1,438,563 $1,399,105 $1,478,021 $4,623 
    72 Months  $1,557,309 $1,515,318 $1,599,300 $5,004 
    84 Months  $1,580,670 $1,537,888 $1,623,453 $5,079 
    96 Months  $1,546,901 $1,504,924 $1,588,879 $4,971 
 
Neither 
 
315.5 
    
    14 Months  $2,632,303 $2,568,874 $2,695,732 $8,343 
    24 Months  $1,068,466 $1,042,055 $1,094,878 $3,387 
    36 Months  $1,186,270 $1,157,389 $1,215,151 $3,760 
    48 Months  $1,348,810 $1,310,506 $1,387,115 $4,275 
    60 Months  $1,444,057 $1,403,731 $1,484,383 $4,577 
    72 Months  $1,556,465 $1,513,974 $1,598,956 $4,933 
    84 Months  $1,583,623 $1,535,562 $1,631,684 $5,019 
    96 Months  $1,559,896 $1,516,888 $1,602,904 $4,944 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither =                                                            
No Comorbidities; Mean = Mean Total Costs; Low & High = 95% Confidence Interval;                                                                  
Mean per Patient = Mean Cost/N; Time Point = Interval From Previous Time Point to the One               
Listed; N = Sample Size 
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4.5 Response to Treatment 
 
 The average response rates to either treatment varied little across gender, 
comorbidity type, or time point. 
 
 
     4.5.1 Trends Over Time: Medication Management 
 
The response rates for boys and girls on medication management over time 
remained relatively stable (Table 42). The 95 percent confidence intervals indicated that 
response rates for boys with internalizing, both, or neither types of comorbidities were 
statistically equivalent over time (Table 43). However, boys with externalizing comorbidities 
at 24 months had significantly lower response rates (95 percent confidence interval, 44 
percent to 46 percent) than those at 72 months (47 percent to 50 percent), 84 months (48 
percent to 50 percent), or 96 months (48 percent to 51 percent).   
Girls with internalizing comorbidities had significantly lower response rates at 24 
months than those at 14 months, while girls with externalizing comorbidities had 
significantly higher response rates at 72 months than those at 14 months or 24 months 
(Table 44). Additionally, girls with both types of comorbidities had significantly lower 
response rates at 14 months than those at 36 months or 60 to 96 months, while girls 
without comorbidity had significantly higher response rates at 14 months than those at 36 
to 96 months. 
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Table 42: Mean Responder Percentage by Gender, Comorbidity, and Treatment Type over Time 
Comorbidity/ 
Time Point 
Boys - 
Medications 
Girls - 
Medications 
Boys - Combination Girls – Combination 
 
Intern 
 
 
   
    14 Months 48% 51% 49% 52% 
    24 Months 48% 47% 48% 53% 
    36 Months 49% 48% 47% 49% 
    48 Months 47% 48% 47% 48% 
    60 Months 49% 48% 49% 50% 
    72 Months 50% 49% 49% 49% 
    84 Months 50% 49% 49% 49% 
    96 Months 49% 49% 50% 50% 
 
Extern 
    
    14 Months 47% 47% 47% 52% 
    24 Months 45% 47% 46% 52% 
    36 Months 47% 48% 46% 49% 
    48 Months 47% 48% 48% 50% 
    60 Months 47% 48% 48% 49% 
    72 Months 49% 50% 48% 49% 
    84 Months 49% 50% 49% 50% 
    96 Months 49% 49% 49% 50% 
 
Both 
    
    14 Months 47% 45% 50% 49% 
    24 Months 47% 47% 46% 48% 
    36 Months 47% 48% 47% 48% 
    48 Months 49% 48% 48% 48% 
    60 Months 49% 48% 48% 49% 
    72 Months 49% 49% 49% 49% 
    84 Months 50% 51% 50% 49% 
    96 Months 49% 49% 50% 50% 
 
Neither 
    
    14 Months 51% 54% 52% 52% 
    24 Months 51% 52% 50% 53% 
    36 Months 50% 51% 49% 49% 
    48 Months 50% 50% 49% 50% 
    60 Months 49% 50% 50% 49% 
    72 Months 49% 49% 50% 50% 
    84 Months 49% 49% 51% 49% 
    96 Months 49% 50% 49% 49% 
Intern = Internalizing; Extern = Externalizing; Both = Internalizing + Externalizing; Neither = No 
Comorbidities; Medications = Medication Management; Combination = Combination Therapy 
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Table 43: Medication Management Responders                                                                                                                     
over Time- Boys 
Comorbidity/ 
Time Point 
N Mean Low High 
 
Intern 
 
314.6 
   
    14 Months  48% 47% 49% 
    24 Months  48% 46% 49% 
    36 Months  49% 47% 50% 
    48 Months  47% 46% 49% 
    60 Months  49% 47% 50% 
    72 Months  50% 49% 51% 
    84 Months  50% 48% 51% 
    96 Months  49% 47% 51% 
 
Extern 
 
307.2 
   
    14 Months  47% 45% 48% 
    24 Months  45% 44% 46% 
    36 Months  47% 45% 49% 
    48 Months  47% 45% 49% 
    60 Months  47% 46% 49% 
    72 Months  49% 47% 50% 
    84 Months  49% 48% 50% 
    96 Months  49% 48% 51% 
 
Both 
 
310.1 
   
    14 Months  47% 45% 48% 
    24 Months  47% 45% 48% 
    36 Months  47% 45% 48% 
    48 Months  49% 47% 50% 
    60 Months  49% 47% 50% 
    72 Months  49% 47% 50% 
    84 Months  50% 48% 51% 
    96 Months  49% 48% 50% 
 
Neither 
 
313.1 
   
    14 Months  51% 49% 53% 
    24 Months  51% 49% 52% 
    36 Months  50% 48% 52% 
    48 Months  50% 48% 52% 
    60 Months  49% 48% 51% 
    72 Months  49% 48% 51% 
    84 Months  49% 47% 51% 
    96 Months  49% 48% 51% 
Intern = Internalizing; Extern = Externalizing; Both =                                                                                                                                       
Internalizing + Externalizing; Neither = No Comorbidities;                                                                                                                  
Mean = Mean Percent Responders; Low – High =                                                                                                                                                                                            
95% Confidence Interval; N = Sample Size 
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Table 44: Medication Management Responders                                                                                                                                               
over Time- Girls 
Comorbidity/ 
Time Point 
N Mean Low High 
 
Intern 
 
314.1 
   
    14 Months  51% 49% 52% 
    24 Months  47% 45% 48% 
    36 Months  48% 47% 49% 
    48 Months  48% 47% 50% 
    60 Months  48% 47% 50% 
    72 Months  49% 47% 51% 
    84 Months  49% 48% 51% 
    96 Months  49% 47% 51% 
 
Extern 
 
320.1 
   
    14 Months  47% 46% 48% 
    24 Months  47% 46% 48% 
    36 Months  48% 47% 50% 
    48 Months  48% 47% 49% 
    60 Months  48% 47% 50% 
    72 Months  50% 49% 51% 
    84 Months  50% 48% 51% 
    96 Months  49% 47% 51% 
 
Both 
 
308.9 
   
    14 Months  45% 44% 46% 
    24 Months  47% 45% 48% 
    36 Months  48% 47% 50% 
    48 Months  48% 46% 49% 
    60 Months  48% 47% 50% 
    72 Months  49% 48% 50% 
    84 Months  51% 49% 52% 
    96 Months  49% 48% 50% 
 
Neither 
 
312.0 
   
    14 Months  54% 53% 56% 
    24 Months  52% 50% 54% 
    36 Months  51% 49% 52% 
    48 Months  50% 49% 52% 
    60 Months  50% 48% 51% 
    72 Months  49% 48% 51% 
    84 Months  49% 47% 51% 
    96 Months  50% 49% 51% 
Intern = Internalizing; Extern = Externalizing; Both =                                                                                                                                       
Internalizing + Externalizing; Neither = No Comorbidities;                                                                                                                  
Mean = Mean Percent Responders; Low – High =                                                                                                                                                                     
95% Confidence Interval; N = Sample Size 
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     4.5.2 Trends Over Time: Combination Therapy 
 
 The response rates for boys and girls on combination therapy also remained 
reasonably stable over time (Table 42). The 95 percent confidence intervals indicated that 
response rates for boys with internalizing, externalizing, or neither types of comorbidities 
were statistically equivalent over time (Table 45). However, boys with both types of 
comorbidities had significantly lower response rates (95 percent confidence interval, 45 
percent to 48 percent) at 24 months than those at 14 months (49 percent to 52 percent).   
 Girls with externalizing and both types of comorbidities had significantly equivalent 
response rates over time (Table 46). However, girls with internalizing comorbidities had 
significantly higher response rates at 14 months than those at 36 months, 48 months, or 72 
months. Girls with internalizing comorbidities had significantly higher response rates at 24 
months than those at 36 to 96 months. Girls without comorbidity had significantly higher 
response rates at 14 months than those at 36 months, while girls without comorbidity had 
significantly higher response rates at 24 months than those at 36 to 60 months or 84 to 96 
months. 
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Table 45: Combination Therapy Responders                                                                                                                                     
over Time- Boys 
Comorbidity/ 
Time Point 
N Mean Low High 
 
Intern 
 
306.8 
   
    14 Months  49% 48% 50% 
    24 Months  48% 47% 49% 
    36 Months  47% 46% 49% 
    48 Months  47% 46% 49% 
    60 Months  49% 47% 50% 
    72 Months  49% 47% 50% 
    84 Months  49% 48% 51% 
    96 Months  50% 49% 52% 
 
Extern 
 
315.5 
   
    14 Months  47% 45% 48% 
    24 Months  46% 44% 47% 
    36 Months  46% 44% 47% 
    48 Months  48% 46% 49% 
    60 Months  48% 47% 50% 
    72 Months  48% 47% 50% 
    84 Months  49% 47% 50% 
    96 Months  49% 48% 51% 
 
Both 
 
316.0 
   
    14 Months  50% 49% 52% 
    24 Months  46% 45% 48% 
    36 Months  47% 45% 49% 
    48 Months  48% 46% 49% 
    60 Months  48% 46% 49% 
    72 Months  49% 47% 50% 
    84 Months  50% 48% 52% 
    96 Months  50% 48% 52% 
 
Neither 
 
308.9 
   
    14 Months  52% 50% 53% 
    24 Months  50% 48% 51% 
    36 Months  49% 48% 51% 
    48 Months  49% 47% 50% 
    60 Months  50% 48% 51% 
    72 Months  50% 48% 52% 
    84 Months  51% 49% 52% 
    96 Months  49% 48% 51% 
Intern = Internalizing; Extern = Externalizing; Both =                                                                                                                                       
Internalizing + Externalizing; Neither = No Comorbidities;                                                                                                                  
Mean = Mean Percent Responders; Low – High =                                                                                                                                                                     
95% Confidence Interval; N = Sample Size 
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     4.5.3 Comparisons Between Genders:  Medication Management 
 
 The 95 percent confidence intervals (Tables 43 and 44) indicated that boys and girls 
had statistically equivalent response rates when matched by comorbidity and time point. 
However, when matched only by comorbidity, statistically significant differences appeared. 
For instance, girls with internalizing comorbidities had significantly lower response rates at 
24 months than boys did at 72 months (confidence intervals: 45 percent to 48 percent 
compared to 49 percent to 51 percent). Girls with internalizing comorbidities had 
significantly higher response rates at 72 months than boys did at 24 months or 48 months. 
Additionally, boys with externalizing comorbidities had significantly lower response rates at 
24 months than girls did at 36 to 96 months, while boys with both comorbidity types had 
significantly higher response rates at 14 months than girls did at 48 to 96 months (Tables 43 
and 44). Finally, girls without comorbidity had significantly higher response rates at 14 
months than boys did at 24 to 96 months. 
 
 
     4.5.4 Comparisons Between Genders:  Combination Therapy 
 
 The 95 percent confidence intervals (Tables 45 and 46) indicated that boys and girls 
had some statistically significant differences in response rates when matched by 
comorbidity and time point. For instance, girls with internalizing or externalizing 
comorbidities had significantly higher response rates at 14 months and 24 months than 
their male counterparts at those time points. Girls without comorbidity had significantly 
higher response rates at 24 months than their male equivalents.   
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 Girls on combination therapy appeared to benefit more than boys when matched 
only by comorbidity (Tables 45 and 46). Girls with internalizing comorbidities had 
significantly higher response rates at 14 months than boys did from 14 to 72 months, while 
girls responded significantly more at 24 months than boys did from 14 to 84 months. Girls 
with externalizing comorbidities had significantly higher response rates at 14 months and 24 
months than boys did from 14 to 48 months. Finally, girls had significantly higher response 
rates from 48 to 96 months than boys did at 24 months or 36 months. The common theme, 
with the exception of those with both types of comorbidities, was that girls responded to 
combination therapy significantly more often than boys did during the earlier time points. 
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Table 46: Combination Therapy Responders                                                                                                                                   
over Time - Girls 
Comorbidity/ 
Time Point 
N Mean Low High 
 
Intern 
 
314.3 
   
    14 Months  52% 51% 53% 
    24 Months  53% 52% 54% 
    36 Months  49% 47% 50% 
    48 Months  48% 46% 50% 
    60 Months  50% 48% 51% 
    72 Months  49% 47% 50% 
    84 Months  49% 48% 51% 
    96 Months  50% 49% 51% 
 
Extern 
 
311.9 
   
    14 Months  52% 50% 54% 
    24 Months  52% 50% 53% 
    36 Months  49% 47% 50% 
    48 Months  50% 48% 51% 
    60 Months  49% 48% 51% 
    72 Months  49% 48% 50% 
    84 Months  50% 48% 51% 
    96 Months  50% 48% 51% 
 
Both 
 
311.2 
   
    14 Months  49% 48% 51% 
    24 Months  48% 47% 50% 
    36 Months  48% 46% 49% 
    48 Months  48% 47% 50% 
    60 Months  49% 47% 51% 
    72 Months  49% 48% 51% 
    84 Months  49% 47% 51% 
    96 Months  50% 48% 52% 
 
Neither 
 
315.5 
   
    14 Months  52% 51% 54% 
    24 Months  53% 52% 55% 
    36 Months  49% 47% 50% 
    48 Months  50% 48% 51% 
    60 Months  49% 48% 51% 
    72 Months  50% 49% 52% 
    84 Months  49% 48% 51% 
    96 Months  49% 48% 51% 
Intern = Internalizing; Extern = Externalizing; Both =                                                                                                                                       
Internalizing + Externalizing; Neither = No Comorbidities;                                                                                                                  
Mean = Mean Percent Responders; Low – High =                                                                                                                                                                                            
95% Confidence Interval; N = Sample Size 
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     4.5.5 Comparisons Between Treatments 
 
 Boys and girls with internalizing comorbidities on medication management 
responded 47 percent to 51 percent of the time, while those on combination therapy 
responded 47 percent to 53 percent of the time (Table 42). Patients with externalizing 
comorbidities on medication management responded 45 percent to 50 percent of the time, 
while those on combination therapy responded 46 percent to 52 percent of the time. 
Children with both types of comorbidities on medication management responded 47 
percent to 51 percent of the time, while patients on combination therapy responded 46 
percent to 50 percent of the time. Finally, patients without comorbidity on medication 
management responded 49 percent to 54 percent of the time, while those on combination 
therapy responded 49 percent to 53 percent of the time. In sum, all patients across 
treatments, gender, comorbidites, and time points responded to treatment 45 percent to 
54 percent of the time. 
 
4.6 Cost-Effectiveness 
 
 Tables 47 and 48 contain the simulation results for medication management and 
combination therapy, respectively. The results are the average for each entity-type across 
the 50 replications. I presented the percent of time normalized per patient-type as well as 
the NALYs over the eight-year time horizon. NALYs were calculated as follows: 
 
NALYs = % of time normalized * 8 years 
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Therefore, each patient normalized (responds to treatment) for 50 percent of the eight-year 
time horizon accrued 4 NALYs. The average costs per patient (total, treatment, non-
treatment) also refer to the costs over the eight-year time horizon. 
 
Table 47: Normalization and Costs of Medication Management by Entity 
Gender_Comorbidity N % Time Normalized per 
Patient 
Number of Years Normalized 
(NALYs) 
Costs per 
Patient 
 
Total Costs 
    
 
     Boy_Int 314.6 55% 4.40 $22,657 
     Boy_Ext 307.2 48% 3.80 $22,964 
     Boy_B 310.1 48% 3.85 $22,917 
     Boy_N 313.1 50% 3.98 $22,686 
     Girl_Int 314.1 49% 3.89 $22,689 
     Girl_Ext 320.1 48% 3.87 $22,911 
     Girl_B 308.9 48% 3.85 $22,963 
     Girl_N 312.0 51% 4.07 $22,813 
 
Treatment Costs 
    
 
     Boy_Int 314.6 55% 4.40 $8,325 
     Boy_Ext 307.2 48% 3.80 $8,709 
     Boy_B 310.1 48% 3.85 $8,251 
     Boy_N 313.1 50% 3.98 $8,378 
     Girl_Int 314.1 49% 3.89 $8,506 
     Girl_Ext 320.1 48% 3.87 $8,754 
     Girl_B 308.9 48% 3.85 $8,641 
     Girl_N 312.0 51% 4.07 $8,366 
 
Non-Treatment 
Costs 
    
 
     Boy_Int 314.6 55% 4.40 $14,332 
     Boy_Ext 307.2 48% 3.80 $14,255 
     Boy_B 310.1 48% 3.85 $14,666 
     Boy_N 313.1 50% 3.98 $14,307 
     Girl_Int 314.1 49% 3.89 $14,183 
     Girl_Ext 320.1 48% 3.87 $14,157 
     Girl_B 308.9 48% 3.85 $14,322 
     Girl_N 312.0 51% 4.07 $14,447 
Int = Internalizing; Ext = Externalizing; B = Internalizing + Externalizing; N = No Comorbidities; NALY = 
Average Normalized-Adjusted Life Years; Costs per Patient = Average Costs per Entity; N = Sample Size 
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Table 48: Normalization and Costs of Combination Therapy by Entity 
Gender_Comorbidity N % Time Normalized per 
Patient 
Number of Years Normalized 
(NALYs) 
Costs per 
Patient 
 
Total Costs 
    
 
     Boy_Int 306.8 47% 3.80 $39,501 
     Boy_Ext 315.5 48% 3.83 $39,574 
     Boy_B 316.0 49% 3.89 $39,605 
     Boy_N 308.9 50% 3.98 $39,891 
     Girl_Int 314.3 51% 4.11 $39,198 
     Girl_Ext 311.9 50% 3.98 $39,770 
     Girl_B 311.2 49% 3.90 $39,564 
     Girl_N 315.5 50% 4.00 $39,239 
 
Treatment Costs 
    
 
     Boy_Int 306.8 47% 3.80 $22,092 
     Boy_Ext 315.5 48% 3.83 $22,171 
     Boy_B 316.0 49% 3.89 $22,231 
     Boy_N 308.9 50% 3.98 $22,441 
     Girl_Int 314.3 51% 4.11 $21,847 
     Girl_Ext 311.9 50% 3.98 $22,364 
     Girl_B 311.2 49% 3.90 $22,119 
     Girl_N 315.5 50% 4.00 $21,906 
 
Non-Treatment 
Costs 
    
 
     Boy_Int 306.8 47% 3.80 $17,409 
     Boy_Ext 315.5 48% 3.83 $17,403 
     Boy_B 316.0 49% 3.89 $17,374 
     Boy_N 308.9 50% 3.98 $17,451 
     Girl_Int 314.3 51% 4.11 $17,351 
     Girl_Ext 311.9 50% 3.98 $17,407 
     Girl_B 311.2 49% 3.90 $17,445 
     Girl_N 315.5 50% 4.00 $17,333 
Int = Internalizing; Ext = Externalizing; B = Internalizing + Externalizing; N = No Comorbidities; NALY = 
Average Normalized-Adjusted Life Years; Costs per Patient = Average Costs per Entity; N = Sample Size 
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     4.6.1 Percent of Time Normalized per Patient/NALYs: Medication      
 Management 
 
Boys with internalizing comorbidities spent the most time in the normalized state at 
55 percent (4.40 NALYs) (Table 47). Boys with externalizing or both types of comorbidities 
spent approximately 48 percent of the time in the normalized state (3.80 to 3.85 NALYs). 
Boys without comorbidity spent 50 percent of the time normalized (3.98 NALYs). Girls 
without comorbidity spent 51 percent of the time in the normalized state (4.07 NALYs), 
while girls with internalizing comorbidities spent 49 percent of the time normalized (3.89 
NALYs). Girls with externalizing or both comorbidity types spent approximately 48 percent 
of the time in the normalized state (3.85 to 3.87 NALYs). 
 
     4.6.2 Costs per Patient: Medication Management 
 Costs per patient were quite similar across each of the eight entity-types, indicating 
that gender and comorbidity (in my model) do not play a strong role in predicting costs 
(Table 47). Non-treatment costs drove total costs, accounting for approximately 63 percent 
of total costs. Total costs ranged from $22,657 (boys with internalizing comorbidities) to 
$22,963 (girls with both types of comorbidities). Treatment costs varied slightly more than 
total costs. Boys with both types of comorbidities accrued the least treatment costs 
($8,251) over the eight-year time horizon, while girls with externalizing comorbidities 
accumulated the most treatment costs ($8,754). Non-treatment costs ranged from $14,157 
(girls with externalizing comorbidities) to $14,666 (boys with both types of comorbidities).   
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     4.6.3 Percent of Time Normalized per Patient/NALYs: Combination Therapy 
 Boys with internalizing comorbidities spent the least time in the normalized state, at 
47 percent (3.80 NALYs) (Table 48) – the opposite of those on medication management. 
Boys without comorbidity spent 50 percent of the time in the normalized state (3.98 
NALYs), while boys with externalizing and both types of comorbidities spent 48 percent 
(3.83 NALYs) and 49 percent (3.89 NALYs), respectively, of the time normalized. Girls with 
internalizing comorbidities spent the most time normalized, at 51 percent of the time (4.11 
NALYs), while girls with externalizing or no comorbidities spent approximately 50 percent of 
the time normalized (3.98 – 4.00 NALYs). Girls with both types of comorbidities spent 49 
percent of the time normalized (3.90 NALYs). 
 
     4.6.4 Costs per Patient: Combination Therapy 
 Similar to the costs of medication management, the costs per patient on 
combination therapy varied little among patient-types. Yet unlike medication management, 
treatment costs were higher than non-treatment costs for patients on combination therapy. 
Treatment costs accounted for approximately 56 percent of total costs for patients on 
combination therapy. Total costs ranged from $39,198 (girls with internalizing 
comorbidities) to $39,891 (boys without comorbidity) (Table 48). Treatment costs varied 
slightly more, as was the case with medication management. Girls with internalizing 
comorbidities accrued the lowest treatment costs ($21,847), while boys without 
comorbidity accumulated the highest treatment costs ($22,441). Non-treatment costs 
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varied little and ranged from $17,333 (girls without comorbidity) to $17,451 (boys without 
comorbidity).  
     4.6.5 Medication Management Compared to Combination Therapy 
 
 Medication management was more effective than combination therapy only in boys 
with internalizing comorbidities and girls without comorbidity. Boys with internalizing 
comorbidities on medication management spent an average of 0.6 years more in the 
normalized state than those on combination therapy (4.40 NALYs to 3.80 NALYs), while boys 
with externalizing comorbidities on medication management spent an average of 0.03 years 
less in the normalized state (3.83 NALYs to 3.80 NALYs) than those on combination therapy 
(Tables 47 and 48). Boys with both types of comorbidities on medication management 
spent an average of 0.04 years less as normalized than those on combination therapy (3.89 
NALYs to 3.85 NALYs), and boys without comorbidity accrued 3.98 NALYs in both treatment 
arms. 
 Girls with internalizing comorbidities on medication management spent an average 
of 0.22 years less in the normalized state than those on combination therapy (4.11 NALYs to 
3.89 NALYs), while girls with externalizing comorbidities on medication management spent 
an average of 0.12 years less in the normalized state (3.97 NALYs to 3.87 NALYs) than those 
on combination therapy (Tables 47 and 48). Girls with both types of comorbidities on 
medication management spent an average of 0.05 years less as normalized than those on 
combination therapy (3.90 NALYs to 3.85 NALYs), and girls without comorbidity on 
medication management spent an average of 0.07 years more as normalized than those on 
combination therapy (4.07 NALYs to 4.00 NALYs).     
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     4.6.6 Incremental Costs and NALYs 
 
 Incremental costs (Table 49) refer to the costs of combination therapy minus the 
costs of medication management. The incremental total, treatment, and non-treatment 
costs varied little across entity-types, though each category of costs was higher among the 
entities on combination therapy. For instance, incremental total costs ranged from $16,436 
(girls without comorbidity) to $17,088 (girls with externalizing comorbidities), incremental 
treatment costs ranged from $13,384 (girls without comorbidity) to $14,079 (girls with 
externalizing comorbidities), and incremental non-treatment costs ranged from $2,969 
(boys with internalizing comorbidities) to $3,100 (boys without comorbidity).    
 Incremental NALYs refer to the number of years normalized for patients on 
combination therapy minus the number of years normalized for patients on medication 
management. The incremental NALYs were negative for boys with internalizing 
comorbidities (-0.60) and girls without comorbidities (-0.07), indicating that medication 
management was more effective than combination therapy over the eight-year time 
horizon (Table 49). The remaining entity-types had positive values, indicating that 
combination therapy was more effective. 
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Table 49: Cost-Effectiveness of Combination Therapy vs. Medication Management                                                           
by Entity 
Gender_Comorbidity Incremental 
Costs 
Incremental 
Years 
Normalized 
Incremental Cost per  
NALY 
 
Total Costs 
   
 
     Boy_Int $16,575 -0.60 -$27,683 
     Boy_Ext $16,496 0.02 $663,223 
     Boy_B $16,822 0.04 $405,987 
     Boy_N $17,059 0.00 -$3,951,830 
     Girl_Int $16,495 0.22 $74,333 
     Girl_Ext $17,088 0.11 $159,662 
     Girl_B $16,690 0.05 $330,562 
     Girl_N $16,436 -0.07 -$250,304 
 
Treatment Costs 
   
 
     Boy_Int $13,606 -0.60 -$22,724 
     Boy_Ext $13,527 0.02 $543,822 
     Boy_B $13,726 0.04 $331,285 
     Boy_N $13,959 0.00 -$3,233,765 
     Girl_Int $13,453 0.22 $60,626 
     Girl_Ext $14,079 0.11 $131,541 
     Girl_B $13,650 0.05 $270,355 
     Girl_N $13,384 -0.07 -$203,831 
 
Non-Treatment Costs 
   
 
     Boy_Int $2,969 -0.60 -$4,959 
     Boy_Ext $2,970 0.02 $119,401 
     Boy_B $3,095 0.04 $74,702 
     Boy_N $3,100 0.00 -$718,065 
     Girl_Int $3,042 0.22 $13,707 
     Girl_Ext $3,010 0.11 $28,121 
     Girl_B $3,040 0.05 $60,208 
     Girl_N $3,052 -0.07 -$46,473 
Int = Internalizing; Ext = Externalizing; B = Internalizing + Externalizing; N = No Comorbidities;                                                  
Incremental Costs = Average Costs of Combination Therapy – Average Costs of Medication                                                             
Management; Incremental Years Normalized = Average Number of Years Normalized for                                                                  
Combination Therapy – Average Number of Years Normalized for Medication Management;                                                                                  
Incremental Costs per NALY = Incremental Costs/Incremental Number of Years Normalized                                                            
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     4.6.7 Incremental Cost per NALY 
 
 The incremental cost per NALY (the ICER) is the final metric of my study. The ICER 
indicates the relative cost-effectiveness of combination therapy compared to medication 
management and is calculated by dividing the incremental costs by the incremental NALYs 
for each entity. A negative value indicates that combination therapy is more costly and less 
effective than medication management, and a positive value indicates that combination 
therapy is both more costly and more effective than medication management. The negative 
ICERs across each category of costs for boys with internalizing comorbidities, boys without 
comorbidities, and girls without comorbidities indicate that medication management 
dominated combination therapy (Table 49).   
 The incremental total cost per NALY was highest for boys with externalizing 
comorbidities ($663,223) and lowest for girls with internalizing comorbidities ($74,333) 
(Table 49). Boys and girls with both comorbidity types accrued total costs ICERs of $405,987 
and $330,562, respectively. Girls with externalizing comorbidities had a total costs ICER of 
$159,662. 
 The incremental treatment cost per NALY followed the same pattern: highest for 
boys with externalizing comorbidities ($543,882) and lowest for girls with internalizing 
comorbidities ($60,626) (Table 49). Boys and girls with both comorbidity types had 
treatment costs ICERs of $331,285 (boys) and $270,355 (girls). Girls with externalizing 
comorbidities had a treatment costs ICER of $131,541. 
 The incremental non-treatment cost per NALY also followed the same pattern: 
highest for boys with externalizing comorbidities ($119,401) and lowest for girls with 
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internalizing comorbidities ($13,707) (Table 48). Boys and girls with both comorbidity types 
had non-treatment costs ICERs of $74,702 (boys) and $60,208 (girls). Girls with externalizing 
comorbidities had a non-treatment costs ICER of $28,121. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 5: Discussion 
 
 In the treatment of ADHD, reducing impairment caused by symptoms is critical. 
Though long-term combination therapy and medication management appear to have 
similar effectiveness over an eight-year time horizon, the costs of combination therapy from 
both the payer and societal perspectives far outweigh the costs of medication management. 
The ensuing subsections first summarize and interpret the findings of my study, then 
discuss the meaningful differences in total costs, the non-meaningful differences in 
response to treatments, and reasons why patients on both arms tend to respond similarly. I 
outline the strengths and weaknesses of the study and end with policy recommendations 
and directions for future research.  
 
5.1 Summary of Findings: Treatment Costs 
 Treatment costs of medication management trend upward over time. Costs of 
behavioral therapy are quite high from baseline to 14 months, due to the intensity of 
therapy, but fall from 14 to 24 months, only to rise steadily throughout the rest of the time 
horizon. At each time point, boys and girls on medication management have significantly 
lower treatment costs than those on combination therapy. By the 84 months to 96 months 
interval, patients on medication management average between $1,244 and $1,310 in 
treatment costs, while those on combination therapy average between $2,866 and $2,990.  
Gender and comorbidity do not play a strong role in driving treatment costs within 
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treatment type. Boys and girls at each time point accrued statistically equivalent treatment 
costs (within both treatment arms) when matched by comorbidity. 
 The results of the gender comparison should be interpreted in light of one 
methodological constraint. I determined treatment costs by compliance state, but the MTA 
sample size made it difficult to vary medication and behavioral therapy costs by gender. 
Nevertheless, I modeled medication costs as a function of treatment arm. Therefore, the 
simulation of treatment costs represents the differences across treatments but not across 
gender subgroups.               
 
5.2 Summary of Findings: Non-Treatment Costs 
 Regardless of gender, comorbidity, or time point, patients on combination therapy 
accrued significantly higher non-treatment costs than those on medication management – 
perhaps the most interesting finding of the study. To my knowledge, the literature neither 
supports nor refutes this finding. My results show that non-treatment costs for patients on 
either treatment follow a general upward trend over time, reaching their highest point at 36 
months. Presumably, the costs of juvenile justice rise considerably over time because 
younger children are less likely to be arrested. The 95 percent confidence intervals indicate 
statistically significant rises in non-treatment costs of either treatment in the early years of 
the time horizon. Gender and comorbidity do not appear to play a key role in driving non-
treatment costs. Boys and girls within either treatment arm accumulated statistically 
equivalent non-treatment costs when matched by comorbidity.   
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 Despite the results of gender and comorbidity, the sample size of the data, once 
again, did not permit the subgroup analyses of non-treatment costs. The results should be 
interpreted with caution. However, the significant differences across treatment arms 
suggest that non-treatment costs should be explored further in future studies.   
 
5.3 Summary of Findings: Total Costs 
 Because treatment and non-treatment costs of combination therapy were 
significantly higher than those of medication management, total costs operated in the same 
manner. Treatment costs played a stronger role in total costs among patients on 
combination therapy, due to the intensive behavioral therapy component. While total costs 
for patients on medication management steadily rose over time, total costs for patients on 
combination therapy began high, dropped significantly, and rose to a plateau around 84 
months. Once again, neither gender nor comorbidity played a strong role in total costs. 
Costs among each gender-comorbidity pair were statistically equivalent (within treatments). 
 Because total costs are a function of treatment and non-treatment costs, the results 
suffer from the same sample size problems. Therefore, my study cannot determine which 
treatment is more costly by gender and comorbidity. My results can maintain only that total 
costs of combination therapy are significantly higher than those of medication 
management. 
 The total costs results should be interpreted as the eight-year costs of each 
treatment arm. Thus, the total costs for combination therapy average approximately $5,000 
per year ($39,000 over eight years), while total costs for medication management average 
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approximately $3,000 per year ($22,000 over eight years). Because ADHD is quite prevalent 
in the U.S., $2,000 per year is a significant amount to pay per patient, especially for public 
health care payers and federal/state governments, who are facing some of the most 
financially trying times in history. To justify paying 66 percent more for combination 
therapy, the incremental benefits should correspond to the incremental costs.   
 
5.4 Summary of Findings: Effectiveness of Treatment 
 The response rates over time for boys and girls on medication management 
remained stable. Although I found some statistically significant differences among patients 
at different time points, the differences in magnitude were quite small. Gender and 
comorbidity did not play a strong role in predicting response to medication management 
when matched by time point. However, I did find some statistically significant differences 
among boys and girls on combination therapy. Girls appeared to respond to combination 
therapy more often than boys at the earlier time points, regardless of comorbidity.  
The differences in average response rates between treatments were largest at 14 
months and 24 months. Presumably, the differences in treatment patterns were due to 
patients leaving the tightly controlled trial after 14 months to return to the community.  For 
instance, patients on combination therapy might receive different levels of intensity (or 
comprehensiveness), while patients on medication management would receive treatment 
from doctors with different backgrounds and prescribing patterns. Thus, response rates 
between (and/or within) treatments could be biased towards the null. Recent research 
using MTA data had similar findings. 
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     5.4.1 The MTA at Eight Years 
 A new report by Molina et al. (2009) claims that the initial randomized provision of 
treatment did not affect long-term treatment effectiveness. At the 14-month evaluation, 
both combination therapy and medication management were clearly superior to 
community care (‘treatment as usual’) and behavioral therapy. Following the 14-month 
tightly controlled trial, the patients left the randomized groups, the intensive interventions 
concluded, and the children returned to community care – free to choose their own 
treatment (MTA Cooperative Group 1999).  A three-year follow-up study reported that 
intent-to-treat analyses showed few differences between groups (Jensen et al. 2007). The 
current eight-year report found that all four treatment groups had a similar outcome – each 
showed improvement over baseline scores, but no treatment was more effective than 
others. Banaschewski et al. (2009) hypothesized that both medication and behavioral 
therapy are valuable, and self-selection of patients for treatments after the end of 
randomization led to the similar outcomes. In other words, families and clinicians might 
have chosen the treatment that best fit the individual child, so each treatment provided 
similar effectiveness.  
 
5.5 Cost-Effectiveness of Combination Therapy Compared to Medication Management 
 
 Boys on medication management with internalizing comorbidities spent the most 
time in the normalized state, while boys with internalizing comorbidities on combination 
therapy spent the least time in the normalized state. The remaining gender-comorbidity 
pairs (within treatments) spent similar time in the normalized state. However, medication 
management was more effective than combination therapy only among boys with 
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internalizing comorbidities and girls without comorbidity.  Therefore, incremental NALYs 
were negative only for these entities.  
The costs per patient (within treatment) were quite similar across gender-
comorbidity pairs; therefore, the incremental costs varied little across entities. However, 
the costs of medication management were significantly lower than those on combination 
therapy, regardless of gender and comorbidity. The incremental total costs per NALY were 
highest for boys with externalizing comorbidities and lowest for girls with internalizing 
comorbidities, and the incremental treatment costs per NALY followed the same pattern. 
Though no threshold of willingness to pay has been established for the NALY, the lowest 
treatment ICER ($60,626) and total ICER ($74,333) are presumably too high to deem 
combination therapy more cost-effective than medication management. Therefore, 
combination therapy is not cost-effective relative to medication management from either 
the health care payer or societal/taxpayer perspectives. 
 
5.6 Model Strengths 
 Because of the paucity of cost-effectiveness studies, Banaschewski et al. (2009) 
suggested that the health economic costs and benefits of long-term therapy should be 
quantified. To the best of my knowledge, my study is the first to estimate the relative long-
term cost-effectiveness of the two superior MTA treatments at 14 months. Other studies 
have reported the cost-effectiveness of specific medications compared to other 
medications, behavioral therapy, and/or combination therapy, but their time horizons are 
not long enough to determine which treatment/s are most efficient at tackling this long-
term chronic condition. The strengths of my model are that patient-level data were used to 
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estimate parameters from the MTA trial. In addition, the equations used to estimate 
response were guided by both a controlled clinical trial and actual clinical practice 
(community care after 14 months). Together with the advantages of discrete-event 
simulation, these factors allowed me to take into account each individual’s risk profile and 
its impact on ADHD treatment effectiveness. Additionally, the discrete-event simulation 
technique provided a means to realistically represent health care processes and, in turn, 
better address the specific research questions posed without forcing unnecessary 
compromises on the effects of disease progression (Caro 2005).   
 
5.7 Model Limitations 
 The model has some important limitations. The subsections below detail the 
limitations of small sample sizes, lack of medication-specific estimates, missing data and the 
multiple imputation approach, MTA data integrity, treatment switching, model validation, 
methodological assumptions, and the common limitations of discrete-event simulations. 
 
     5.7.1 Small Sample Size of the MTA Data 
Because I relied on MTA data to estimate state transitions of compliance, severity, 
and service utilization, the data were insufficient to vary by gender and comorbidity. The 
response to treatment parameter was the only variable that incorporated gender and 
comorbidity in its estimates (Table 6). By not varying the other parameters by gender and 
comorbidity, I might not be capturing the complete picture. If the sample size were too 
small to pick up a tendency for girls on medication management to be hospitalized or end 
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up in the juvenile justice system with greater frequency than boys or girls on combination 
therapy – all else held constant – the conclusions I might draw about treatment cost-
effectiveness would be inaccurate. Additionally, the small sample size of each treatment 
arm in the MTA made it difficult to estimate parameters with high precision and to estimate 
parameter distributions which forced me to use the triangular distribution for most of the 
variables. However, simulating a large number of patients ensured that the incremental 
cost-effectiveness values still would be normally distributed (Muennig 2008, pg. 146). 
Future studies using my model framework will focus on utilizing the strengths of discrete-
event simulation by using multiple data sources to populate the model. A fully 
parameterized model, making use of several datasets, might provide a different picture as 
to the comparative cost-effectiveness of treatments for comparing boys and girls.   
    
     5.7.2 No Medication-Specific Estimates 
My model does not specify which actual medications the patients were taking 
(although a vast majority took methylphenidate) or which specific comorbidities the 
patients had. The model estimates costs and response to being managed on medications, 
and patients were grouped into internalizing/externalizing/both comorbidities/no 
comorbidities categories. Therefore, I am unable to make inferences about specific 
medications or specific comorbidities. For instance, patients with comorbid anxiety 
generally would not benefit from stimulants as much as others, because stimulants can 
exacerbate anxiety symptoms. Atomoxetine would be an ideal non-stimulant candidate, but 
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I am unable to make assertions as to the differential cost-effectiveness of atomoxetine for 
boys and girls with and without anxiety. 
 
     5.7.3 Missing Data and the Multiple Imputation Approach 
 I used a multiple imputation approach to address the missing MTA data. Although no 
rule exists stating how much missing data is too much, I am missing a considerable amount 
– especially among the medication management cohort. Interestingly, the combination 
therapy cohort has substantially fewer missing data than the medication management 
cohort.  Additionally, among patients on combination therapy, generally fewer data are 
missing toward the end of the time horizon. One explanation for the discrepancy in missing 
data among the treatment arms is that combination therapy is much more intense and 
requires the active participation of the parent/guardian. Because the caretaker answers the 
study surveys, a caretaker who actively participates may be more likely to be meticulous 
about filling out the data collection forms. Ultimately, the results of my analyses must be 
interpreted in light of a good deal of missing data.  
 
     5.7.4 MTA Data Integrity 
 The issue of missing data may prompt the question, are the MTA service utilization 
data believable? For instance, the juvenile justice data, in particular, frequently are missing 
more than half the data. Therefore, the multiple imputation approach is generally using less 
than half of the data to predict the missing observations. For instance, 51.9 percent of the 
juvenile justice data for medication management are missing at 96 months; therefore, 48.1 
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percent of the data are being used to predict the missing values. My data analysis suggests 
patients on medication management are significantly more likely to be arrested at 96 
months than patients on combination therapy (difference of 6.97 percent, p < 0.05). I find it 
hard to believe that approximately 10 percent of patients on medication management are 
arrested at 96 months, while about 3 percent of patients on combination therapy are 
arrested. Granted, the large standard errors incorporated into the model account for some 
of the variability, but the true impact of the treatments on arrest rates is difficult to tease 
out. 
Even more perplexing are the vast differences in special education utilization over 
the time horizon, each of which was statistically significant. Patients on medication 
management were less likely to be in special education from baseline through 36 months, 
at 76 months, and at 96 months.  However, they were much more likely to be in special 
education from 48 to 60 months and at 84 months. The magnitude of the differences is 
remarkable – the data suggest that patients on medication management are almost three 
times more likely to be in special education at 60 months than are patients on combination 
therapy. One could argue that behavioral therapy teaches children educational coping skills 
that may reduce the need for special education; however, that would not explain their 
higher rates of special education use during the earlier time points. Another argument is 
that patients on medication management may have more significant impairment than those 
on combination therapy; however, the opposite appears to be true.   
Ultimately, the output of a model is only as valid as the input data. The non-
treatment costs for patients on combination therapy
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those on medication management ($17,000 compared to $14,000), regardless of gender or 
comorbidity.  However, these differences are far outweighed by the differences in 
treatment costs when calculating the ICERs. Therefore, I believe the differences in non-
treatment costs among treatment arms do not affect my conclusions regarding cost-
effectiveness. Future studies should incorporate more than one data source into calculating 
the input parameters of the model. Confirming the MTA data with other data sources would 
further improve the data’s integrity, and could help determine if real differences in service 
utilization exist.     
      
     5.7.5 Treatment Switching 
Treatment switching is indeed prevalent in medicine. Patients are more likely to 
discontinue a given therapy if it is not working, just as they are more likely to drop out of a 
clinical trial if the investigational drug is not of benefit. In this case, treatment switching can 
produce misleading results, especially if switching is strongly correlated with treatment 
response. My study included data from a randomized clinical trial and follow-up (non-
randomized period).  Treatment switching occurred throughout the time horizon.  During 
the first 14 months of randomization, I used intent to treat analyses to control for 
treatment switching.  However, only 69 patients were on medication management 
throughout the time horizon, and only one patient was on combination therapy throughout 
the time horizon. In the follow-up period, I intended to model actual clinical practice, which 
can include treatment switching if deemed in the patient’s best interest by the physician.  
Therefore, I allowed treatment switching post-14 months, and controlled for switching 
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(partially) by including baseline demographics in the fixed portion of the multilevel 
regression model. The control variables included patient ethnicity, living in an urban/rural 
area, caregiver’s education level, family income, and age of the patient at baseline. These 
demographic variables were predictors of treatment switching, explaining between 2 
percent and 11 percent of the variation in the data. By partially controlling for treatment 
switching in this manner, I reduce the biases in the treatment response estimates (to the 
extent possible) resulting from patients switching therapies.   
 
     5.7.6 Model Validation 
To validate my conceptual model, I used a structured interview with an experienced 
clinician to draft the model, and I further validated it with a panel of key opinion leaders in 
the treatment of ADHD. Typically, the model validation process is both more structured and 
more intensive. For instance, many conceptual models are created via Delphi panels, which 
are structured, systematic forecasting techniques that rely on a panel of experts. Typically 
the experts answer questionnaires in several rounds. After each round, the researcher 
provides a summary of the experts’ answers as well as the justifications for their judgments. 
The experts are then asked to revise their answers based on the consensus of the group. 
Theoretically, over multiple rounds, the array of answers will converge to a “correct” 
answer. Future studies should strive to develop conceptual models with rigorous 
techniques, such as a Delphi panel.   
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     5.7.7 Methodological Assumptions 
 Several of my methodological assumptions, possibly affecting the validity of the 
model results, must be outlined. First, my definition of compliance to medication therapy 
(at least 80 percent of medications taken) was toward the high end of definitions in the 
peer-reviewed literature.  As explained earlier, clinicians and researchers have defined 
compliance to medication regimens in different ways. The construct I used (percentage of 
medications taken) is prevalent in the literature, though the actual percentages vary. To test 
the model’s dependence on my definition of compliance, I conducted a sensitivity analysis 
using a lower-end estimate (at least 50 percent of medications taken) found in the literature 
(Appendix H). The model results were robust to my definition of compliance, strengthening 
my confidence in the definition I chose. 
 Next, my model might not completely represent the process of care for all children 
with ADHD. For instance, my model dictates that children visit a psychiatrist only for both 
their medication visits and behavioral therapy. In reality, children could receive care from 
multiple sources, such as nurse practitioners, primary care physicians, physician assistants, 
and psychologists, among others. Also, the likelihood of receiving multimodal care is a 
function of which provider-type a patient uses. Bussing et al. (1998) found that children 
treated by a primary care provider were much less likely to receive psychosocial 
interventions than those treated by a mental health specialist. By not accounting for 
different provider-types, my results must be interpreted with caution. Additionally, because 
psychiatrists earn more than other provider-types, the costs of combination therapy are 
likely inflated in my model. Moreover, the number of provider visits and the length of each 
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visit tend to vary as a function of provider type. Bussing et al. (1998) found that patients 
seen by mental health specialists visited their provider approximately four times as often as 
those seen by primary care providers only. That number balloons to five times, if the patient 
is seen by both provider types. Ultimately, the type of physician a child sees has a 
differential impact on the nature (and likely) quality of services provided. Future studies 
should focus on the impact of specific providers to account for the variation of care seen in 
the “real world.”   
 Next, the frequency of follow-up visits varies in actual practice (Sloan, Jensen et al. 
1999). Physicians generally schedule follow-up visits every two to three months (Kwasman 
et al. 1995), although in as many as 20 percent of initial visits, no follow-ups are provided 
(Jensen et al. 1989). I have modeled physician (medication) visits on a monthly basis to 
mimic the MTA trial as closely as possible. Additionally, modeling monthly visits allows the 
parent to obtain a handwritten refill prescription, which is necessary for many controlled 
substances (stimulants). The implication of modeling monthly visits is a potential 
overestimation of treatment costs; however, the frequency of visits (and their distributions) 
did not vary by treatment. Therefore, the model conclusions should not be affected. Future 
studies should create several models to account for the variation of physician visit 
frequency.   
 
     5.7.8 Discrete-Event Simulation Limitations 
Discrete-event simulation modeling has its own limitations. As with all models, a 
simulation model can never perfectly imitate the actual phenomena – the key is to balance 
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the validity of the model with the analytical complexity.  Also, simulation error may be 
present; any incorrect key stroke has the potential to alter results of the simulation and lead 
to incorrect conclusions. Additionally, the model may not be applicable to similar situations 
without some adjustments. For example, my model may not reflect the health care system 
overseas as it pertains to ADHD, because the diagnostic process can be more stringent in 
the U.K. The verification and process give me assurance that I have overcome these 
simulation limitations so that I can be confident about the conclusions.   
 
5.8 Policy Implications 
This study examined the cost-effectiveness of different alternatives for the long-
term treatment of ADHD, while serving as a foundation to provide valuable information to 
support policymakers in making difficult decisions about allocating scarce public resources. 
Cost-effectiveness analyses are primarily used to compare different strategies for treating 
disease. The importance of cost-effectiveness analyses is connected to the challenge that 
decision-makers encounter in trying to maximize the effectiveness of limited resources. 
Choosing treatments that are most cost-effective can provide a greater impact (given 
available resources) than choosing less cost-effective treatments. Analyses that produce 
only information on the effectiveness of treatments are not sufficient for guiding decision-
making in an atmosphere of limited resources. Differences in cost-effectiveness of long-
term combination therapy versus medication management, for both boys and girls with 
ADHD, suggest that resources can be used more efficiently when allocated to medication 
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management. This is important to health care payers and societal decision-makers at a time 
when most are facing stringent budgets and a rising demand for ADHD services.   
 But the question remains: Do cost-effectiveness analyses actually change the way 
things are done? The answer is yes and no. Canada, Australia, and many European countries 
use cost-effectiveness to help decide what should and should not be paid for, while U.S. 
private and public payers have not overtly incorporated cost-effectiveness analyses into 
their payment policies (Muennig, p. 17). U.S. public and private payers have tried to 
influence treatment patterns by altering reimbursement policies to reflect the relative cost-
effectiveness of treatment for various diseases. For instance, most private payers (e.g., Blue 
Cross and Blue Shield) structure tiered reimbursement plans for prescription drugs, which 
provide an incentive for patients, doctors, and pharmacies to use less costly generic drugs 
to treat a given condition.     
 Cost-effectiveness analyses have been controversial in the U.S. when used to deny 
treatment to certain populations of patients without taking the broader social implications 
of health treatments into account. For instance, cost-effectiveness analyses were used to 
prioritize interventions paid for by the Oregon state government. Those interventions 
deemed unaffordable were not paid for, leading to state and national uproar from groups 
denied treatment on these grounds (Muennig, p. 18). This illustrates the ethical pitfalls in 
using cost-effectiveness analysis to establish who can receive a treatment deemed superior 
to another. My study found that girls and boys, regardless of comorbidity, had statistically 
equivalent cost-effectiveness profiles. But if I had found differences, one can only imagine 
the potential outcry if services were denied to one gender and granted to the other.  
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 Ultimately, my study was not able to provide policymakers or payers with 
differential cost information by gender for reasons described earlier. However, stakeholders 
can use the results of my analyses of treatment effectiveness. Similar to recent MTA 
studies, my study found no significant differences over time in treatment options when 
subgroups were stratified by gender, comorbidity, ADHD severity, and treatment 
compliance. With equal treatment effectiveness, payers can effectively make 
reimbursement decisions based on cost.  However, decision-makers must keep in mind that 
my study modeled effectiveness using the SNAP-IV, an ADHD-specific measure of 
impairment. Other studies may define effectiveness using a more global measure of 
impairment. For instance, Foster et al. (2007) used the Columbia Impairment Scale (CIS), 
which is a comprehensive measure of child functioning. The CIS measures impairments 
across four areas: interpersonal relations, psychopathology domains (e.g., comorbidities), 
schoolwork, and the use of leisure time.  Using this measure of effectiveness, the authors 
found that the cost-effectiveness can vary as a function of a patient’s comorbidity status. 
For instance, combination therapy might be more cost-effective than medication 
management for patients with comorbid conduct disorder, while the opposite might be true 
for patients without comorbidity. Policymakers should heed which outcome measures a 
given study uses and appropriately match specific studies to their interests. For example, 
juvenile justice or educational system policymakers should focus on studies that cater to 
their needs. Juvenile justice policymakers might want to focus on benefits of reducing the 
costs of crime to victims (Foster et al. 2007), whereas educational system policymakers 
might want to focus on special education cost-containment or treatment effects on school 
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functioning. Still, it takes an intuitive policymaker to realize that present health care 
expenditures may produce future cost-savings – especially if the cost-savings are outside 
the domain of the policymaker. For instance, policymakers for state Medicaid agencies 
might find it difficult to rationalize spending a great deal of money on a treatment that 
would not provide benefits to society (i.e. lower rates of crime, more worker productivity) 
until years down the road.    
 
5.9 Recommendations for Future Research 
 Future research should address the limitations of my study: 
1. Multiple individual-level data sources should be incorporated to increase the 
precision of parameter estimates. 
2. Other databases should be analyzed to enable all model parameters to vary by 
gender and comorbidity. 
3. More reliably assign the appropriate distributions to the input parameters by 
analyzing more data. 
4. Explore medication-specific parameter estimates. 
5. Compare sub-threshold ADHD cases to patients exceeding the DSM-IV requirements 
for ADHD. 
6. Gather reliable quality of life data (from U.S. patients and parents) in a systematic 
way (i.e., standard gamble interviews) to calculate QALYs. Then, policymakers could 
compare the relative cost-effectiveness of these treatments with interventions 
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outside the realm of ADHD and calculate the opportunity costs of providing specific 
ADHD treatments. 
In addition, to fully inform each model parameter where individual-level data are 
unavailable, researchers should perform systematic reviews and meta-analyses of the 
literature – synthesizing prior research into a single estimate for inclusion in the model. 
A value of information analysis could guide researchers and policymakers alike, given 
the interest in the value of acquiring more precise estimates of model inputs.  
 
5.10 Conclusion 
 My study is the first to examine the long-term cost-effectiveness of different 
treatments for pediatric ADHD as a function of gender and comorbidity. Specifically, the 
study examined the costs per NALY from the health care payer and societal/taxpayer 
perspectives. The results of the analyses suggest that medication management is more cost-
effective than combination therapy over an eight-year time horizon under both 
perspectives; however, more data is required to produce robust gender-comorbidity 
subgroup conclusions.   
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Appendix A: MTA Sample Characteristics 
 
 This appendix presents demographic and clinical characteristics of patients in each 
treatment arm (Tables A1 and A2), treatment sample sizes and attrition over time (Table 
A3), as well as the number of treatment switchers over time (Table A4). 
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Table A1: Demographic and Clinical Characteristics -- Medication Management 
Time Point 14mo 24mo 36mo 48mo 60mo 72mo 84mo 96mo 
         
Age, Mean (SD) 
 
8.60 
(0.8) 
7.83 
(0.8) 
7.78  
(0.8) 
7.75 
(0.8) 
7.75  
(0.8) 
7.76  
(0.8) 
7.77  
(0.8) 
7.79  
(0.8) 
Gender (%) 
     Male 
     Female 
 
82 
18 
 
81 
19 
 
83 
17 
 
81 
19 
 
81 
19 
 
84 
16 
 
81 
19 
 
84 
16 
Race (%) 
     White 
     Black 
     Other 
 
63 
19 
18 
 
68 
15 
17 
 
66 
14 
20 
 
63 
17 
20 
 
63 
17 
20 
 
63 
15 
22 
 
64 
15 
21 
 
64 
16 
20 
Grade (%) 
     1st 
     2nd 
     3rd 
     4th 
     5th 
 
12 
36 
38 
13 
0.7 
 
15 
39 
33 
13 
0 
 
17 
39 
32 
12 
0 
 
17 
42 
31 
10 
0.3 
 
17 
41 
31 
11 
0.3 
 
18 
40 
31 
11 
0.4 
 
17 
39 
33 
11 
0.4 
 
16 
40 
31 
13 
0.4 
City Size (%) 
     100,000+ 
     < 100,000    
 
56 
44 
 
53 
47 
 
54 
46 
 
53 
47 
 
55 
45 
 
56 
44 
 
55 
45 
 
59 
41 
Mother Education (%) 
     High School+ 
 
91 
 
93 
 
93 
 
94 
 
94 
 
95 
 
94 
 
94 
Family Income (%) 
     < $20,000 
     $20,000 - $50,000 
     > $50,000 
 
21 
45 
34 
 
17 
42 
41 
 
18 
42 
40 
 
20 
39 
41 
 
19 
40 
41 
 
17 
42 
41 
 
20 
39 
41 
 
19 
42 
39 
Comorbidity Status (%) 
     Internalizing 
     Externalizing 
     Both  
     Neither 
 
24 
16 
11 
59 
 
13 
13 
7 
67 
 
13 
13 
10 
64 
 
16 
16 
13 
55 
 
16 
14 
9 
61 
 
7 
19 
9 
65 
 
16 
13 
10 
61 
 
11 
18 
10 
61 
ADHD Severity (%) 
     Severe 
     Not Severe 
 
48 
52 
 
40 
60 
 
46 
54 
 
55 
45 
 
49 
51 
 
45 
55 
 
49 
51 
 
51 
49 
Response to Treatment (%) 
     Responder 
     Non-Responder 
 
-- 
-- 
 
48 
52 
 
44 
56 
 
34 
66 
 
35 
65 
 
38 
62 
 
37 
63 
 
37 
63 
SD = Standard Deviation; mo = Months; % = Percentage; High School+ = At Least a High School Education;          
Both = Internalizing + Externalizing Comorbidities; Neither = No Comorbidities  
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Table A2: Demographic and Clinical Characteristics – Combination Therapy 
Time Point 14mo 24mo 36mo 48mo 60mo 72mo 84mo 96mo 
         
Age, Mean (SD) 8.40  
(0.8) 
7.69 
(0.8) 
7.79  
(0.8) 
7.85 
(0.8) 
7.80  
(0.8) 
7.68  
(0.8) 
7.70 
(0.8) 
7.67  
(0.8) 
Gender (%) 
     Male 
     Female 
 
79 
21 
 
83 
17 
 
77 
23 
 
85 
15 
 
83 
17 
 
81 
19 
 
85 
15 
 
72 
28 
Race (%) 
     White 
     Black 
     Other 
 
60 
17 
23 
 
49 
26 
25 
 
56 
24 
20 
 
52 
28 
20 
 
63 
17 
20 
 
64 
19 
17 
 
64 
18 
18 
 
69 
20 
11 
Grade (%) 
     1st 
     2nd 
     3rd 
     4th 
     5th 
 
14 
43 
31 
12 
0 
 
18 
39 
32 
11 
0 
 
14 
45 
27 
14 
0 
 
18 
39 
28 
15 
0 
 
17 
43 
30 
10 
0 
 
15 
46 
31 
8 
0 
 
19 
44 
29 
8 
0 
 
20 
41 
33 
6 
0 
City Size (%) 
     100,000+ 
     < 100,000    
 
49 
51 
 
60 
40 
 
57 
43 
 
63 
37 
 
48 
52 
 
56 
44 
 
56 
44 
 
54 
46 
Mother Education (%) 
     High School+ 
 
96 
 
97 
 
97 
 
100 
 
97 
 
97 
 
99 
 
98 
Family Income (%) 
     < $20,000 
     $20,000 - $50,000 
     > $50,000 
 
21 
38 
41 
 
24 
38 
38 
 
22 
38 
40 
 
17 
46 
37 
 
15 
41 
44 
 
19 
37 
44 
 
15 
45 
40 
 
20 
35 
45 
Comorbidity Status (%) 
     Internalizing 
     Externalizing 
     Both  
     Neither 
 
18 
7 
10 
65 
 
13 
18 
19 
50 
 
17 
19 
12 
52 
 
22 
11 
19 
48 
 
8 
15 
15 
62 
 
10 
31 
18 
41 
 
18 
19 
11 
52 
 
13 
20 
13 
54 
ADHD Severity (%) 
     Severe 
     Not Severe 
 
47 
53 
 
55 
45 
 
55 
45 
 
50 
50 
 
53 
47 
 
69 
31 
 
63 
37 
 
62 
38 
Response to Treatment (%) 
     Responder 
     Non-Responder 
 
-- 
-- 
 
32 
68 
 
33 
67 
 
33 
67 
 
32 
68 
 
28 
72 
 
40 
60 
 
31 
69 
SD = Standard Deviation; mo = Months; % = Percentage; High School+ = At Least a High School Education;          
Both = Internalizing + Externalizing Comorbidities; Neither = No Comorbidities 
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Table A3: Treatment Sample Size and Attrition 
Time Point Sample Size Changes Medication 
Management 
Combination 
Therapy 
 
14 Months 
 
N 144 145 
24 Months 
 
N 318 120 
36 Months Remain 
Enter Cohort 
Exit Cohort 
N 
 
252 
73 
66 
325 
60 
47 
60 
107 
48 Months Remain 
Enter Cohort 
Exit Cohort 
N 
 
256 
96 
69 
352 
25 
21 
82 
46 
60 Months Remain 
Enter Cohort 
Exit Cohort 
N 
 
257 
55 
95 
312 
14 
46 
32 
60 
72 Months Remain 
Enter Cohort 
Exit Cohort 
N 
 
225 
52 
87 
277 
32 
48 
28 
80 
84 Months Remain 
Enter Cohort 
Exit Cohort 
N 
 
210 
46 
67 
256 
50 
23 
30 
73 
96 Months Remain 
Enter Cohort 
Exit Cohort 
N 
 
178 
66 
78 
244 
25 
36 
48 
61 
Remain = Number of Patients Remaining in the Cohort from the Previous Period; Enter Cohort = Number of 
Patients Who Join the Cohort during the Given Period; Exit Cohort = Number of Patients Who Exited the 
Cohort From the Previous Period; N = Sample Size 
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Table A4:  Treatment Switching Over Time 
Index Treatment/Period Treatment Next Period Number of Treatment 
Switchers 
 
Medication Management at 
14 Months 
 
 
Combination Therapy at  
24 Months 
 
37 
Medication Management at 
24 Months 
 
Combination Therapy at  
36 Months 
 
40 
Medication Management at 
36 Months 
 
Combination Therapy at  
48 Months 
 
14 
Medication Management at 
48 Months 
 
Combination Therapy at  
60 Months 
 
44 
Medication Management at 
60 Months 
 
Combination Therapy at  
72 Months 
 
41 
Medication Management at 
72 Months 
 
Combination Therapy at  
84 Months 
 
21 
Medication Management at 
84 Months 
 
Combination Therapy at  
96 Months 
 
27 
Combination Therapy at  
14 Months 
Medication Management at 
24 Months 
 
 
105 
Combination Therapy at  
24 Months 
Medication Management at 
36 Months 
 
 
55 
Combination Therapy at  
36 Months 
Medication Management at 
48 Months 
 
 
69 
Combination Therapy at  
48 Months 
Medication Management at 
60 Months 
 
 
27 
Combination Therapy at  
60 Months 
Medication Management at 
72 Months 
 
 
20 
Combination Therapy at  
72 Months 
Medication Management at 
84 Months 
 
 
17 
Combination Therapy at  
84 Months 
Medication Management at 
96 Months 
 
38 
181 
 
Appendix B: Missing Data and Multiple Imputation Equations 
 
 This appendix presents tables detailing patient dropout over time (Table B1), the 
extent of missing data by variable (Table B2), statistically significant differences in 
demographic variables among missing and non-missing values of ADHD severity, 
comorbidity status, compliance with medication management, and compliance with 
combination therapy (Table B3), as well as the specific imputation equations used in the 
multiple imputation procedure. 
 
 
Table B1: Number of Patient Dropouts over Time by Treatment Arm 
Dropout at: Medication Management  Combination Therapy 
 
24 Months 
 
12 
 
6 
 
36 Months 
 
23 
 
6 
 
48 Months 
 
11 
 
2 
 
60 Months 
 
4 
 
1 
 
72 Months 
 
5 
 
0 
 
84 Months 
 
16 
 
2 
 
96 Months 
 
6 
 
1 
  
 
 
 
182 
 
Table B2:  Missing Data over Time 
Variable/Time Point Medication Management 
% Missing 
Combination Therapy 
% Missing 
Medication Compliance 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
 
   0.00% 
12.3 
21.1 
24.9 
30.0 
39.1 
47.6 
51.9 
 
 
 
   0.00% 
1.70 
1.85 
6.38 
0.00 
0.00 
2.70 
1.64 
Behavioral Therapy Compliance 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
 
 
 
   0.00% 
1.67 
1.85 
4.26 
0.00 
0.00 
0.00 
0.00 
 
Psychiatric Hospitalizations 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
 
   0.00% 
10.2 
20.8 
24.1 
28.2 
33.7 
44.3 
47.3 
 
 
 
   0.00% 
1.67 
0.93 
4.26 
0.00 
0.00 
0.00 
0.00 
Treatment Response 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
   0.00% 
17.8 
26.2 
  n/a 
  n/a 
40.0 
  n/a 
58.8 
 
 
                          0.00% 
9.17 
6.48 
  n/a 
  n/a 
1.25 
  n/a 
11.5 
n/a = Not Applicable Because Data Were Not Collected During the Interval; % = Percent 
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Table B2 Cont’d:  Missing Data over Time 
Variable/Time Point Medication Management 
% Missing 
Combination Therapy 
% Missing 
ADHD Severity 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
 
   0.00%            
12.3 
21.1 
24.9 
30.0 
39.1 
47.6 
51.9 
 
 
 
   0.00% 
1.70 
1.85 
6.38 
0.00 
0.00 
2.70 
1.64 
Comorbidity Status 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
 
   12.5% 
13.2 
25.6 
  n/a 
  n/a 
40.8 
  n/a 
58.8 
 
 
  7.60% 
8.33 
4.60 
  n/a 
  n/a 
2.50 
  n/a 
14.8 
Juvenile Justice Use 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
 
   90.3% 
91.7 
54.8 
30.4 
28.2 
33.7 
44.7 
51.9 
 
 
   90.0% 
92.5 
51.9 
12.8 
0.00 
0.00 
0.00 
0.00 
Special Education Use 
 
     14 Months 
     24 Months 
     36 Months 
     48 Months 
     60 Months 
     72 Months 
     84 Months 
     96 Months 
 
 
   1.99%         
10.2 
20.8 
  n/a 
  n/a 
33.7 
  n/a 
47.3 
 
 
  1.30% 
1.67 
0.93 
  n/a 
  n/a 
0.00 
  n/a 
0.00 
n/a = Not Applicable Because Data Were Not Collected During the Interval; % = Percent 
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Table B3: Significant Differences between Missing and Non-Missing     
     Patients as a Function of Demographic Variables 
Time Point 
  
Severity 
Sig 
Severity 
Not Sig 
Comorbidity 
Sig 
Comorbidity 
Not Sig 
 
24 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
* 
* 
* 
* 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
* 
* 
* 
* 
 
36 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
 
 
 
* 
 
 
 
 
 
 
* 
* 
* 
 
* 
* 
 
 
 
 
 
 
* 
 
 
 
 
 
* 
* 
* 
 
* 
* 
 
72 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
* 
* 
 
* 
 
* 
 
 
 
 
 
* 
 
* 
 
 
 
 
* 
* 
* 
* 
 
 
 
 
 
 
 
 
 
* 
* 
 
96 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
* 
* 
* 
 
 
* 
 
 
 
 
 
 
* 
* 
 
 
 
 
* 
 
* 
 
* 
 
 
 
 
 
* 
 
* 
 
* 
Severity = ADHD Severity; Comorbidity = Comorbidity Status; Sig = Statistically         
Significant Differences among Missing vs. Non-Missing Patients; Not Sig = No                                       
Statistically Significant Differences; Mom Ed = Mother’s Educational Level 
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Table B3 Cont’d: Significant Differences between Missing and Non-Missing    
  Values as a Function of Demographic Variables 
Time Point 
  
Compliance 
Meds 
Sig 
Compliance  
Meds 
Not Sig 
Compliance  
Combo 
Sig 
Compliance 
Combo 
Not Sig 
 
24 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
 
 
* 
 
* 
 
 
 
 
* 
* 
 
* 
 
* 
 
 
 
 
 
* 
 
* 
 
 
 
 
* 
* 
 
* 
 
* 
 
36 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
 
 
 
* 
 
* 
 
 
 
 
* 
* 
* 
 
* 
 
 
 
 
 
 
 
* 
 
 
 
 
 
* 
* 
* 
 
* 
* 
 
48 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
 
* 
 
 
* 
* 
 
 
 
* 
 
* 
* 
 
 
 
 
 
 
* 
 
 
* 
* 
 
 
 
* 
 
* 
* 
 
 
 
60 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
* 
* 
 
 
 
* 
 
 
 
 
 
* 
* 
* 
 
 
 
 
* 
 
 
* 
 
* 
 
 
 
 
* 
* 
 
* 
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72 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
* 
 
 
* 
* 
 
 
* 
 
* 
* 
 
 
 
* 
* 
 
* 
 
* 
 
 
 
 
* 
 
* 
 
84 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
* 
* 
 
 
* 
* 
 
 
 
 
 
* 
* 
 
 
 
 
 
* 
* 
* 
* 
 
* 
 
 
 
 
 
 
 
* 
 
 
96 Months 
 
   Gender 
   Race 
   Grade 
   City Size 
   Mom Ed 
   Income 
 
 
 
 
* 
* 
* 
* 
* 
* 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
* 
* 
 
* 
 
 
 
 
 
 
 
* 
 
Sig = Statistically Significant Differences Among Missing vs. Non-Missing Patients;                                                                             
Not Sig = No Statistically Significant Differences; Meds = Medication Management;                                                                        
Combo = Combination Therapy; Mom Ed = Mother’s Education 
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Multiple Imputation Equations 
 
 The multiple imputation equations used to predict missing values for each 
parameter are located below. The numbered subscripts refer to the time period during 
which the variable was measured.    
 
Response = Ordinary Least Squares Regression 
Response24 = b(gender) + b(compliance) + b(comorbidity) + b(severity) +b(Response14) 
Response36 = b(gender) + b(compliance) + b(comorbidity) + b(severity) +b(Response24) 
Response48 = b(gender) + b(compliance) + b(comorbidity) + b(severity) +b(Response36) 
Response60 = b(gender) + b(compliance) + b(comorbidity) + b(severity) +b(Response48) 
Response72 = b(gender) + b(compliance) + b(comorbidity) + b(severity) +b(Response60) 
Response84 = b(gender) + b(compliance) + b(comorbidity) + b(severity) +b(Response72) 
Response96 = b(gender) + b(compliance) + b(comorbidity) + b(severity) +b(Response84) 
 
Comorbidity = Multinomial Logistic Regression 
Comorbidity24 = b(Comorbidity14) 
Comorbidity36 = b(Comorbidity24) 
Comorbidity48 = b(Comorbidity36) 
Comorbidity60 = b(Comorbidity48) 
Comorbidity72 = b(Comorbidity60) 
Comorbidity84 = b(Comorbidity72) 
Comorbidity96 = b(Comorbidity84) 
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Severity = Ordinary Least Squares Regression 
Severity 24 = b(gender) + b(compliance) + b(comorbidity) + b(Severity14) 
Severity 36 = b(gender) + b(compliance) + b(comorbidity) + b(Severity24) 
Severity 48 = b(gender) + b(compliance) + b(comorbidity) + b(Severity36) 
Severity 60 = b(gender) + b(compliance) + b(comorbidity) + b(Severity48) 
Severity 72 = b(gender) + b(compliance) + b(comorbidity) + b(Severity60) 
Severity 84 = b(gender) + b(compliance) + b(comorbidity) + b(Severity72) 
Severity 96 = b(gender) + b(compliance) + b(comorbidity) + b(Severity84) 
 
Medication Compliance = Ordinary Least Squares Regression 
Medication Compliance24 = b(gender) + b(Medication Compliance14) 
Medication Compliance36 = b(gender) + b(Medication Compliance24) 
Medication Compliance48 = b(gender) + b(Medication Compliance36) 
Medication Compliance60 = b(gender) + b(Medication Compliance48) 
Medication Compliance72 = b(gender) + b(Medication Compliance60) 
Medication Compliance84 = b(gender) + b(Medication Compliance72) 
Medication Compliance96 = b(gender) + b(Medication Compliance84) 
 
Behavioral Therapy Compliance = Ordinary Least Squares Regression 
Behavioral Therapy Compliance24 = b(gender) + b(Behavioral Therapy Compliance14) 
Behavioral Therapy Compliance36 = b(gender) + b(Behavioral Therapy Compliance24) 
Behavioral Therapy Compliance48 = b(gender) + b(Behavioral Therapy Compliance36) 
Behavioral Therapy Compliance60 = b(gender) + b(Behavioral Therapy Compliance48) 
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Behavioral Therapy Compliance72 = b(gender) + b(Behavioral Therapy Compliance60) 
Behavioral Therapy Compliance84 = b(gender) + b(Behavioral Therapy Compliance72) 
Behavioral Therapy Compliance96 = b(gender) + b(Behavioral Therapy Compliance84) 
 
Special Education Use = Logistic Regression 
Special Education14 = b(gender) + b(comorbidity) 
Special Education24 = b(gender) + b(comorbidity) + b(Special Education14) 
Special Education36 = b(gender) + b(comorbidity) + b(Special Education24) 
Special Education48 = b(gender) + b(comorbidity) + b(Special Education36) 
Special Education60 = b(gender) + b(comorbidity) + b(Special Education48) 
Special Education72 = b(gender) + b(comorbidity) + b(Special Education60) 
Special Education84 = b(gender) + b(comorbidity) + b(Special Education72) 
Special Education96 = b(gender) + b(comorbidity) + b(Special Education84) 
 
Juvenile Justice = Logistic Regression 
Juvenile Justice14 = b(gender) + b(severity) + b(comorbidity)  
Juvenile Justice24 = b(gender) + b(severity) + b(comorbidity) + b(Juvenile Justice14) 
Juvenile Justice36= b(gender) + b(severity) + b(comorbidity) + b(Juvenile Justice24) 
Juvenile Justice48 = b(gender) + b(severity) + b(comorbidity) + b(Juvenile Justice36) 
Juvenile Justice60 = b(gender) + b(severity) + b(comorbidity) + b(Juvenile Justice48) 
Juvenile Justice72 = b(gender) + b(severity) + b(comorbidity) + b(Juvenile Justice60) 
Juvenile Justice84 = b(gender) + b(severity) + b(comorbidity) + b(Juvenile Justice72) 
Juvenile Justice96 = b(gender) + b(severity) + b(comorbidity) + b(Juvenile Justice84) 
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Psychiatric Hospitalizations = Logistic Regression 
Psychiatric Hospitalization14 = b(gender) + b(severity) + b(response) + b(comorbidity) 
Psychiatric Hospitalization24 = b(gender) + b(severity) + b(response) + b(comorbidity) + 
b(Psychiatric Hospitalization14) 
Psychiatric Hospitalization36 = b(gender) + b(severity) + b(response) + b(comorbidity) + 
b(Psychiatric Hospitalization24) 
Psychiatric Hospitalization48 = b(gender) + b(severity) + b(response) + b(comorbidity) + 
b(Psychiatric Hospitalization36) 
Psychiatric Hospitalization60 = b(gender) + b(severity) + b(response) + b(comorbidity) + 
b(Psychiatric Hospitalization48) 
Psychiatric Hospitalization72 = b(gender) + b(severity) + b(response) + b(comorbidity) + 
b(Psychiatric Hospitalization60) 
Psychiatric Hospitalization84 = b(gender) + b(severity) + b(response) + b(comorbidity) + 
b(Psychiatric Hospitalization72) 
Psychiatric Hospitalization96 = b(gender) + b(severity) + b(response) + b(comorbidity) + 
b(Psychiatric Hospitalization84) 
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Appendix C: Testing Distributional Assumptions 
 
 Cost-effectiveness analyses that employ probabilistic sensitivity analyses assume a 
distributional form (e.g., uniform, normal, triangular) for each estimated parameter. These 
distributions represent the uncertainty around a given parameter estimate. The data for 
each parameter can be tested for normality, the preferred distributional assumption. I 
plotted each variable against a standardized normal probability plot in STATA™ (STATA 
Corp, 2007). Only three variables fit a normal distribution: response (Figure C1), severity 
(Figure C2), and compliance (Figure C3). The closer the plotted line is to the main diagonal, 
the more it truly represents normality. Below are the plots for treatment response, ADHD 
severity, and treatment compliance. 
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Figure C1: Standardized Normal Probability Plot: Treatment Response 
 
Normal F[(snadhdx-m)/s] = Ordered Swanson, Nolan, and Pelham-IV Scores; Empirical P[i]=i/(N+1) = Normal            
Order Statistic Means 
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Figure C2: Standardized Normal Probability Plot: ADHD Severity 
 
Normal F[(cisp13t-m)/s] = Ordered Columbia Impairment Scale Scores; Empirical P[i]=i/(N+1) = Normal  
Order Statistic Means 
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Figure C3: Standardized Normal Probability Plot: Treatment Compliance 
 
Normal F[(admedpc-m)/s] = Ordered Medication Use Estimates; Empirical P[i]=i/(N+1) = Normal Order         
Statistic Means 
 
 
The plots of response to treatment and ADHD severity are quite normally 
distributed, and the treatment compliance graph follows the same trend, departing only 
slightly from the main diagonal.  However, the remaining variables either departed greatly 
from the normal distribution or were estimates found in the literature. One preferred 
distribution in cases like these is the triangular distribution. In the triangular distribution, 
the lowest and highest values are given a probability of zero, and the middle value is 
assigned the highest probability (Muennig, p.146). Use of the triangular distribution 
indicates that I am unsure about what the actual distribution looks like, so the low and high 
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values should be sampled infrequently. This subjective distribution is of use when limited 
data exist – it is based on the minimum and maximum, and an “inspired guess” of the modal 
value (Hesse 2000).  Despite the unpretentiousness of the triangular distribution, simulation 
will cause the ICERs to be normally distributed (Muennig, p.146). 
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Appendix D: State Transitions 
                 
           This appendix presents the mean probabilities and standard deviations of ADHD 
severity (Tables D1 and D2) and treatment compliance (Tables D3 and D4) state transitions 
for each treatment over time.   
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  Table D1:  Combination Therapy Severity Transitions 
Index Time Point 
Index Severity Level 
Probability (SD) of  
Severe ADHD at: 
 
14 Months 
 
     Severe 
     Not Severe 
 
24 Months 
 
0.66 (0.48) 
0.38 (0.50) 
 
24 Months 
 
     Severe 
     Not Severe  
 
36 Months 
 
0.73 (0.45) 
0.50 (0.51) 
 
36 Months 
 
     Severe 
     Not Severe 
 
48 Months 
 
0.50 (0.52) 
0.56 (0.53) 
 
48 Months 
 
     Severe 
     Not Severe 
 
60 Months 
 
0.56 (0.53) 
0.56 (0.53) 
 
60 Months 
 
     Severe 
     Not Severe 
 
72 Months 
 
0.56 (0.51) 
0.79 (0.43) 
 
72 Months 
 
     Severe 
     Not Severe 
 
84 Months 
 
0.68 (0.47) 
0.63 (0.50) 
 
84 Months 
 
     Severe 
     Not Severe 
 
96 Months 
 
0.68 (0.48) 
0.63 (0.50) 
  SD = Standard Deviation 
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                                      Table D2:  Medication Management Severity Transitions 
Index Time Point 
Index Severity Level 
Probability (SD) of  
Severe ADHD at: 
 
14 Months 
 
     Severe 
     Not Severe 
 
24 Months 
 
0.49 (0.50) 
0.28 (0.45) 
 
24 Months 
 
     Severe 
     Not Severe  
 
36 Months 
 
0.67 (0.47) 
0.33 (0.47) 
 
36 Months 
 
     Severe 
     Not Severe 
 
48 Months 
 
0.59 (0.49) 
0.51 (0.50) 
 
48 Months 
 
     Severe 
     Not Severe 
 
60 Months 
 
0.53 (0.50) 
0.46 (0.50) 
 
60 Months 
 
     Severe 
     Not Severe 
 
72 Months 
 
0.47 (0.50) 
0.35 (0.48) 
 
72 Months 
 
     Severe 
     Not Severe 
 
84 Months 
 
0.50 (0.50) 
0.46 (0.50) 
 
84 Months 
 
     Severe 
     Not Severe 
 
96 Months 
 
0.46 (0.50) 
0.52 (0.50) 
  SD = Standard Deviation  
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                                      Table D3:  Combination Therapy Compliance Transitions 
Index Time Point 
Index Compliance State 
Probability (SD) of  
Compliance at: 
 
14 Months 
 
     Compliant 
     Not Compliant 
 
24 Months 
 
0.37 (0.50) 
0.46 (0.51) 
 
24 Months 
 
     Compliant 
     Not Compliant 
 
36 Months 
 
0.74 (0.45) 
0.39 (0.50) 
 
36 Months 
 
     Compliant 
     Not Compliant 
 
48 Months 
 
0.80 (0.41) 
0.20 (0.42) 
 
48 Months 
 
     Compliant 
     Not Compliant 
 
60 Months 
 
0.25 (0.46) 
0.33 (0.52) 
 
60 Months 
 
     Compliant 
     Not Compliant 
 
72 Months 
 
0.55 (0.52) 
0.29 (0.46) 
 
72 Months 
 
     Compliant 
     Not Compliant 
 
84 Months 
 
0.61 (0.50) 
0.41 (0.50) 
 
84 Months 
 
     Compliant 
     Not Compliant 
 
96 Months 
 
0.50 (0.52) 
0.11 (0.33) 
  SD = Standard Deviation 
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                                      Table D4:  Medication Management Compliance Transitions 
Index Time Point 
Index Severity Level 
Probability (SD) of  
Severe ADHD at: 
 
14 Months 
 
     Compliant 
     Not Compliant 
 
24 Months 
 
0.50 (0.50) 
0.47 (0.50) 
 
24 Months 
 
     Compliant 
     Not Compliant 
 
36 Months 
 
0.71 (0.46) 
0.46 (0.50) 
 
36 Months 
 
     Compliant 
     Not Compliant 
 
48 Months 
 
0.66 (0.48) 
0.39 (0.49) 
 
48 Months 
 
     Compliant 
     Not Compliant 
 
60 Months 
 
0.73 (0.45) 
0.36 (0.48) 
 
60 Months 
 
     Compliant 
     Not Compliant 
 
72 Months 
 
0.61 (0.49) 
0.39 (0.49) 
 
72 Months 
 
     Compliant 
     Not Compliant 
 
84 Months 
 
0.51 (0.50) 
0.22 (0.41) 
 
84 Months 
 
     Compliant 
     Not Compliant 
 
96 Months 
 
0.61 (0.49) 
0.26 (0.44) 
  SD = Standard Deviation 
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Appendix E: Unadjusted Response Rates and Regression Output 
 
 This appendix presents the unadjusted response rates for patients on medication 
management and combination therapy over time (Tables E1 and E2, respectively), as well as 
the statistical output from the mixed effect logistic regression models of response to 
medication management (Tables E3 to E10) and combination therapy (Tables E11 to E18) 
over each time point.  
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Table E1:  Medication Management Unadjusted Response Rates Over Time 
Group Number 14 Mo 24 Mo 36 Mo 48 Mo 60 Mo 72 Mo 84 Mo 96 Mo 
 
Girls 
1 0.67 0.30 0.33 0.14 0.13 0.00 0.25 0.00 
2 0.81 0.00 0.27 0.00 0.17 0.13 0.08 0.06 
3 0.00 0.53 0.81 0.00 0.53 0.59 0.00 0.00 
4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
5 0.67 0.50 1.00 1.00 0.50 0.00 1.00 0.50 
6 1.00 0.00 1.00 0.33 0.00 0.00 0.33 0.06 
7 0.50 0.00 0.33 1.00 0.25 0.00 0.00 0.00 
8 0.20 0.00 0.00 0.11 0.00 0.00 0.00 1.00 
9 0.67 0.50 0.50 1.00 0.00 0.00 0.00 0.50 
10 0.81 0.00 0.27 0.50 0.00 0.50 0.00 0.06 
11 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17 
12 0.00 0.25 0.50 0.00 0.00 0.00 0.00 1.00 
13 0.67 0.74 0.40 0.40 0.50 0.60 0.67 0.50 
14 0.79 0.57 0.79 0.50 0.63 0.67 0.83 0.67 
15 0.50 0.00 0.29 0.33 0.20 0.20 0.25 0.00 
16 1.00 0.67 0.67 0.29 0.29 0.00 0.50 0.40 
 
Boys 
17 0.11 1.00 0.00 0.17 0.00 0.00 0.00 0.00 
18 0.14 0.50 0.33 0.22 0.25 0.00 0.60 0.00 
19 0.00 0.11 0.14 0.00 0.00 0.10 0.00 0.33 
20 0.29 0.17 0.10 0.00 0.00 0.00 0.00 0.00 
21 0.50 0.50 0.57 0.50 0.60 0.75 0.43 0.00 
22 0.73 0.63 0.50 0.63 0.75 0.13 0.40 0.40 
23 0.00 0.00 0.25 0.20 0.19 0.25 0.36 0.00 
24 0.38 0.30 0.19 0.23 0.38 0.33 0.22 0.00 
25 1.00 0.00 0.00 0.38 0.00 0.00 0.33 0.33 
26 0.00 0.40 0.75 0.50 0.74 0.50 0.00 0.00 
27 0.00 0.20 0.00 0.13 0.08 0.10 0.10 0.17 
28 0.13 0.10 0.17 0.12 0.21 0.19 0.00 0.29 
29 0.83 0.66 0.65 0.47 0.53 0.59 0.57 0.65 
30 0.76 0.72 0.68 0.64 0.58 0.57 0.58 0.62 
31 0.00 0.34 0.22 0.34 0.12 0.14 0.30 0.35 
32 0.33 0.30 0.41 0.31 0.19 0.35 0.08 0.13 
         
Total 0.55 0.48 0.44 0.34 0.35 0.38 0.37 0.37 
Group Number = Refers to Table 14 in Chapter 3; Mo = Months 
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Table E2:  Combination Therapy Unadjusted Response Rates Over Time 
Group Number 14 Mo 24 Mo 36 Mo 48 Mo 60 Mo 72 Mo 84 Mo 96 Mo 
 
Girls 
1 0.86 0.67 0.25 0.00 0.75 0.33 0.00 0.25 
2 1.00 0.38 0.09 0.00 0.00 0.17 0.00 0.13 
3 0.85 0.00 0.25 0.50 0.00 0.00 0.50 0.00 
4 0.00 0.00 0.50 0.00 1.00 0.00 0.00 0.60 
5 0.86 0.67 0.00 0.00 0.75 0.33 0.00 0.25 
6 0.00 0.38 0.00 0.00 0.00 0.17 0.00 0.13 
7 1.00 1.00 0.00 0.50 0.00 0.50 0.50 0.00 
8 1.00 1.00 0.00 0.67 0.50 0.00 1.00 0.00 
9 0.86 0.67 0.25 0.00 0.75 0.33 1.00 1.00 
10 0.17 0.38 0.00 1.00 0.00 0.16 0.00 0.13 
11 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.33 
12 0.60 1.00 0.67 0.67 0.00 1.00 1.00 0.60 
13 0.60 1.00 1.00 0.67 0.50 1.00 1.00 0.50 
14 1.00 0.80 0.50 0.00 0.00 0.50 1.00 0.13 
15 0.00 0.67 0.00 0.00 0.00 0.50 0.00 0.00 
16 1.00 1.00 0.21 0.67 1.00 0.00 1.00 0.33 
 
Boys 
17 0.47 0.00 0.20 0.25 0.00 0.19 0.50 0.00 
18 1.00 0.16 0.00 0.14 0.13 0.26 0.00 0.10 
19 0.00 0.10 0.20 0.00 0.00 0.14 1.00 0.00 
20 0.33 0.00 0.00 0.00 0.00 0.33 0.00 0.00 
21 0.33 1.00 0.67 0.33 1.00 0.00 0.22 0.00 
22 1.00 0.50 0.20 0.14 0.13 0.00 0.00 0.50 
23 0.00 0.13 0.00 0.00 0.67 0.00 0.00 0.00 
24 0.50 0.00 0.00 0.25 0.00 0.36 0.50 0.00 
25 0.00 0.00 0.00 1.00 0.00 0.00 0.22 1.00 
26 1.00 0.00 0.20 0.14 0.50 0.00 0.22 0.10 
27 0.00 0.00 0.20 0.00 0.00 0.40 0.00 0.00 
28 0.00 0.17 0.20 0.00 0.00 0.13 0.50 0.00 
29 0.53 0.50 0.56 0.80 0.45 0.45 0.78 0.78 
30 0.72 0.25 0.64 0.60 1.00 0.67 0.88 0.50 
31 0.38 0.43 0.25 0.50 0.20 0.25 0.44 0.22 
32 0.60 0.17 0.25 0.00 0.00 0.20 0.00 0.33 
         
Total 0.54 0.32 0.33 0.33 0.32 0.28 0.40 0.31 
Group Number = Refers to Table 14 in Chapter 3; Mo = Months 
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Table E3:  Mixed Effects Logistic Regression – Medication Management at 14 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.10 0.14 0.69 0.49 
 
Large City 0.23 0.25 0.89 0.37 
 
Mom – HS -0.26 0.22 -1.21 0.23 
 
Income -0.09 0.11 -0.88 0.38 
 
Age at Baseline -0.29 0.28 -1.04 0.30 
 
Current Home 0.05 0.25 0.20 0.84 
 
_Constant 2.42 2.54 0.95 0.34 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 1.64 0.58 0.83  - 3.27 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E4:  Mixed Effects Logistic Regression – Medication Management at 24 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.04 0.07 0.52 0.60 
 
Large City -0.01 0.14 -0.07 0.94 
 
Mom – HS -0.12 0.13 -0.96 0.34 
 
Income 0.00 0.06 0.00 1.00 
 
Age at Baseline -0.12 0.16 -0.77 0.44 
 
Current Home 0.10 0.13 0.76 0.45 
 
_Constant 0.42 1.44 0.29 0.77 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 0.92 0.25 0.53  - 1.57 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E5:  Mixed Effects Logistic Regression -- Medication Management at 36 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity -0.01 0.07 -0.20 0.84 
 
Large City -0.18 0.14 -1.26 0.21 
 
Mom – HS 0.00 0.13 -0.03 0.98 
 
Income 0.09 0.07 1.42 0.16 
 
Age at Baseline -0.49 0.17 -2.93 0.00 
 
Current Home -0.14 0.13 -1.05 0.30 
 
_Constant 3.72 1.52 2.44 0.02 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 1.06 0.27 0.65  - 1.75 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E6:  Mixed Effects Logistic Regression -- Medication Management at 48 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity -0.03 0.07 -0.40 0.69 
 
Large City 0.15 0.14 1.12 0.26 
 
Mom – HS 0.02 0.12 0.17 0.87 
 
Income -0.01 0.06 -0.24 0.81 
 
Age at Baseline 0.04 0.16 0.22 0.82 
 
Current Home 0.05 0.13 0.42 0.67 
 
_Constant -1.64 1.41 -1.16 0.25 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 0.83 0.24 0.47  - 1.45 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E7:  Mixed Effects Logistic Regression -- Medication Management at 60 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.10 0.07 1.37 0.17 
 
Large City -0.09 0.16 -0.57 0.57 
 
Mom – HS 0.01 0.13 0.07 0.94 
 
Income 0.07 0.07 1.07 0.28 
 
Age at Baseline -0.06 0.17 -0.34 0.73 
 
Current Home 0.01 0.14 0.06 0.95 
 
_Constant -1.16 1.57 -0.74 0.46 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 0.96 0.28 0.55  - 1.69 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E8:  Mixed Effects Logistic Regression -- Medication Management at 72 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.17 0.07 2.31 0.02 
 
Large City 0.04 0.17 0.24 0.81 
 
Mom – HS -0.22 0.15 -1.48 0.14 
 
Income 0.19 0.08 2.50 0.01 
 
Age at Baseline 0.06 0.18 0.32 0.75 
 
Current Home -0.29 0.15 -1.92 0.05 
 
_Constant -0.90 1.69 -0.53 0.59 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 1.06 0.31 0.59  - 1.89 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E9:  Mixed Effects Logistic Regression -- Medication Management at 84 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.00 0.08 0.06 0.95 
 
Large City -0.08 0.17 -0.47 0.64 
 
Mom – HS -0.02 0.15 -0.16 0.87 
 
Income 0.09 0.07 1.23 0.22 
 
Age at Baseline -0.07 0.19 -0.39 0.70 
 
Current Home -0.07 0.14 -0.48 0.63 
 
_Constant -0.52 1.73 -0.30 0.76 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 1.13 0.34 0.63  - 2.04 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E10:  Mixed Effects Logistic Regression -- Medication Management at 96 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.00 0.08 -0.06 0.95 
 
Large City 0.09 0.18 0.53 0.59 
 
Mom – HS -0.12 0.15 -0.77 0.44 
 
Income 0.08 0.07 1.06 0.29 
 
Age at Baseline -0.18 0.19 -0.90 0.37 
 
Current Home 0.13 0.15 0.83 0.41 
 
_Constant -0.29 1.83 -0.16 0.87 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 0.98 0.32 0.52  - 1.86 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E11:  Mixed Effects Logistic Regression -- Combination Therapy at 14 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.02 0.12 0.15 0.88 
 
Large City 0.13 0.24 0.56 0.57 
 
Mom – HS -0.29 0.25 -1.18 0.24 
 
Income 0.16 0.10 1.54 0.12 
 
Age at Baseline -0.39 0.28 -1.42 0.16 
 
Current Home -0.06 0.19 -0.32 0.75 
 
_Constant 3.13 2.52 1.24 0.22 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 2.10 0.83 0.97   -  4.57 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E12:  Mixed Effects Logistic Regression – Combination Therapy at 24 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity -0.46 0.22 -2.13 0.03 
 
Large City -1.09 0.45 -2.41 0.02 
 
Mom – HS 0.22 0.30 0.73 0.47 
 
Income 0.07 0.13 0.52 0.60 
 
Age at Baseline 0.29 0.36 0.81 0.42 
 
Current Home -0.39 0.28 -1.40 0.16 
 
_Constant -0.55 3.28 -0.17 0.87 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 2.04 0.71 1.03   - 4.04 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E13:  Mixed Effects Logistic Regression -- Combination Therapy at 36 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity -0.21 0.18 -1.13 0.26 
 
Large City 0.37 0.29 1.28 0.20 
 
Mom – HS 0.14 0.27 0.52 0.60 
 
Income -0.05 0.12 -0.42 0.67 
 
Age at Baseline 0.27 0.28 0.98 0.33 
 
Current Home -0.03 0.22 -0.12 0.90 
 
_Constant -3.68 2.47 -1.49 0.14 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 0.77 0.40 0.28  - 2.14 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E14:  Mixed Effects Logistic Regression -- Combination Therapy at 48 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.63 0.57 1.11 0.27 
 
Large City 2.76 1.97 1.40 0.16 
 
Mom – HS -1.26 1.14 -1.11 0.27 
 
Income -0.46 0.43 -1.07 0.29 
 
Age at Baseline -3.96 3.18 -1.24 0.21 
 
Current Home -0.01 1.02 -0.01 0.99 
 
_Constant 30.24 24.02 1.26 0.21 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 4.46 3.13 1.13  - 17.7 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E15:  Mixed Effects Logistic Regression -- Combination Therapy at 60 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.13 0.22 0.57 0.57 
 
Large City 0.25 0.50 0.50 0.62 
 
Mom – HS 1.15 0.57 2.03 0.04 
 
Income -0.16 0.19 -0.82 0.41 
 
Age at Baseline -0.52 0.58 -0.90 0.37 
 
Current Home -0.53 0.64 -0.82 0.41 
 
_Constant -0.36 4.62 -0.08 0.94 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 3.02 1.85 0.91  - 10.1 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E16:  Mixed Effects Logistic Regression -- Combination Therapy at 72 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.44 0.19 2.35 0.02 
 
Large City 0.54 0.39 1.39 0.16 
 
Mom – HS -0.68 0.33 -2.08 0.04 
 
Income 0.36 0.14 2.51 0.01 
 
Age at Baseline 0.77 0.42 1.84 0.07 
 
Current Home -0.18 0.33 -0.55 0.58 
 
_Constant -7.09 3.82 -1.86 0.06 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 1.14 0.62 0.24  - 2.10 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Table E17:  Mixed Effects Logistic Regression -- Combination Therapy at 84 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.55 0.40 1.36 0.17 
 
Large City 0.25 0.54 0.46 0.65 
 
Mom – HS 0.37 0.46 0.80 0.43 
 
Income -0.13 0.22 -0.60 0.55 
 
Age at Baseline -0.94 0.58 -1.63 0.10 
 
Current Home -0.31 0.43 -0.72 0.47 
 
_Constant 5.31 4.72 1.13 0.26 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 2.59 1.09 1.13  - 5.93 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
 
 
 
 
 
 
 
 
 
 
219 
 
 
Table E18:  Mixed Effects Logistic Regression -- Combination Therapy at 96 Months 
Responder Coefficient Standard Error Z P > |Z| 
 
Ethnicity 0.55 0.33 1.64 0.10 
 
Large City 0.75 0.53 1.39 0.16 
 
Mom – HS -0.57 0.50 -1.14 0.25 
 
Income 0.11 0.16 0.70 0.48 
 
Age at Baseline -0.91 0.65 -1.40 0.16 
 
Current Home 0.77 0.51 1.53 0.13 
 
_Constant 2.10 4.73 0.44 0.66 
     
     
Random Effects Parameter Estimate Standard Error 95% CI 
 
Group 1.33 0.84 0.38  - 4.62 
     
Large City = Population of at least 100,000; Mom – HS = Mother With at Least a High School                                                                 
Education; Current Home = Type of Residence (i.e. Home, Townhouse, Trailer, etc.); Z = Z-Score                                                                 
P = P-Value; CI = Confidence Interval; Group = Clustered Variable -- a Function of Gender,                 
Comorbidity, ADHD Severity, and Compliance to Treatment 
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Appendix F: Inflating/Deflating Costs 
 
 Costs obtained from datasets and/or the literature often requires some adjustment 
before they can be included in a cost-effectiveness study. Because the MTA provides several 
of the cost parameters, I decided to convert all cost estimates to 2000 dollars. When newer 
cost data were found, they overestimated the cost of care (or providing non-medical 
services), making it necessary to deflate the estimates to 2000 dollars.    
 
Costs of Clinician Time – Medication Visits 
 The costs of care by a psychiatrist were calculated using psychiatrists’ hourly wage 
based on their respective annual salaries. The Bureau of Labor Statistics (BLS) provided the 
salary information in 2000 dollars (Bureau of Labor Statistics). The national mean annual 
salary for psychiatrists in 2000 was $108,060, and assuming 52 40-hour work weeks, their 
hourly salary was $52, with a relative standard error (RSE) of $0.022. To create the 95 
percent confidence interval for hourly wage, the calculation was as follows: 
&
 '
 ( 1.96 - .&
 '
 - !/ 0 
The resulting 95 percent confidence interval for psychiatrists’ wage was $50 to $54.   
The latest year of BLS data is 2009, and psychiatrists’ average annual salary was 
$163,660 – or 51 percent higher than in 2000. The average hourly wage was $79 with an 
RSE of $0.016, yielding a 95 percent confidence interval of $76 to $81 per hour. Inflation 
over the past 10 years has drastically increased the compensation of psychiatrists – and 
psychiatrist time is one of the largest components of treatment costs, especially for patients 
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on combination therapy. The first 14 months of combination therapy is by far the most 
costly treatment period for either treatment arm. Because of the high rate of psychiatrist 
salary inflation, the final treatment and total cost ICERs likely overestimate the cost-
effectiveness of combination therapy versus medication management in current terms, 
holding all else constant. 
 
Costs of Teacher Time   
 The costs of teachers’ time were calculated by the MTA Cooperative Group in 2000 
dollars. The BLS estimate of the national annual elementary school teacher’s salary in 2000 
dollars was $41,980, while the 2009 estimate was $53,150 (Bureau of Labor Statistics). 
Inflation has increased teachers’ salaries by approximately 27 percent. Because the cost of 
teachers’ time was a relatively small portion of the first 14 months of combination therapy – 
$265 to $569 for compliers, $0 to $531 for non-compliers – inflation most likely has a 
negligible impact on the final cost-effectiveness relationships. 
 
Costs of Medications 
 The pharmaceutical-specific yearly inflation rates, as well as the inflationary impact 
on medication costs for patients on medication management, over the past decade can be 
found below (Santerre and Neun 2009). Inflation has caused the price of the average 
medication to increase by approximately 41 percent over the past decade. Because, on 
average, patients on medication management took less medication than patients on 
combination therapy (MTA Cooperative Group 1999), medication costs were higher among 
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patients on medication management. The pharmaceutical inflationary impact on the ICERs 
is weaker for patients on combination therapy. Consequently, the ICERs for combination 
therapy versus medication management are slightly overestimated. However, because the 
difference is minimal, the study’s conclusions are most likely robust to pharmaceutical price 
inflation. Table F1 presents the pharmaceutical inflation rates over the past decade, as well 
as how my cost estimates (2000 dollars) would appear in today’s terms.     
 
Table F1:  Yearly Pharmaceutical Inflation Rates over the Past Decade 
Year Medication 
Inflation 
Rate 
Complier 
Low 
Complier 
Mean 
Complier 
High 
Non-
Complier 
Low 
Non-
Complier 
Mean 
Non-
Complier 
High 
 
Baseline 
 
 $0 $669 $1,415 $0 $428 $1,078 
 
2000 3.8% $0 $694 $1,469 $0 $444 $1,119 
 
2001 6.0% $0 $736 $1,557 $0 $471 $1,186 
 
2002 4.8% $0 $771 $1,632 $0 $494 $1,243 
 
2003 2.5% $0 $791 $1,672 $0 $506 $1,274 
 
2004 3.7% $0 $820 $1,734 $0 $525 $1,321 
 
2005 4.1% $0 $854 $1,805 $0 $546 $1,375 
 
2006 2.0% $0 $871 $1,842 $0 $557 $1,403 
 
2007 3.2% $0 $899 $1,900 $0 $575 $1,448 
 
2008 2.1% $0 $917 $1,940 $0 $587 $1,478 
 
2009 
__ 
 $0 $946 $2,001 $0 $605 $1,524 
Low = Lowest (Min) Estimate; Mean = Mean Estimate; High = Highest (Max) Estimate 
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 Costs of Hospitalizations 
 The hospitalization-specific inflation rates, as well as their impact on hospitalization 
costs, are presented in Table F2 (Santerre and Neun 2009). The point estimates of 
hospitalizations suggest that patients on combination therapy are more likely to be 
hospitalized; however, the standard errors indicate no real differences. Therefore, the 
hospitalization-specific inflation rates should impact each treatment arm similarly, with 
little impact on the final ICERs.    
 
Table F2: Hospital-Specific Inflation Rates Over the Past Decade 
Year Hospitalization 
Inflation Rate 
Low Mean High 
 
Baseline 
 
 $700 $1,300 $1,900 
 
2000 6.0% $742 $1,378 $2,014 
 
2001 7.3% $796 $1,478 $2,160 
 
2002 10.0% $875 $1,626 $2,376 
 
2003 6.3% $930 $1,727 $2,525 
 
2004 5.3% $979 $1,818 $2,657 
 
2005 5.2% $1,030 $1,913 $2,795 
 
2006 6.0% $1,092 $2,027 $2,963 
 
2007 8.0% $1,179 $2,189 $3,200 
 
2008 10.0% $1,297 $2,408 $3,520 
 
2009 
 
8.0% $1,401 $2,601 $3,802 
Low = Lowest (Min) Estimate; Mean = Mean Estimate;                                                   
High = Highest (Max) Estimate 
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Costs of Juvenile Justice 
 Unfortunately, I could not find any juvenile justice-specific inflation rates in the 
literature. Therefore, I used the overall inflation rate to deflate my 2005 estimates of the 
costs of arrests to 2000 dollars. In 2005, the costs of arrests ranged from $11 to $935, with 
a mean of $440. The BLS inflation calculator deflated the costs to 2000 dollars:  costs ranged 
from $10 to $824, with a mean of $388. In 2009 dollars, the costs ranged from $12 to 
$1,027, with a mean of $483. The rates of arrests (point estimates) were higher among 
those on combination therapy through 84 months; however, the standard errors indicated 
no real difference between treatment arms. At 96 months, patients on medication 
management were significantly more likely to be arrested (p < 0.05). Because arrest rates 
are so low, and the costs of arrests are rather minimal, I believe the juvenile justice-specific 
inflation rates impact the final ICERs minimally. At most, they slightly overestimate the 
ICERs.   
 
Costs of Special Education 
 The costs of special education were derived from the BLS. Initially, I had special 
education costs in 2005 dollars and deflated the costs to 2000 dollars. To determine the 
costs in 2009 dollars, I used the national mean salary information for special education 
teachers. Using the range of costs for special education found in the literature, as well as 
the BLS estimate of the average annual salary for special education teachers, I calculated 
the percent of the yearly salary used by a special education student (Table F3). To 
determine the costs in 2009 dollars, I applied the percentages to the 2009 BLS estimate of 
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special education teachers’ salaries ($53,770). The range in 2009 dollars was $4,412 to 
$6,842, with a mean of $5,178. The range in 2000 dollars was $3,681 to $5,709, with a 
mean of $4,320. The main limitation of this method is that it does not account for the effect 
of diminishing marginal returns. For instance, if a teacher instructs 20 special education 
students, the salary is not 20 times the cost of special education for one student. Materials, 
overhead, and other costs help to account for the full costs of special education.  
    
Patients on medication management were much more likely to utilize special 
education at 48 months, 60 months, and 84 months, while patients on combination therapy 
were more likely to utilize special education at the remaining time points. However, the 
inflationary impact of the rising costs of special education on the ICERs is difficult to 
determine.     
 
      Table F3: Varying Estimates of the Per-Student Cost of Special 
                        Education as a Percentage of Teachers’ Salaries 
2005 Average Salary – 
Special Education Teacher 
Low 
 
Mean 
 
High 
 
$50,880 
 
$4,175 
 
$4,900 
 
$6,474 
    
Percent of  
Yearly Salary 
 
8% 
 
10% 
 
13% 
Low = Lowest (Min) Estimate; Mean = Mean Estimate; High = Highest               
(Max) Estimate 
 
Costs of Parental Work Absenteeism 
 Finally, because each treatment arm was equally likely to accrue absenteeism costs, 
the inflationary impact of absenteeism on the ICERs should be minimal, if any.   
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Appendix G: Differences in Service Use Among Treatment Arms 
 
 This appendix presents the statistically significant differences in service use between 
patients on medication management and patients on combination therapy (Table G1). 
While the summary statistics may indicate large differences in juvenile justice and 
hospitalizations, these differences are generally not real, and likely the result of small 
sample sizes. 
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Table G1:  Service Utilization Differences between Medication Management and Combination   
Therapy 
Variable Time Point  Mean % Difference (SE) 
 
Special Education Use 
 
14 Months 
24 Months 
36 Months 
48 Months 
60 Months 
72 Months 
84 Months 
96 Months 
 
                   -11.9 (5.32) * 
    -15.7 (5.32) ** 
                   -12.5 (5.42) * 
                     36.2 (7.18) *** 
        43.3 (6.22) *** 
     -16.0 (5.92) ** 
         42.0 (5.64) *** 
      -15.2 (6.17) ** 
 
Percent of the Year in Special 
Education 
 
14 Months 
24 Months 
36 Months 
48 Months 
60 Months 
72 Months 
84 Months 
96 Months 
 
       -10.4 (3.96) ** 
         -14.8 (4.38) *** 
                     4.63 (6.00) 
                     1.89 (4.53) 
                    -3.84 (3.62) 
                    -1.31 (6.34) 
                    -1.67 (2.96) 
                     0.94 (2.59) 
 
Juvenile Justice Use 
 
14 Months 
24 Months 
36 Months 
48 Months 
60 Months 
72 Months 
84 Months 
96 Months 
 
-0.51 (1.91) 
-1.97 (2.01) 
-0.33 (1.48) 
-1.32 (2.23) 
-5.06 (3.32) 
-2.97 (3.48) 
-1.77 (2.52) 
     6.97 (3.99) * 
 
Psychiatric Hospitalizations 
 
14 Months 
24 Months 
36 Months 
48 Months 
60 Months 
72 Months 
84 Months 
96 Months 
 
-0.53 (0.50) 
-0.68 (1.21) 
-0.32 (1.03) 
-6.42 (4.28) 
-3.01 (2.36) 
-1.78 (1.83) 
-2.11 (2.27) 
-2.05 (2.41) 
% Difference = Medication Management – Combination Therapy; SE = Standard Error; Time Point = 
Represents the Interval From the Prior Time Point to the one listed (i.e. 48 Months = Utilization from 36 – 48 
Months); * = p < 0.05; ** = p < 0.01; *** = p < 0.001 
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Appendix H: Sensitivity Analyses 
 
 Sensitivity analyses are methods to explore the uncertainty associated with 
estimated parameters to test the robustness of the analysis results. By building distributions 
around each parameter estimate, SIMIO performs a probabilistic sensitivity analysis, which 
attributes distributions of probabilities and cost estimates to uncertain variables 
incorporated within the model (King et al. 2006). In addition to the probabilistic sensitivity 
analysis, I performed both a one-way sensitivity analysis (varies a parameter individually) 
and an analysis of extremes, which examines both the most pessimistic and optimistic 
scenarios. The next subsections present the results of these analyses.    
 
Definition of Compliance 
 Because different studies often use different definitions of what constitutes 
adherence, estimating treatment compliance can be complicated. Some studies define a 
minimal cutoff point of the percentage of medication taken. Other studies determine 
compliance by the number of days each week that medication was taken as prescribed 
(Adler and Nierenberg 2010). If patients with ADHD do not comply with the medication 
regimen, providers will have trouble determining treatment efficacy.  But the question 
remains: How does one define treatment compliance? 
 I used the compliance measure from the MTA Cooperative Group (1999): 80 percent 
of medications must be taken as prescribed. However, Ibrahim (2002) stated that patients 
who took at least 70 percent of their medication as prescribed had “very high adherence.” 
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Pappadopulos et al. (2009) used an adherence rate cutoff of 50 percent to determine 
compliers. Therefore, patients who might be considered a complier in one study could be 
considered a non-complier in another study. To test the robustness of my study results with 
respect to the compliance definition, I re-ran the model using a 50 percent cutoff for 
treatment compliance.   
 The sensitivity analysis affected response (NALYs), costs, and ICER estimates. By 
expanding my definition of compliance, estimates of response for patients on either 
treatment dropped for almost all gender-comorbidity groups. Boys with externalizing and 
both types of comorbidities on combination therapy were affected the most, dropping 6.9 
percent and 6.6 percent, respectively (Tables H1 and H2). The drop in response rates 
follows logical reason – lower compliance leads to lower rates of response.         
 The total costs of either treatment remained fairly stable, changing by no more than 
2 percent (Tables H3 and H4). I conclude that my model’s cost results are robust to different 
definitions of compliance. However, the ICERs varied substantially with the new definition 
of compliance (Table H5). Boys with internalizing comorbidities varied modestly (6.4 
percent), with medication management continuing to dominate combination therapy. The 
ICER for boys without comorbidity dropped by 665 percent (-$3,951,830 to -$516,317); 
however, medication management continued to dominate. With the operational change in 
compliance, medication management now dominates for boys with externalizing and both 
types of comorbidities. Combination therapy for girls with internalizing and externalizing 
comorbidities is now less cost-effective with the new compliance definition, rising by 
roughly 50 percent; however combination therapy for girls with both types of comorbidities 
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is more cost-effective than before, with the ICER falling by more than 200 percent. Finally, 
combination therapy is no longer dominated for girls without comorbidity, although the 
new ICER is roughly $730,000/NALY. Ultimately, while the ICERs under the new compliance 
definition vary by as much as 665 percent, the conclusions from the sensitivity analysis 
remain the same. Medication management for each gender-comorbidity pair remains more 
cost-effective than combination therapy.     
 
Table H1: Sensitivity Analysis -- NALYs for Combination Therapy 
Patient Type Sensitivity Analysis Initial Analysis Percent Difference 
 
Boys 
  
 
 
 
 
   Internalizing 
 
3.77 
 
3.80 
 
-0.8% 
 
   Externalizing 
 
3.58 
 
3.83 
 
-6.9% 
 
   Both 
 
3.65 
 
3.89 
 
-6.6% 
 
   Neither 
 
3.96 
 
3.98 
 
-0.5% 
 
Girls 
 
 
 
 
 
 
 
   Internalizing 
 
4.01 
 
4.11 
 
-2.5% 
 
   Externalizing 
 
3.80 
 
3.98 
 
-4.6% 
 
   Both 
 
3.89 
 
3.90 
 
-0.1% 
 
   Neither 
 
4.08 
 
4.00 
 
2.0% 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities; NALYs = Normalized                                                     
Adjusted Life Years 
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Table H2: Sensitivity Analysis -- NALYs for Medication Management 
Patient Type Sensitivity Analysis Initial Analysis Percent Difference 
 
Boys 
  
 
 
 
 
   Internalizing 
 
4.32 
 
4.40 
 
-1.8% 
 
   Externalizing 
 
3.63 
 
3.80 
 
-4.7% 
 
   Both 
 
3.77 
 
3.85 
 
-2.2% 
 
   Neither 
 
3.99 
 
3.98 
 
0.3% 
 
Girls 
 
 
 
 
 
 
 
   Internalizing 
 
3.89 
 
3.89 
 
0.1% 
 
   Externalizing 
 
3.75 
 
3.87 
 
-3.3% 
 
   Both 
 
3.73 
 
3.85 
 
-3.3% 
 
   Neither 
 
4.06 
 
4.07 
 
-0.2% 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities; NALYs = Normalized                                                     
Adjusted Life Years 
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Table H3:  Sensitivity Analysis -- Total Costs of Medication Management 
Patient Type Sensitivity Analysis 
Total Costs 
Initial Analysis 
Total Costs 
Percent Difference 
Total Costs 
 
Boys 
  
 
 
 
 
   Internalizing $23,086 $22,657 1.9% 
 
   Externalizing $22,861 $22,964 -0.5% 
 
   Both $22,978 $22,917 0.3% 
 
   Neither $22,979 $22,686 1.3% 
 
Girls 
 
 
 
 
 
 
 
   Internalizing $23,058 $22,689 1.6% 
 
   Externalizing $22,951 $22,911 0.2% 
 
   Both $23,186 $22,963 1.0% 
 
   Neither $23,036 $22,813 1.0% 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities 
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Table H4: Sensitivity Analysis -- Total Costs of Combination Therapy 
Patient Type Sensitivity Analysis 
Total Costs 
Initial Analysis 
Total Costs 
Percent Difference 
Total Costs 
 
Boys 
  
 
 
 
 
   Internalizing $39,409 $39,501 -0.2% 
 
   Externalizing $39,322 $39,574 -0.6% 
 
   Both $39,495 $39,605 -0.3% 
 
   Neither $39,791 $39,891 -0.3% 
 
Girls 
   
 
   Internalizing $39,449 $39,198 0.6% 
 
   Externalizing $40,154 $39,770 1.0% 
 
   Both $39,529 $39,564 -0.1% 
 
   Neither $39,620 $39,239 1.0% 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities 
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Table H5: Sensitivity Analysis – ICERs for Total Costs 
Patient Type Sensitivity Analysis 
ICER – Total Costs 
Initial Analysis 
ICER – Total Costs 
Percent Difference 
ICER – Total Costs 
 
Boys 
  
 
 
 
 
   Internalizing -$29,569 -$27,683 6.4% 
 
   Externalizing -$351,412 $663,223 288.7% 
 
   Both -$139,671 $405,987 390.7% 
 
   Neither -$516,317 -$3,951,830 -665.4% 
 
Girls 
   
 
   Internalizing $144,233 $74,333 48.5% 
 
   Externalizing $298,518 $159,662 46.5% 
 
   Both $96,731 $330,562 -241.7% 
 
   Neither $729,083 -$250,304 134.3% 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities; ICER = Incremental                                                                
Cost-Effectiveness Ratio (Combination Therapy – Medication Management) 
 
Range of ICERs Based on 95 Percent Confidence Intervals of Response and Cost 
 Measures of response and cost were estimated with a 95 percent confidence 
interval. Therefore, I have presented a sensitivity analysis of the ICER based on the low and 
high estimates of both response and cost (Tables H6 to H10). 
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Table H6: Low Estimates of Incremental NALYs 
Patient Type Combination Therapy 
NALYs 
Medication Management 
NALYs 
Incremental 
NALYs 
 
Boys 
  
 
 
 
 
   Internalizing 
 
3.65 
 
4.31 
 
-0.66 
 
   Externalizing 
 
3.72 
 
3.71 
 
0.01 
 
   Both 
 
3.78 
 
3.78 
 
-0.003 
 
   Neither 
 
3.88 
 
3.87 
 
0.01 
    
 
Girls 
 
 
 
 
 
 
 
   Internalizing 
 
3.91 
 
3.80 
 
0.11 
 
   Externalizing 
 
3.91 
 
3.79 
 
0.11 
 
   Both 
 
3.80 
 
3.77 
 
0.03 
 
   Neither 
 
3.91 
 
3.97 
 
-0.06 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities; NALYs = Normalized                                                     
Adjusted Life Years 
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Table H7: High Estimates of Incremental NALYs  
Patient Type Combination Therapy 
NALYs 
Medication Management 
NALYs 
Incremental 
NALYs 
 
Boys 
  
 
 
 
 
   Internalizing 
 
3.98 
 
4.48 
 
-0.50 
 
   Externalizing 
 
3.90 
 
3.90 
 
-0.005 
 
   Both 
 
3.99 
 
3.92 
 
0.07 
 
   Neither 
 
4.09 
 
4.09 
 
-0.002 
    
 
Girls 
  
 
 
 
 
   Internalizing 
 
4.20 
 
3.99 
 
0.21 
 
   Externalizing 
 
4.09 
 
3.95 
 
0.14 
 
   Both 
 
4.01 
 
3.92 
 
0.09 
 
   Neither 
 
4.12 
 
4.16 
 
-0.05 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities; NALYs = Normalized                                                     
Adjusted Life Years 
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Table H8: Low Estimates of Incremental Costs 
Patient Type Combination Therapy 
Total Costs 
Medication Management 
Total Costs 
Incremental 
Total Costs 
 
Boys 
  
 
 
 
 
   Internalizing $38,385 $22,429 $15,956 
 
   Externalizing $38,546 $22,409 $16,137 
 
   Both $38,332 $22,242 $16,090 
 
   Neither $38,655 $22,239 $16,416 
    
 
Girls 
   
 
   Internalizing $38,173 $22,191 $15,982 
 
   Externalizing $38,775 $22,086 $16,689 
 
   Both $38,490 $22,329 $16,161 
 
   Neither $38,190 $22,153 $16,038 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities 
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Table H9: High Estimates of Incremental Costs 
Patient Type Combination Therapy 
Total Costs 
Medication Management 
Total Costs 
Incremental 
Total Costs 
 
Boys 
  
 
 
 
 
   Internalizing $40,617 $23,423 $17,194 
 
   Externalizing $40,602 $23,747 $16,855 
 
   Both $40,877 $23,324 $17,553 
 
   Neither $41,128 $23,425 $17,702 
    
 
Girls 
   
 
   Internalizing $40,223 $23,215 $17,008 
 
   Externalizing $40,766 $23,279 $17,487 
 
   Both $40,638 $23,418 $17,220 
 
   Neither $40,288 $23,454 $16,834 
Internalizing = Internalizing Comorbidities; Externalizing = Externalizing Comorbidities; Both =                                                       
Internalizing + Externalizing Comorbidities; Neither = No Comorbidities 
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Table H10: Sensitivity Analysis -- Low and High Estimates of the ICERs 
Patient Type Low Estimate of 
ICER 
High Estimate of  
ICER 
 
Boys 
  
 
 
   Internalizing -$24,113 -$34,323 
 
   Externalizing $1,208,705 -$3,465,044 
 
   Both -$6,380,729 $267,259 
 
   Neither $1,641,577 -$10,137,644 
   
 
Girls 
  
 
   Internalizing $140,973 $80,989 
 
   Externalizing $148,855 $129,430 
 
   Both $549,429 $198,865 
 
   Neither -$278,822 -$366,628 
Internalizing = Internalizing Comorbidities; Externalizing =      
Externalizing Comorbidities; Both = Internalizing + Externalizing                 
Comorbidities; Neither = No Comorbidities; ICER = Incremental                                                                           
Cost-Effectiveness Ratio (Combination Therapy – Medication Management) 
 
 The sensitivity analysis of the ICERs based on the 95 percent confidence intervals for 
response and total costs reveals that medication management remains more cost-effective 
compared to combination therapy. Medication management continues to dominate for 
boys with internalizing comborbidities and girls without comorbidity, even when using the 
low estimate of the ICERs. Combination therapy for girls with internalizing, externalizing, 
and both comorbidity types remains both more costly and more effective, in both the high 
estimate and low estimate scenarios. However, combination therapy cannot be considered 
cost-effective compared to medication management when using any realistic threshold 
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willingness to pay. Boys with externalizing, both types, and without comorbidity vary from 
dominance to more costly/more effective; however, combination therapy should not be 
considered cost-effective in any of these groups. Ultimately, the study conclusions remain 
the same whether using the low, mean, or high estimates of costs and response to 
treatment.    
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